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Maternal obesity is associated with adverse pregnancy outcomes, especially the 
development of gestational diabetes mellitus (GDM), with associated risks for 
mother and infant. Improved understanding of glucose intolerance in obese women 
and better prediction and prevention of GDM is key to improving the health of 
mother and her child. 
This thesis reports two related projects. The first explored mechanisms of insulin 
resistance and prediction of GDM in obese pregnant women participating in the pilot 
study for the UK Pregnancies Better Eating and Activity Trial (UPBEAT), a lifestyle 
intervention RCT. The second investigated the potential of a dietary intervention to 
improve glycaemic profiles in this high-risk group.  
Following an 8 week dietary and physical activity intervention, a panel of 
biomarkers associated with obesity and insulin resistance were measured in 117 
women in the pilot trial. At 27+0-28+6 weeks’ no difference was observed between 
the intervention and control arms but at 34+0-35+6 weeks’, significant reductions in 
plasma visfatin, cholesterol and LDL cholesterol were observed. Analysis by GDM 
status, confirmed greater concentrations of fructosamine, AST and insulin and lower 
plasma leptin and adiponectin in women who developed GDM. An algorithm based 
on clinical factors alone (age, parity, ethnicity and blood pressure at 15+0-18+6 weeks’ 
gestation) showed predictive potential which increased significantly with the 
addition of plasma adiponectin measured at 15+0-18+6 weeks. 
In obese pregnant women without GDM (n=16,) the effect of a slow-digesting low 
glycaemic index (SD-LGI) supplement drink was evaluated at 24+0-28+6 weeks’ 
gestation. Linear regression analysis with mixed modelling (LMM) showed a 
significant reduction in glycaemia over the 24 hour period following consumption of 
the test compared to the control supplement and habitual diet. Fasting and nocturnal 
glucose concentrations were also significantly improved 
In summary biomarkers associated with insulin resistance were identified as 
potential targets for lifestyle interventions aimed at reducing GDM in obese women. 
A prediction model for GDM identified those at greatest risk and pending validation 
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in the UPBEAT RCT may have the potential for translation into clinical care. 
Extending the role of interventions further, multiple improvements in parameters of 
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1 INTRODUCTION 
1.1 Current trends in obesity 
The worldwide prevalence of obesity has rapidly increased over the past decade with 
over 1.1 billion adults and 10% of children classified as overweight or obese, in the 
most recent review by Stevens et al., representing a doubling from 6.4% to 12% 
(Stevens, Singh et al. 2012). Obesity is now considered to be the seventh most 
important determinant of adverse health and reduced adult life expectancy globally 
through an increased risk of cardiovascular disease, type two diabetes (T2DM) and 
multiple cancers (Whitlock, Lewington et al. 2009, Vineis and Wild 2014).  
 
Figure 1 Prevalence of male and female obesity (BMI>30kg/m2), standardised for age in 2008 
Source http://gamapserver.who.int/mapLibrary/Files/Maps/Global_Obesity_BothSexes_2008.png 
The universal distribution of obesity remains greatest in developed countries with the 
lowest prevalence seen in sub-Saharan Africa but a recent shift in trends, parallel to 
those in Western countries has been observed in regions of high poverty (Popkin and 
Slining 2013). 
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Accurate measurement of total body fat remains technically difficult, time 
consuming and relatively costly therefore obesity is determined and classified in 
routine clinical practice by measurement of the body mass index (BMI), calculated 
by the standard formula; weight (kg)/height (m)2. Other techniques such as 
bioelectrical impedance, measurement of total body water or potassium and duel 
energy x-ray absorptiometry (DEXA) are reserved for research purposes primarily, 
with limited availability. Using BMI as a surrogate measure of obesity has multiple 
advantages but awareness of its limitations is important for translation into clinical 
medicine.  Whilst providing a rapid, inexpensive and replicable estimate of total 
body fat, measurements are indirect and do not reflect distribution of fat, particularly 
excess abdominal fat, which is strongly associated with cardiovascular morbidity 
(Sattar, Tan et al. 1998). Individuals from specified regions, namely South Asia and 
the South Pacific, have significantly greater risk of adverse health at lower BMI 
values when compared to White European subjects; nonetheless, the World Health 
Organisation (WHO) retains the standard international classification system for all, 
with no adjustment for ethnicity, age or sex (World Health Organisation 2004) 
(Table 1). 
Table 1 WHO classification of weight by body mass index (BMI) 
Classification BMI (kg/m2) 
Normal range 18.5-24.9 
Overweight (pre obese) 25.0-29.9 
Obese ≥ 30 
Class I or moderately obese 30.0-34.9 
Class II or severely obese 35.0-39.9 
Class III or morbidly obese ≥40.0 
The National Health and Nutrition Examination Survey (NHANES) has been 
examining US trends in adult obesity every two years since 1999, with analysis of a 
nationally representative sample, aged 20 years and more.  The last published survey 
of 2009-2010 found an age adjusted prevalence of obesity (BMI ≥30kg/m2) of 35.7% 
(95% CI [33.8-37.7]) in 8397 men and women across all ethnic groups with similar 
figures reported in women of reproductive age (20-39 years 31.9%, 95% CI [34.0-
37.7])(Flegal, Carroll et al. 2012). 
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In the United Kingdom, figures for obesity in women of reproductive age have 
followed a similar trajectory to those in the United States, with a doubling of 
maternal obesity over the past twenty years observed at the first antenatal visit 
(Kanagalingam, Forouhi et al. 2005). National data from the Health Survey for 
England (HSE) showed a rise in obesity rates from 12 to 18.5% in 1993, increasing 
further to 18.5% in 2006 (HSE 2008). More recently, the latest WHO Global 
Infobase of statistics, reports an age adjusted prevalence of 26.3% across all ethnic 
groups in the UK for all women greater than 15 years (WHO 2010).  
Maternal obesity is consistently associated with a range of demographic factors. A 
population based review of pregnancies in England by Heslehurst et al., including 
620,000 women with a 1st trimester obesity prevalence of 16%, reported positive 
associations with age, parity and black ethnicity (Heslehurst, Rankin et al. 2010). 
Obese women were more likely to be from socially deprived backgrounds with the 
greatest levels of unemployment observed in women with morbid obesity (BMI ≥ 40 
kg/m2). 
1.1.1 Gestational weight gain, BMI and anthropometry 
Gestational weight gain (GWG) is essential to support the growth of the developing 
fetus however the optimal amount of gain continues to be re-examined and indeed 
questions remain as to whether GWG should be the primary measure and targeted 
modifiable factor, in the management of pregnant women, to reduce disease burden.  
Table 2 Institute of Medicine recommendations for total weight gain in pregnancy by pre-pregnancy 
BMI 
Pre-pregnancy BMI (kg/m2) Total weight gain (kg) Rate of weight gain (kg/week)* (2nd 
& 3rd trimester) 
Underweight (<18.5) 12.5-18 0.51 (0.44-0.58) 
Normal (18.5-24.9) 11.5-16 0.42 (0.35-0.50) 
Overweight (25.0-29.9) 7-11.5 0.28 (0.23-0.33) 
Obese (≥30) 5-9 0.22 (0.17-0.27) 
*Calculations assume a first-trimester weight gain of 0.5-2.0 kg 
The 2009 revision of the Institute of Medicine (IOM) guidelines on weight gain in 
pregnancy advise a stricter reduction in GWG in an attempt to minimize adverse 
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pregnancy outcomes for both mother and offspring and reduce the complications of 
post partum weight retention, childhood obesity and metabolic dysfunction (Table 2) 
(Rasmussen and Yaktine 2009). 
The variation and degree of GWG is directly related to the number of fetuses per 
pregnancy (singleton pregnancy 10-16.7kg, twin pregnancy 15-22kg, triplet 
pregnancy 20.5-23kg) and appears to be influenced by ethnicity and socio-economic 
class (Rasmussen and Yaktine 2009, Bowers, Laughon et al. 2013). Primiparous 
women have a tendency for larger GWG in comparison to multiparous women 
however a recent study by Rasmussen et al., examining almost 3,000 women who 
participated in a national US cohort study, supports pre-existing data that GWG is 
inversely related to pre-pregnancy BMI, irrespective of parity (Lan-Pidhainy, Nohr 
et al. 2013). In the primiparous group (n=822) mean GWG within each BMI 
category was as follows: BMI<25 17.3 ±5.9kg, BMI 25-29.9 16.4 ±6.9kg and BMI 
≥30 12.1 ±7.8kg. 
Women with GWG above recommend targets not only have greater risk of obstetric 
complications including LGA but have been repeatedly shown to have a greater 
lifetime risk of obesity and metabolic disease (Nelson, Matthews et al. 2010, Fraser, 
Tilling et al. 2011, Lan-Pidhainy, Nohr et al. 2013). Limitations of this approach 
include self-reporting of early or pre-pregnancy weight routinely documented at the 
initial antenatal visit together with the poorly defined composition of total GWG in 
terms of essential physiological adaptations including placental, blood and fetal 
weight in contrast to excess adipose accretion.  
Debate remains as to the best method of measuring obesity and longitudinal changes 
in pregnant women which are relevant in research settings and applicable to clinical 
practice. Aside from gold standard techniques with limited availability including 
DEXA and Body Plethysmography, BMI, GWG and maternal anthropometry are all 
surrogate markers of excess adipose tissue.  Guidelines published on GWG 
acknowledge the high inter-person variability and difficulties in determining the 
changing composition of GWG during pregnancy as the fetus develops suggesting 
that GWG is a poor measure of accretion of fat mass. The frequently quoted ‘Y-Y 
paradox’ of two men with the same BMI and very different body composition 
described in 2004 clearly highlights limitations of using BMI as a surrogate marker 
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of adiposity; both had a BMI of 22.3kg/m2 but DEXA scanning revealed a significant 
difference in total body fat of 9.1% and 21.2% (Yajnik and Yudkin 2004). Adipose 
tissue is now recognised as an important endocrine organ with varied clinical risk 
attributed to the pattern of fat distribution (Lee, Wu et al. 2013). BMI does not 
reflect body fat distribution and since the developing fetus and normal physiological 
increase in fluids are the main contributors of GWG, it remains valid only in pre-
pregnancy or the early stages (Figure 2).  
 
Figure 2 Estimated composition of Maternal GWG (Rasmussen and Yaktine 2009) 
Maternal anthropometry, measured by skin fold thickness using validated callipers at 
selected sites, can be used as a surrogate maker of adiposity in pregnant women with 
the benefit of reflecting longitudinal changes during gestation and being easily 
replicated in clinical practice. In adults, body composition is considered a better 
predictor of health outcome than body weight alone (Thibault, Genton et al. 2012). 
Ongoing collaborative work by international experts participating in the European 
EarlyNutrition Academy and EarlyNutrition Project (www.project-earlynutrition.eu) 
continues to determine the optimal methods of measuring neonatal/offspring 
adiposity to enable prediction of disease risk later in life (Ward, Poston et al. 2013).  
1.2 Adverse pregnancy outcomes in obese pregnant women 
A large body of supporting data has identified numerous adverse health outcomes to 
mother and fetus during an obese pregnancy which describe a linear continuous 
relationship with increasing BMI (Sebire, Jolly et al. 2001, Chu, Callaghan et al. 















to complications during pregnancy, labour and the postpartum period with 
consequences to maternal and offspring health in later life. 
In addition to disease burden, the resource implications and logistics of providing 
more intensive obstetric and lifetime healthcare to obese women and their offspring, 
continues to be an important issue as shown in a case controlled study by Galtier-
Dereure et al. comparing the duration of hospitalisation in women with a pregravid 
BMI>25kg/m2 (Galtier-Dereure, Boegner et al. 2000). Overweight women had a 
longer duration of hospitalisation (by 3.9 and 6.2 fold for day and night periods 
respectively) and spent an average of 4.43 more days in hospital compared to lean 
matched controls (BMI 18-25kg/m2) when data for pre and post pregnancy care were 
combined.  The most recent cost analysis of obstetric care for obese women in 
Scotland found similar results with more frequent and prolonged hospital 
admissions, equating to a mean additional admission cost of £202.46 compared to 
lean women following analyses adjusted for maternal age, parity, smoking status and 
deprivation (mean additional cost £202.46, 95% CI [178.61-226.31], p<0.001) 
(Denison, Norwood et al. 2014).  
 
1.2.1 Maternal adverse outcomes 
Obstetric Complications 
Several recent large cohorts, systematic reviews and meta-analyses have provided 
estimated risks for pregnancy complications following maternal obesity.  
Pre-gravid obesity is associated with sub-fertility and increased rate of both incident 
and recurrent miscarriage (OR for recurrent miscarriage 4.68, 95% CI [1.21 to 
18.13]) (Metwally, Ong et al. 2008). The risk of the most frequently observed 
congenital anomalies are greater including spina bifida and cardiac malformations 
(OR 2.24, 95% CI [1.86 to 2.69] and OR 1.3, 95% CI [1.12-1.51] respectively) 
(Stothard, Tennant et al. 2009) whilst  gestational hypertension (RR 3.19, 95% CI 
[2.36 to 4.30]) (Athukorala, Rumbold et al. 2010, Stuebe, Landon et al. 2012), pre-
eclampsia (OR 2.14, 95% CI [1.85 to 2.47]) (Sebire, Jolly et al. 2001), and venous 
 26 
thromboembolism are all more prevalent (Centre for Maternal and Child Enquiries 
(CMACE) 2010).   
Obstetric complications are significantly more common in obese women, for 
example preterm birth, induction of labour, elective and emergency caesarean 
section, instrumental delivery and postpartum haemorrhage (Sebire, Jolly et al. 2001, 
Heslehurst, Simpson et al. 2008, Athukorala, Rumbold et al. 2010, Nelson, 
Matthews et al. 2010, Denison, Norwood et al. 2014). The administration of 
anaesthesia, whether regional or general, poses greater hazards in this population and 
the risks of standard post-operative complications such as respiratory ventilation, 
wound infection and length of stay are all increased.  
Abnormal Glucose Homeostasis 
Pregnancy in healthy subjects is a period of metabolic stress characterised by hepatic 
and peripheral insulin resistance (IR), with co-existing alterations in lipid and protein 
metabolism aimed at meeting the energy requirements of the developing fetus 
(Nelson, Matthews et al. 2010, Catalano and Hauguel-De Mouzon 2011). Obese 
women, with an already heightened pregravid risk of T2DM, have a 2 to 4 fold 
increased risk of developing GDM (Table 3). A recent Scottish population study of 
124, 280 deliveries reported significantly greater odds of developing GDM for obese 
and morbidly obese women when compared to healthy weight women, when 
adjusted for maternal age, social deprivation and smoking following multiple 
regression (obese OR 11.90, 95% CI [7.54-18.79], morbidly obese OR 67.40, 95% 
CI [37.84-120.03]) (Denison, Norwood et al. 2014). The actual numbers of GDM 
cases in this national database cohort were very low however affecting only 0.9% of 
obese (205/21,634) and 3% of morbidly obese (87/2720) women. Chu et al. analysed 
20 studies in their meta-analysis, eight of which were conducted in the United States 
and the remaining 12 from Europe, Australasia, the Middle East, and Nova Scotia 
including subjects from the Native Cree Indians known to have a very high risk of 
developing T2DM (Zimmet 2003).   
The influence of ethnicity on the development of GDM is well established with 
women from certain ethnic groups, particularly from South Asia, Latin America, 
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South Pacific islands and Native Indian groups, having substantially greater risk of 
developing GDM than white European women of equivalent BMI (Ferrara 2007).  
Table 3 Summary of four studies investigating the association of maternal BMI and development of 
GDM 
 Maternal BMI category versus normal (odds ratio [95% CI]) 
 Overweight Obese BMI (>40kg/m2) 
Sebire  (2001) 1.68 (1.56-1.84) 3.6 (3.25-3.98) - 
Chu (2007)* 2.14 (1.82-2.53) 3.56 (3.05-4.21) 8.56 (5.07-16.04) 
Athukorala (2010) 1.21 (0.66-2.21) 2.10 (1.17-3.79) - 
Denison (2014) 3.39 (2.30-4.99) 11.90 (7.54-18.79) 67.40 (37.84-120.03) 
* Meta-analysis of 20 studies 
The obese groups in the two additional studies detailed in Table 3 (Sebire et al. 
[n=287, 213]) and Athukorala et al. [n= 1611]) were composed of predominantly 
Caucasian subjects (71.4% and 96% respectively).   Other co-founding factors for 
the development of GDM are similar to those for obesity and include maternal age, 
parity, ethnicity, family history of diabetes and low socio-economic class 
(Heslehurst, Rankin et al. 2010).  
Until recently, there has been no internationally agreed diagnosis for GDM and 
clinical practice has varied considerably. Following the seminal Hyperglycaemia and 
Adverse Pregnancy Outcome Study (HAPO), (The HAPO Study Cooperative 
Research Group 2008),  the International Association of the Diabetes and Pregnancy 
Study Groups (IADPSG)  published new diagnostic criteria which have been 
recommended by the American Diabetes Association (ADA) (IADPSG 2010) and 
more recently the WHO (WHO 2013). Table 4 illustrates the different glucose 
concentrations required for a diagnosis of GDM prior to the adoption of the 2010 
IADPSG guidelines.  
Controversies remain as to the best approach to diagnosing GDM since the new 
glucose thresholds are lower than any previous cut offs, thereby identifying 
significantly more cases of GDM and changing clinical care for substantially more 
women. Although the HAPO study was an observational prospective study, the 
authors demonstrated a clear, continuous, linear relationship between glucose 
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concentration and a composite primary endpoint of adverse events (birth weight 
≥90th centile, primary cesarean delivery, neonatal hypoglycemia, and cord-blood 
serum C-peptide ≥90th centile). At the time of the HAPO study it was considered 
ethical to not treat GDM therefore the results provide insight into the adverse effects 
of non-treatment of varying glucose concentrations below those generally accepted 
as indicative of overt diabetes. 
Table 4 Comparison of criteria for diagnosis of GDM 
Test IADPSG      
(any 1 of)  
ADA*              
(at least 2 of) 
WHO (2006) 
*IFG/IGT**  (any 1 of)                  
Fasting glucose (mmol/l) ≥5.1 ≥5.3 ≥6.1 
1h-glucose (mmol/l) ≥10.0 ≥10.0 - 
2h-glucose (mmol/l) ≥8.5 ≥8.6 ≥7.8 
*The ADA and WHO have since endorsed the IADPSG recommendations 
**IFG/IGT: Impaired fasting glucose/impaired glucose tolerance 
 
O’Sullivan et al. assessed the impact of the new IADPSG guidelines on maternal 
outcomes in 5500 women of predominantly white European descent participating in 
the Atlantic Diabetes in Pregnancy study (DIP).  As anticipated, the prevalence of 
pregnancy complications was significantly greater in women with IADPSG GDM 
versus women with normal glucose tolerance (gestational hypertension 13.8% v 
7.5% p<0.0001, preeclampsia 6.3% v 4.0% p=0.007, polyhydramnios 3.4% v 0.8% 
p<0.0001, normal vaginal delivery 51.4% v 57.9% p=0.002 and caesarean section 
37.2% v 24.9% p<0.0001) (O’Sullivan, Avalos et al. 2011). A direct comparison of 
adverse outcomes for GDM diagnosed by IADPSG and WHO 2006 criteria to 
explore the effects of the lower glucose concentration was not performed but 
following its introduction, centres have observed a 2-8 fold increase in cases of 
GDM depending on local ethnicity and obesity (Langer, Umans et al. 2013). 
 
Pregnancy complicated by GDM confers a substantially greater lifetime risk of 
developing type 2 diabetes (T2DM) (Lauenborg, Hansen et al. 2004). Considering 
the multiple limitations of attempting to quantify this risk in large meta-analyses, 
including different diagnostic criteria of GDM and T2DM, wide variations in the 
duration of post-natal follow up and multiple confounding factors including 
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ethnicity, Bellamy et al. reported an overall relative risk of 7.43 (RR 7·43, 95% CI 
[4·79–11·51]) (Bellamy, Casas et al. 2009). Women with GDM have progressive 
changes with advancing gestation, to measures of insulin sensitivity, insulin 
resistance and beta cell function, reflecting a worsening degree of glucose 
intolerance. Xiang et al., followed up women 5 years from their last pregnancy, with 
and without a previous history of GDM over a median of 4 years, measuring insulin 
resistance and changes in adiposity using DEXA (Xiang, Takayanagi et al. 2013). 
Women with GDM not only had significantly more impaired fasting glycaemia 
(IFG) and impaired glucose tolerance (IGT) at enrolment (baseline IFG: 35.5% v 
13.4% and IGT: 71.0 v 39.4%, GDM v non-GDM respectively) and four years later 
but an accelerated rate of decline in glucose tolerance, measured during an 
intravenous glucose tolerance test (IVGTT).  
 
Pre-pregnancy obesity and GDM are independent predictors of multiple adverse 
pregnancy outcomes however the presence of both confers additional risk than either 
one alone. Catalano et al. analysed all women who participated in the HAPO study 
(n=23,316); 13.7% were classified as obese and 16.1% diagnosed with GDM with 
25% of this cohort obese also (Catalano, McIntyre et al. 2012). Increased odds ratios 
were found for a combination of the two conditions than either alone for six adverse 
outcomes including cord C-peptide, preeclampsia, birth weight >90th centile and 
newborn percentage fat, with an almost doubling of effect for selected outcomes. 
The independent effect of obesity and GDM on adverse outcomes is complex and 
remains difficult to disentangle due to the physiological interrelationship and 
causality between the two and study design.    
In response to extensive data detailing increased pregnancy complications for obese 
women, with particular reference to the Centre for Maternal and Child Enquiries 
(CMACE) 2010 report titled “Maternal obesity in the UK: Findings from a national 
project,” guidelines have been published in conjunction with the Royal College of 
Obstetrics and Gynaecology (RCOG) to provide and support alternate clinical 
pathways for this high risk group (Modder and Fitzsimmons 2010).  
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1.2.2 Offspring adverse outcomes  
Maternal obesity influences growth and development of the fetus. Pre-pregnancy 
BMI is a strong predictor of mean birth weight, with obese women having 2-5 fold 
increased risk of delivering an infant who is large for gestational age (defined as 
>90th centile [LGA]) or macrosomic (>4000g) (Heslehurst, Simpson et al. 2008, 
Athukorala, Rumbold et al. 2010, Bowers, Laughon et al. 2013), with some evidence 
to suggest that obesity has a greater influence than GDM on LGA despite the strong 
interrelationship (Catalano and Ehrenberg 2006).  
Observational data indicates a higher risk of pregnancy complications associated 
with excess GWG for obese women when compared to lean subjects, suggesting a 
potentially greater influence of pre-pregnancy BMI rather than GWG on adverse 
outcomes (Nohr, Vaeth et al. 2008). A retrospective analysis of 57,700 women 
participating in the Danish National Birth Cohort (DNBC) from 1996–2002, 
demonstrated an inverse relationship between the risk of giving birth to a small for 
gestational age infant (defined as <10th centile [SGA]) with pre-pregnancy BMI and 
GWG. Furthermore the opposite effect was observed for LGA whereby obese 
women or those with excessive GWG had the greatest risk.  For all maternal and 
neonatal outcomes measured (pre-eclampsia, hypertension, GDM caesarean section 
rate, instrumental delivery, SGA, LGA and low Apgar score at 5min), pre-pregnancy 
BMI was the strongest predictor although GWG was significant for postpartum 
weight retention at six months for all categories of BMI (Figure 3).  
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Figure 3 Adjusted absolute risks for SGA (●), LGA (○) emergency CS (▲) and PPWR ≥5kg at 6m 
(∆) according to pre-pregnancy BMI and WHO GWG categories (low<10kg, medium 10-15kg, high 
16-19kg and very high ≥20kg) (Nohr, Vaeth et al. 2008) 
 
Neonatal macrosomia increases the risk of shoulder dystocia, birth trauma and 
depression of Apgar scores whilst infants of women with GDM face a significantly 
higher risk of neonatal hypoglycaemia requiring treatment (Sebire, Jolly et al. 2001).  
Subsequently, infants are more likely to require admission to intensive care areas, 
with longer periods of hospitalisation.  
Findings from the 2010 CMACE national survey corroborate previous data 
identifying a greater prevalence of stillbirth and perinatal loss in obese women (Chu, 
Kim et al. 2007). With a background population rate of 3.9 per 1000 birth, women 
with a BMI≥35kg/m2 were almost twice as likely to have a stillbirth in the United 
Kingdom (8.6 stillbirths per 1000 total births) (Centre for Maternal and Child 
Enquiries (CMACE) 2010). 
Although the differences in birth weight may be considered small and subtle 
initially, longitudinal cohort studies have confirmed increased associated lifelong 
risk of obesity and metabolic disease for these children (Fraser, Tilling et al. 2010). 
In The Early Childhood Longitudinal Study (n=7738), 12% of the children born with 
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macrosomia represented 36% of 14 year olds who were obese (Cunningham, Kramer 
et al. 2014).  
1.2.3 Long term offspring metabolic sequelae  
Multiple large prospective birth cohorts examining the effect of GWG and pre-
pregnancy BMI on infant outcomes report strong positive associations with offspring 
adiposity from childhood, (Oken, Taveras et al. 2007) through to adolescence 
(Yajnik and Yudkin 2004) and adulthood (Lee, Yuanyuan et al.). Most recently in a 
meta-analysis of 45 studies of medium to high quality, offspring of obese women 
had a three-fold increased risk of adult obesity (Yu, Han et al. 2013) associated with 
a significantly heightened risk of morbidity and excess mortality notably from 
cardiovascular disease (Reynolds, Allan et al. 2013, Yu, Han et al. 2013).  Data for 
37,709 mother:infant pairs extracted from the Aberdeen Maternity and Neonatal 
Databank (AMND) demonstrated that offspring of obese women had increased all 
cause mortality (hazard ratio 1.35, 95% CI 1.17 to 1.55) including premature 
mortality secondary to cardiovascular disease (stroke, angina and myocardial 
infarction aged<55 years) and were more likely to require hospital admission for a 
cardiovascular event (Reynolds, Allan et al. 2013). While these results were adjusted 
for many confounding factors (maternal age at birth, offspring sex, socioeconomic 
status, gestational age at delivery and current age and birth weight), quantifying and 
assessing the influence of non-modifiable factors including ethnicity and inherited 
transmission is challenging.  
Attempts to identify the risk of offspring obesity and diabetes, following a pregnancy 
affected by diabetes, over and above that attributable to genetic factors alone, have 
been made with interesting results.  
Dabelea et al. identified 19 families where at least one pregnancy occurred either 
side of a diagnosis of maternal T2DM. In doing so, they were able to follow up 
siblings from the same parents who had been exposed to different intrauterine 
environments but with similar genetic susceptibility (Dabelea, Hanson et al. 2000). 
When examined at a comparable age, those siblings exposed to maternal diabetes 
were more likely to develop T2DM themselves (OR 3.7, 95% CI [1.3-11.3], p=0.02) 
and have a higher BMI than their older siblings (mean difference in BMI 2.6kg/m2, 
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95% CI [0.9-4.3], p=0.003]) up to early adulthood. In a similar analysis examining 
the paternal influence, where only the father had T2DM, no difference was observed 
between siblings for risk of diabetes or obesity therefore strengthening the 
association of abnormal maternal glucose tolerance with offspring metabolic 
outcomes. Appreciably the results may be skewed since the sample was comprised 
of Native Pima Indians of Arizona, an ethnic group known to have extremely high 
prevalence of both obesity and T2DM. Nonetheless the importance of the 
intrauterine environment with reference to abnormal glucose homeostasis, as a 
determinant off offspring adverse health, independent of genetic risk, is illustrated.  
For women with normal pre-pregnancy BMI, excessive GWG also increases the risk 
of metabolic dysfunction although pre-gravid obesity remains the stronger 
determinant. The Avon Longitudinal Study of Parents and Children (ALSPAC) is an 
on-going prospective population-based birth cohort (n=14,541) of mother:infant 
pairs, delivered between 1991-1992. In a sub study of 6668 pairs, with complete data 
up to 9 years, offspring of women who exceeded the 2009 IOM recommendations 
for GWG not only had significant differences in clinical measurements (BMI, waist 
circumference, SBP, DBP and total fat mass) but positive and negative changes in 
selected biomarker concentrations (HDL-C, leptin and apolipoprotein A1) associated 
with cardiovascular disease (Fraser, Tilling et al. 2010). 
The positive linear relationship between GWG and offspring adiposity was present 
for all women up to 14 weeks but stronger for those who gained more than 
500g/week. During the 1st trimester, weight gain typically represents an increase in 
physiologically active maternal fat stores rather than fetal mass. Thereafter from 14-
36 weeks gestation, GWG was only associated with infant adiposity for women with 
accelerated weight gain.  
In contrast, the relationship between GWG and adverse biomarker concentrations 
attenuated towards the null in the first trimester and was only significant from 14-36 
weeks. The authors suggest a possible lack of statistical power for the absence of a 
significant relationship until 14 weeks however the transmission of fat related CV 
risk may be mediated by alternative pathways related to the location of adipose 
stores, accrued at different stages of pregnancy, rather than total fat gain. It is likely 
that the production of adipokines is not uniform since depot-specific hormonal 
 34 
changes, conferring varied degrees of adverse risk, have been observed for different 
compartments e.g. visceral, subcutaneous, upper and lower body (Wajchenberg, 
Giannella-Neto et al. 2002). An independent relationship between GWG and 
offspring adiposity has now been identified in several different mother-child cohort 
studies (Poston 2012).  
1.3  Potential mechanisms of adverse outcomes in obese 
pregnancies 
1.3.1 Distribution of adipose tissue in lean and obese women 
1.3.1.1 Non-Pregnant State 
Multiple international collaborations totalling almost 400,000 subjects, including the 
European Prospective Investigation into Cancer and Nutrition (EPIC) (Pischon, 
Boeing et al. 2008) and case-controlled INTERHEART (Yusuf, Hawken et al. 2005) 
studies have consistently found strong associations between measures of central 
obesity and visceral fat with features of the metabolic syndrome, cardiovascular 
morbidity and mortality (Schneider, Friedrich et al. 2010). Results from the 
Emerging Risk Factors Collaboration reported that BMI, waist circumference and 
waist-to-hip ratio all had comparable strength of association with ischaemic stroke 
and coronary heart disease suggesting no additional benefit of taking further 
anthropometry measurements than those already routinely used (Wormser, Kaptoge 
et al. 2011).  
Evidence however continues to demonstrate that visceral fat exhibits increased 
metabolic and functional activity compared to subcutaneous fat depots, secreting a 
wide array of pro-inflammatory cytokines, adipokines and increased concentrations 
of free fatty acids (FFA), all implicated in the causal pathway of the metabolic 
syndrome (Wajchenberg 2000, Wajchenberg, Giannella-Neto et al. 2002, 2010). In 
contrast to upper body adiposity, lower body fat stores appear to be associated with a 
reduced risk of metabolic dysfunction however the relative contributions of upper 
body subcutaneous and visceral fat to this heightened risk remains undifferentiated 
(Snijder, Dekker et al. 2004). As a surrogate measure, BMI is unable to distinguish 
between obesity caused by muscle or fat accumulation, an important limitation 
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considering the different physiological and potentially pathogenic roles of adipose 
tissue. Since pregravid maternal BMI has been shown to be a stronger predictor of 
adverse outcome than GDM and excessive GWG, examining different fat stores in 
non-pregnant subjects and how these change during pregnancy seems warranted 
(Catalano and Ehrenberg 2006, Nohr, Vaeth et al. 2008). 
1.3.1.2 During Pregnancy 
In a small study longitudinal prospective study, Ehrenberg et al. quantified maternal 
adiposity in lean and obese subjects with and without GDM following calculation of 
fat mass (FM), lean body mass (LBM) and percentage body fat (BF) using 
hydrodensitometry corrected for residual lung volume at preconception, in early and 
late gestation (12-14 and 33-36 weeks’ respectively) (Ehrenberg, Huston-Presley et 
al. 2003). Central adiposity was measured antenatally using waist:thigh ratio and 
subcutaneous fat determined with serial skinfold measurements at 7 sites (biceps, 
triceps, subscapular, iliac, costal, mid thigh and lower thigh). Lean women gained 
significantly more fat mass than obese women during pregnancy (change in percent 
of BF 3.3% v 0.1%, p=0.004) with a preference for peripheral deposition (biceps, 
triceps, costal, p<0.05 for all) compared to central deposition in obese women 
(suprailiac and subscapular skin folds).  Women who developed GDM had similar 
accretion and distribution of weight gain when lean and obese groups were compared 
suggesting a stronger influence of pregravid weight rather than impaired glucose 
tolerance on adipose stores and function. 
The hypothesis that different compartments of adipose tissue confer greater risk for 
metabolic disease later in life whilst others stores may be considered “safer” or even 
“protective” has been established in the non pregnant state (Yusuf, Hawken et al. 
2005, Pischon, Boeing et al. 2008, Schneider, Friedrich et al. 2010) but studies in 
pregnancy with detailed measures of weight and fat distribution related to clinical 
outcomes are limited (Yusuf, Hawken et al. 2005, Pischon, Boeing et al. 2008, 
Schneider, Friedrich et al. 2010).  
The relationship and predictive power of longitudinal changes to adipose tissue 
depots during pregnancy and GDM was recently explored by a Norwegian group 
(Sommer, Morkrid et al. 2014). Comparing data obtained prospectively between 15-
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28 weeks’ gestation in 728 women (mean pre-pregnancy BMI 24.5kg/m2), the mean 
weekly weight gain was 0.51kg, thus exceeding the IOM 2009 recommendations 
(0.42kg/week for lean subjects). Total fat mass and truncal adiposity measured using 
bioelectrical impedance, increased by 0.38 and 0.22kg per week respectively and 
using modified IADPSG GDM guidelines (1hour glucose not available) a prevalence 
of 31.5% GDM was recorded.  In keeping with previous evidence examining T2DM 
risk in non-pregnant adults, an increase in central adiposity was strongly associated 
with GDM (OR 1.31, 95% CI [1.10-1.56]) compared to weight gain (OR 1.23, 95% 
CI [1.04-1.16]) and mean skinfold measures (OR 1.22, 95% CI [1.02-1.47]) however 
caution interpreting these results must be used since truncal adiposity is a component 
of total fat mass and the difference in odds ratios were small. Furthermore truncal fat 
measures incorporate subcutaneous and visceral fat both considered to have different 
properties and risk in relation to CVD.  
Concordant with extensive literature, women of South Asian heritage were three 
times more likely to develop GDM than European women when the combined 
effects of pre-pregnancy BMI and truncal fat gain were included in the regression 
model (OR 5.9, 95%CI [3.5-10.0] and OR 2.1, 95% CI [1.6-2.8]). The single effect 
of pre-pregnancy BMI was greater than change in central adiposity (Figure 4) 
highlighting the importance of targeting pre-conception weight loss as the preferred 
time to achieve improved clinical outcomes, albeit difficult to attain in practice. 
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Figure 4 Plot to illustrate the single effect of ethnicity and the combined effects of ethnic origin, 1 
s.d. (0.14kg/week) truncal fat gain and 1 s.d. (4.7kg/m2) higher pre-pregnant BMI for Europeans and 
South Asians on the risk of GDM. Dots are ORs and lines are 95% CI (Sommer, Morkrid et al. 2014) 
1.3.2 Neonatal adiposity and maternal obesity 
Differences in measures of neonatal adiposity are apparent from birth following an 
obese pregnancy and when considering multiple contributory factors including 
smoking status, excess GWG, sex, maternal age, parity and gestational age at birth, 
maternal obesity remains the strongest predictor of percentage body fat and fat mass 
(Waters, Huston-Presley et al. 2012, Dello Russo, Ahrens et al. 2013, Ensenauer, 
Chmitorz et al. 2013).  
The effects of maternal obesity and GDM on fetal outcome are independent and 
additive (Catalano and Ehrenberg 2006, Simmons 2011) however the individual 
influences on fetal adiposity remains difficult to separate and complex to assess. In 
the 1950’s Jorgen Pedersen postulated that fetal overgrowth was related to an 
increase in transplacental glucose transfer secondary to maternal hyperglycaemia, 
resulting in fetal islet cell hypertrophy and hyperinsulinaemia (Pedersen 1952). 
There is work to suggest that infants born to women with abnormal glucose tolerance 
have greater fat mass but not birth weight compared with offspring of healthy 
women when corrected for gestational age (Catalano, Thomas et al. 2003) (Table 5). 
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In this study by Catalano et al., direct comparison of BMI between women with and 
without GDM was not performed therefore BMI remains a significant confounding 
factor. Nonetheless, women in the GDM group were significantly heavier prior to 
conception (81.0 v 65.5kg, p=0.001) and following adjustment for parental height 
and weight the differences observed in fetal adiposity between the GDM and non-
GDM groups remained.  
Table 5 Offspring body composition (total body electrical conductivity TOBEC) and anthropometry 









*Following adjustment for gestational age, maternal pregravid weight, weight at last antenatal visit, 
race, smoking status, and maternal and paternal height **values are given as mean ± SD  
The HAPO study showed a continuous linear relationship between maternal glucose, 
cord C-peptide and birth weight (The HAPO Study Cooperative Research Group 
2008) lending support to the Pedersen hypothesis and extending this further. Data 
from the ALSPAC cohort suggests that any degree of glucose intolerance during 
pregnancy including glycosuria (++ on urinalysis equating to 250mg/ml, present on 
minimum 2 antenatal visits), which may be transient, has an adverse effect on 
offspring adiposity at 9-11 years (Lawlor, Fraser et al. 2010).  Historically, 
macrosomia was considered a consequence of unrecognised maternal 
hyperglycaemia but in the context of optimal glycaemic control, confirmed with 
CGMS, women with all types of diabetes in pregnancy (pre-existing T1 and T2DM 
and GDM), continue to have a threefold greater risk of having a large infant 
Variable** GDM (n=195) NGT (n=220) P value* 
Weight (g) 3398 ± 550 3337 ± 549 0.26 
Fat-free mass (g) 2962 ± 405 2975 ± 408 0.74 
Fat mass 436   ± 206 362   ± 198  0.0002 
Body fat (%) 12.4  ± 4.6 10.4  ± 4.6 0.0001 
Triceps (mm) 4.7   ± 1.1 4.2    ± 1.0 0.0001 
Subscapular (mm) 5.4  ± 1.4 4.6  ± 1.2 0.0001 
Flank (mm) 4.2  ± 1.2 3.8  ± 1.0 0.0001 
Thigh (mm) 6.0  ± 1.4 5.4  ± 1.5 0.0001 
Abdomen (mm) 3.5  ± 0.9 3.0  ± 0.8 0.0001 
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compared to the background population (Evers, de Valk et al. 2002, Langer, Yogev 
et al. 2005, Murphy, Rayman et al. 2008).  
For obese women, the risk of macrosomia is a function of pregravid obesity with 
additional risk conferred by even relatively small changes in glucose tolerance, 
which may not meet the threshold for a formal diagnosis of GDM (Yogev, Ben-
Haroush et al. 2004). Langer et al. showed that obese women with well-controlled 
GDM managed with diet treatment alone still have a 50% greater chance of having a 
large infant compared to lean women with GDM on similar treatment. The risk of 
macrosomia reduced only for obese women with GDM requiring insulin therapy to 
optimise glycaemia (Langer, Yogev et al. 2005).  The data suggests that the insulin-
mediated effects of reducing excess fetal growth are related to other metabolic 
pathways in addition to glucose, in particular lipid metabolism.  
1.3.3 Metabolic adaptations in obese pregnant women 
Maternal obesity is associated with dysregulation of metabolic, vascular and 
inflammatory pathways (Ramsay, Ferrell et al. 2002, Stewart, Freeman et al. 2007, 
Meyer, Stewart et al. 2013) frequently implicated in the pathogenesis of GDM and 
T2DM (Sattar, Wannamethee et al. 2008, Savvidou, Nelson et al. 2010, Ferreira, 
Rezende et al. 2011). 
Lipid metabolism  
During pregnancy, hyperlipidaemia occurs with a 2-4 fold increase in triglyceride 
(TG) concentration with a concomitant progressive rise in total cholesterol (Nelson, 
Matthews et al. 2010). In addition, concentrations of lipids strongly associated with 
adverse cardiovascular health, very-low density (VLDL) and low-density lipoprotein 
(LDL), increase from early second trimester by a magnitude of 3 to 4, paralleled by 
lesser rise in the more cardio-protective high-density lipoprotein (HDL) (Lain and 
Catalano 2007, Nelson, Matthews et al. 2010).  
Early gestation promotes greater storage of free fatty acids (FFAs) in adipose tissue 
contributing to the required anabolic environment but from mid-late gestation, 
mobilisation of FFAs from increased lipolysis mediated by LPL occurs in response 
to greater energy demands not adequately met by glucose (Huda, Sattar et al. 2009). 
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A 50-80% increase in basal fat oxidation and subsequent release of FFAs plus rising 
concentrations of circulating triglycerides, contributes to overall insulin resistance; a 
response that is exaggerated in obese women.  
The ability of insulin to suppress lipolysis in late pregnancy is diminished in all 
women but to a greater degree in obesity, adding to the overall pool of circulating 
FFAs that cross the placenta and enter the fetal adipocyte (Catalano and Hauguel-De 
Mouzon 2011). In the mature adipocyte, TGs are the primary component of 
intracellular lipid stores, derived from esterification of FFAs and non-lipid precursors, 
precursors, for example glucose derived from carbohydrate metabolism and lipolysis. 
lipolysis. Maternal sources of glucose, including those from dietary sources, are 
transported through the fetal portal circulation to provide substrate for de novo lipid 
synthesis within adipocytes ( 
Figure 5) (Catalano and Hauguel-De Mouzon 2011).  
Lipid dysregulation and increased deposition of visceral fat in obese pregnant 
women contributes to a spectrum of metabolic outcomes which share causal 
pathways including GDM (Lain and Catalano 2007), intrahepatic cholestasis of 
pregnancy (Martineau, Raker et al. 2014)  and pre-eclampsia (Vrijkotte, Krukziener 
N Fau - Hutten et al. 2012).  
Ramsay et al. analysed a detailed panel of biomarkers reflecting lipid metabolism 
and inflammatory processes together with measures of in-vivo endothelial function, 
obtained using doppler imaging, in lean and obese women in the 3rd trimester. Obese 
women had significantly greater concentrations of TG, leptin, fasting plasma insulin, 
Interleukin-6 and C-reactive protein with lower concentrations of HDL in keeping 
with a more atherogenic profile (Ramsay, Ferrell et al. 2002) A similar pattern in 
lipid metabolites was observed in a more recent study by Meyer et al. who sampled 
obese women longitudinally from 12-36 weeks’ gestation (Meyer, Stewart et al. 
2013). Interestingly, in the study by Ramsay et al., fasting plasma insulin 
concentrations in obese women were more than double those in lean counterparts, 
without any alteration in glucose tolerance; glycated haemoglobin (HbA1c) was 
equivalent for both groups of women (mean fasting plasma insulin 14.2mU/l [IQ 
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range 11.3–27] versus 6.15mU/l [IQ range 4.47–9.5], p<0.0001 and HbA1C 4.5% v 
4.4%, p=0.89 for obese and lean respectively) (Ramsay, Ferrell et al. 2002). 
 
 
Figure 5 Energy substrates for lipogenesis in fetal adipocytes. Adapted from Catalano et al., 2011 
(Catalano and Hauguel-De Mouzon 2011) 
TG: triglycerides, FFA: free fatty acid, LPL: lipoprotein lipase, VLDL: very-low density lipoprotein  
1.3.3.1 Lipotoxicity in obese women 
Upper body and subcutaneous fat stores confer greater risk for cardiovascular 
disease than lower body depots and are associated with abnormal lipid metabolism 
(Wajchenberg 2000, Wajchenberg, Giannella-Neto et al. 2002, Schneider, Friedrich 
et al. 2010). Extending this concept further, evidence indicates that upper and lower 
body subcutaneous fat stores respond differently to the actions of insulin-mediated 
lipolysis with upper stores more resistant to insulin suppression of lipolysis thus 
generating approximately 60% of circulating NEFAs in comparison with 15-20% 
derived from lower body stores which are more sensitive to insulin (Jarvie, Hauguel-
de-Mouzon et al. 2010).  
Obese pregnant women preferentially store fat in visceral and upper locations 



























more “pear-shaped” (Ehrenberg, Huston-Presley et al. 2003) (Figure 6). As a 
consequence of increased dietary fat contribution and lipolysis, together with 
suboptimal storage, and impaired adipocyte maturation, concentrations of circulating 
NEFAs are significantly greater (Jarvie, Hauguel-de-Mouzon et al. 2010). This in 
turn promotes accumulation of ectopic fat particularly in the liver where cellular 
dysfunction occurs upon saturation with fatty acids.  
 
Figure 6 Fatty acid metabolism in pregnancy (Jarvie, Hauguel-de-Mouzon et al. 2010) 
1.3.3.2 Mechanisms of insulin resistance  
Prior to detailing individual biomarkers implicated in IR in obese pregnancy, an 
overview of the recent concepts and mechanisms of IR will be discussed.  
Obesity is associated with a state of chronic inflammation, meditated by alterations 
in the concentration of circulating cytokines, reflecting abnormal changes to 
inflammatory and endocrine pathways and vascular dysfunction (Lee, Wu et al. 
2013). Many of these biomarkers are implicated in the pathogenesis of T2DM and 





Cellular mechanisms of insulin resistance 
 
   
Figure 7 Summary of inflammation and changes to energy metabolism secondary to adipocyte 
dysfunction in obesity (Samuel and Shulman 2012) 
 
The main sites involved in the normal cellular cycle of energy homeostasis are the 
liver, skeletal muscle and adipose tissue with additional signaling from the brain. 
Following insulin secretion, inhibition of hepatic gluconeogenesis occurs with the 
promotion of lipogenesis and glycogenesis to conserve dietary sources of energy. 
Glucose transport into skeletal muscle increases with similar accumulation of 
glycogen stores and inhibition of lipolysis in adipose tissue (Figure 7). 
 
In obesity, the excess of dietary fuels coupled with reduced energy expenditure alters 
the cellular environment significantly, giving rise to various hypotheses on the 
complex aetiological pathways of IR. Lipotoxicity, inflammation, hypoxia and 
mitochondrial dysfunction with associated endoplasmic reticulum stress (ERS), also 
known as the unfolded protein response (UPR), have all been cited, with actions in 
the liver and skeletal muscle. 
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A complete understanding of the interrelationship of the multiple pathways involved 
in IR in humans is not yet known but extensive work using animal models, 
summarised in two detailed reviews discussed here, have provided greater insights 




Ectopic lipid accumulation and high concentrations of circulating free fatty acids (or 
non-esterified fatty acids, [NEFA]) alter intracellular signaling. Following cellular 
entry, esterification of fatty acids by coenzyme A followed by coupling with a 
glycerol backbone leads to the formation of secondary messengers diacylglycerol 
(DAG) and ceramide which have been associated with IR in mouse models and 
humans. Ceramides also have a structural role in the cell membrane where they are 
found in high concentration. Diacylglycerols activate members of the protein kinase 
C family (PKC), which catalyze the phosphorylation of a wide variety of protein 
targets and are also involved in diverse signaling pathways.  
 
Excess lipids in skeletal muscle are associated with activation of the novel PKC 
isoform PKCθ, giving rise to the potential link between increased lipid 
concentrations and altered cellular signaling in IR. Other novel isoforms including 
PKCε and PKCδ have been implicated in both muscle and hepatic IR via changes to 
insulin receptor substrate 1 (IRS-1). IRS-1 is a signaling adapter protein which has a 
key role in transmitting signals from extracellular insulin and insulin-like growth 
factor (IGF-1) to intracellular pathways e.g. the MAPK pathway (mitogen-activated 
protein kinases), which communicates signals to nuclear DNA following tyrosine 
phosphorylation of IRS-1.  
  
Considering the central role of the liver in glucose homeostasis, hepatic steatosis as 
seen in non-alcoholic fatty liver disease (NAFLD), a condition characterized by 
insulin resistance and obesity, is a significant contributor to systemic IR. The direct 
relationship between hepatic IR and ectopic fat is illustrated in congenital 
lipodystrophy (CL), a rare autosomal recessive condition, where subjects have 
minimal subcutaneous fat stores and thus deposit fat ectopically; consequently, they 
develop hepatic steatosis and marked IR. Studies in lean subjects with CL have 
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shown that acute treatment with leptin to reduce appetite, lowers caloric intake and 
promotes a reversal in the histology and degree of IR (Petersen, Oral et al. 2002). In 
obese subjects with poorly controlled T2DM, a hypocaloric diet produced similar 
findings with an 85% reduction in hepatic fat, accompanied by improvements in 
hepatic insulin sensitivity and fasting glycaemia after 8 weeks on the diet (Lim, 
Hollingsworth et al. 2011). These results highlight the significant contributory role 
of the liver in systemic IR however do not confirm exclusivity in the process that is 
clearly a combination of altered cellular function within a number of tissues.  
 
Unfolded protein response 
The unfolded protein response (UPR) is initiated secondary to the accumulation of 
unfolded or misfolded proteins within the lumen of the cellular endoplasmic 
reticulum (ER). The aim of the UPR is to restore normal cellular function through 
activation of signaling pathways to produce chemical “chaperones” involved in 
protein folding. This process is mediated by three “arms” of the UPR, inositol 
requiring enzyme-1 (IRE1α), PKR-like ER kinase (PERK) and activating 
transcription factor-6 (ATF6), which reduce unfolding by three methods; increasing 
membrane synthesis and concentration of chaperones and preventing further protein 
translation. Chaperones that induce the UPR are known to impair insulin signaling 
whereas those that reduce the UPR improve it, suggesting an association with IR 
(Ozcan, Cao et al. 2004, Ozcan, Yilmaz et al. 2006). 
 
Hypoxia 
A growing body of evidence in obese and lean healthy subjects has confirmed strong 
associations of chronic and short-term systemic hypoxia with IR and progression to 
T2DM (Foster, Sanders et al. 2009, Siervo, Riley et al. 2014). Obstructive sleep 
apnoea (OSA), characterised by recurrent airway collapse, reduced sleep duration 
and intermittent sleep, affects 60-80% of obese subjects who are at significantly 
greater risk of multiple morbidities including T2DM, cardiovascular disease and 
various cancers. Potential mechanisms linking OSA with glucose intolerance in 
obesity include increased adipocytokine concentration and the generation of reactive 
oxygen species (ROS), perturbations in the hypothalamic-pituitary-adrenal (HPA) 
axis and activation of the autonomic system (Aurora and Punjabi 2013). 
 46 
Furthermore, the failure of angiogenesis to meet the demands of hypertrophied and 
increased adipocyte mass in obesity is thought to promote hypoxia.                                                                                      
 
The role of hypoxia in systemic IR may be independent of hepatic and obesity 
related pathways. Rodent studies by Iiyori et al., examined the effects of acute 
hypoxia on measures of IR following hyperinsulinaemic euglycaemic clamp studies, 
in lean and otherwise healthy animals following a 9 hour exposure period (Iiyori, 
Alonso et al. 2007). Intermittent hypoxia was associated with acute insulin resistance 
and reduced skeletal muscle glucose utilisation however interestingly there was no 
change to hepatic basal glucose output in these non-obese animals, suggesting a 
potentially greater hepatic contribution to systemic IR with obesity.  
 
Recent data from the Caudwell Xtreme Everest Research Group has shown that 
chronic (hypobaric) hypoxia has strong associations with progressive IR in healthy 
subjects in the context of active and significant weight loss (Siervo, Riley et al. 
2014).  A collaborative UK team ascended Mount Everest to the summit (8848m) 
over a total of 8 weeks. As the partial pressure of oxygen steadily declined (SpO2 
98% at sea level and 82% at 5300m), concentrations of fasting insulin and C-peptide 
increased by more than 200%, associated with a paralleled rise in the counter-
regulatory hormones glucagon and adrenaline and mean weight loss of 7.3k±5.0kg 
(p<0.001). Despite these hormonal drives to mobilise energy stores and increase 
plasma glucose in response to the physiological stress, levels remained stable 
throughout indicating adequate pancreatic β-cell compensation. Markers of oxidative 
stress including glutathione, 4-hydroxy-2-neonenal (4-HNE) and isoprostanes were 
sequentially measured in addition to the inflammatory biomarkers Il-6, TNFα and 
macrophage inhibitory factor (MIF). Positive correlations were observed for HOMA-
IR with both Il-6 (r=0.74, p<0.001) and 4-HNE (r=0.42, p<0.001) and an important 
association between oxidative stress (4-HNE) and inflammation (Il-6) was identified 
(r=0.48, p<0.001).  
 
A review of the current evidence has shown that the presence of obesity and other 
co-morbidities such as OSA, make an important contribution to IR and influence the 




Unlike the other mechanisms of IR discussed in this section which can be 
independent of obesity, the relationship of inflammation and T2DM, appears to be 
mediated by nutritional excess and increased adipose stores (Figure 8) (Hotamisligil 
2006). Over the past decade, the significant role of inflammation in the development 
of chronic diseases has become accepted. The positive net effect of acute 
inflammation in tissue repair remains important, however the deleterious 
associations of chronic low-grade inflammation with cardiovascular disease, 
neurodegenerative conditions and multiple cancers have provided mechanistic 
insights and identified pathways for the development of possible therapeutic 
interventions (Couzin-Frankel 2010). 
In the obese state, adipose tissue expresses a number of pro-inflammatory cytokines 
of differing primary origin, most likely as a consequence of immune cell infiltration 
in response to the expanding adipocyte (Table 6). The production of further 
chemotactic signals increases macrophage recruitment and potentiates the 
inflammatory response. Histological examination of fat tissue in obese mice and 
humans by Cinti et al., found that >90% of macrophage infiltration was localised to 
adipocyte cell debris, suggesting a possible clearance role although it is unclear 
whether apoptosis is a direct response to obesity or inflammation (Cinti, Mitchell et 
al. 2005).  Tumour necrosis factor (TNFα) and interleukins IL-1, IL-1β and IL-6 
have strong associations with T2DM (Donath and Shoelson 2011) and have been 
proposed as candidates for prediction of T2DM in combination with the acute phase 
protein CRP, synthesized by the liver in response to IL-6 stimulation (Wannamethee, 
Lowe et al. 2007, Wannamethee, Sattar et al. 2008, Lee, Adler et al. 2009).  
Interestingly a prospective study by Wannamethee et al., found that in 3,599 men 
aged 60-79 years with 108 incident cases of T2DM, the association of IL-6 with 
T2DM was independent of obesity and IR, in contrast to leptin (Wannamethee, Lowe 
et al. 2007).  
Two intracellular signaling pathways, NF-κB and JNK appear to have an important 
role in the pathogenesis of T2DM in response to metabolic stress and inflammation 
via activation of the kinases IκB kinase-β (IKKβ) and JUN N-terminal kinase (JNK) 
(Donath and Shoelson 2011). IKKβ activates the transcription factor nuclear factor-
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κB (NF- κB), which in turn promotes further inflammatory gene expression in the 
liver and adipose tissue. The increase in secretion of TNFα, IL-1β and IL-6, not only 
affects local tissues but more distant sites including skeletal muscle, the myocardium 
and vascular endothelium (Donath and Shoelson 2011).  
A significant increase in JNK activity has been observed in adipose and hepatic 
tissues in obesity. Exposure to ER stress, FFA and cytokines, particularly TNFα, 
activates JNK and downstream transcription factors ELK1, ATF2 and JUN. The 
detailed mechanism of   aberrant signaling in IR is not fully understood but JNK 
inhibits insulin action via serine phosphorylation of IRS-1 in a similar fashion to 
inhibition by PKC as detailed earlier (Hirosumi, Tuncman et al. 2002). 
 
Figure 8 The cycle of inflammation in T2DM  
In response to excess fuel-mediated stress, local production of cytokines and chemokines occurs in 
insulin-sensitive tissues: interleukin‐1β (IL‐1β), tumour necrosis factor (TNF), CC‐chemokine ligand 
2 (CCL2), CCL3 and CXC‐chemokine ligand 8 (CXCL8). Beta-cell production of IL-1 reception 
antagonist (IL-1RA) is reduced, enhancing the immune response and inflammation both within the 
islets and systematically (Donath and Shoelson 2011). 
 
 
Beta cell failure 
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Although obesity is associated with systemic IR and varying degrees of glucose 
tolerance, only a sub-set of those affected progress to T2DM, at a critical point when 
β-cell failure occurs.  
Under normal conditions, glucose metabolism increases the ATP:ADP ratio, causing 
closure of ATP-sensitive K+ channels and depolarisation of the plasma membrane. 
Voltage-gated Ca2+ channels within the cell wall are then activated, allowing an 
influx of Ca2+ required for vesicle release and exocytosis of insulin into the systemic 
circulation.  
Other mechanisms of glucose stimulated insulin secretion, mediated by pyruvate 
generated from intracellular glucose metabolism, have recently been explored. 
Mitochondria of the β-cell express the enzymes pyruvate kinase (PC) and pyruvate 
dehydrogenase (PDH), which enable pyruvate entry, from glycolysis, into the 
tricarboxylic acid cycle (TCA cycle).  This process of pyruvate cycling is part of an 
anapleurotic process where metabolic intermediates such as oxaloacetate and malate 
are generated within the TCA cycle prior to joining cytosolic pathways that 
ultimately return to pyruvate therefore promoting β-cell decompensation. These 
pyruvate cycling pathways are now known to be involved in glucose stimulated 
insulin secretion and identification of specific pathways is a focus of on-going 
research (Muoio and Newgard 2008). 
The production and deposition of toxic amyloid fibrils produced by β-cells from islet 
amyloid polypeptide, is another potential mechanism of β-cell decompensation. 
Examination of islet cells from subjects with T2DM has confirmed the presence of 
amyloid fibrils within the plasma membrane which are associated with accelerated 
β–cell apoptosis, reduced first phase insulin response and low β–cell mass 
(Matveyenko and Butler 2006).   
High-risk individuals have abnormal glucose tolerance for many years prior to a 
formal diagnosis of T2DM. From a review of the data, it is clear that the insidious 
onset of β-cell failure is multifactorial and most likely to be a consequence of 
metabolic overload in conjunction with oxidative stress and the UPR, increased 
cellular apoptosis, failures within the secretory mechanism of insulin granules and 
heightened genetic risk (Figure 9).  
 50 
 
Figure 9 Mechanisms of β-cell failure in type 2 diabetes (Muoio and Newgard 2008) 
 
Adipokines 
Adipose tissue is considered to be an active endocrine organ, secreting a large 
number of peptide hormones and cytokines collectively known as adipokines. These 
include inflammatory mediators, angiogenic proteins and metabolic regulators, 
which possess paracrine and autocrine effects. Via complex signaling mechanisms 
that are not fully understood, adipokines are involved in modulation of blood 
pressure, inflammation, atherosclerosis, lipid and glucose metabolism. The 
production of adipokines is not exclusive to white adipose tissues (WAT) since 
secretion of certain adipokines has been identified in multiple tissues; in pregnancy, 
the role of the placenta as a source remains unclear (Sattar, Wannamethee et al. 
2008).  
Following expansion via increases in cellular number and hypertrophy, as seen in 
obesity, certain adipokines have been identified as being strongly associated with 
metabolic disease in adults, including pregnancy (Briana and Malamitsi-Puchner 
2009).  
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Table 6 Summary of main cytokines implicated in the pathogenesis of metabolic dysfunction 
Primary Source Cytokine 
Adipose tissue Adiponectin (possible placental secretion) 
Leptin (placental secretion) 
Visfatin 
Resistin 
Retinol binding protein 4 (RBP4) 
Monocyte chemotactic protein-1 (MCP-1) 
Macrophages and T-Cells Interleukin-6 (IL-6)* 
Tumour necrosis factor (TNFα)* 
Endothelium  Plasminogen activator inhibitor-1 (PAI-1) 
Tissue Plasminogen Activator (tPA) 
*Also expressed by adipose tissue in obesity  
Adiponectin 
The plasma concentration of adiponectin, synthesized predominantly in adipocytes 
through expression of the ADIPOQ gene, is known to be inversely associated with 
improved glucose metabolism and appears to provide a good ‘read-out’ of whole 
body insulin sensitivity. In a recent meta-analysis low concentrations of adiponectin 
were associated with increasing BMI and found to be strongly predictive of type 2 
diabetes (Li, Shin et al. 2009).  
Low concentrations of adiponectin, as seen in obese women, have also been 
implicated with an increased risk of GDM. Differences have been observed not only 
at 24-28 weeks’ coinciding with routine OGTT screening but as early as 11-13 
weeks (Lacroix, Battista et al. 2013).  More recently, significant associations 
between pre-pregnancy concentrations of adiponectin and subsequent GDM have 
been described in women with prior normal glucose tolerance (NGT) (Hedderson, 
Darbinian et al. 2013). 
Hedderson et al. performed a nested case controlled study of women participating in 
the Kaiser Permanente Northern California Multiphasic Health Check Exam (1984-
1996) with median time from blood test to pregnancy of 6.2 years. Women with 
GDM (n=256) had significantly lower concentrations of adiponectin (7.7µg/ml ±3.5 
v 10.6µg/ml ±4.4, p<0.001).  Linear regression analysis, combining the additive 
effects of low adiponectin (defined as <10.29µg/ml) and obesity (BMI≥25kg/m2), 
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increased the odds of GDM 7 fold compared to lean controls with normal 
adiponectin concentrations (OR 6.7, 95%CI [3.6-12.5]) (Hedderson, Darbinian et al. 
2013).  
There is no compelling evidence thus far that pre-gravid concentrations of 
adiponectin change over the course of pregnancy for women with NGT or GDM, 
despite the normal accretion of additional adipose tissue and possible placental 
production of adipokines (Saben, Lindsey et al. 2014) however appropriate 
longitudinal data is extremely limited. In a prospective cohort of 445 women, of 
whom only 38 developed GDM, the change in adiponectin concentration from the 1st 
(6-13 weeks’) to 2nd trimesters (24-28 weeks’) was non-significant within or between 
the two groups (NGT -0.25±4.66 µg/ml, p=0.27; GDM 0.03±5.24 µg/ml, p=0.97 and 
between groups p=0.72) (Lacroix, Battista et al. 2013).  
Other established adipokines 
As a consequence of obesity, increased secretion of additional cytokines of different 
cellular origin, known to impair insulin signaling and thus compound IR, have been 
confirmed. These include adipose visfatin, leptin and resistin, IL-6 and tumor 
necrosis factor (TNFα) from macrophages and plasminogen activator inhibitor-1 
(PAI-1) and tissue plasminogen activator (tPA) from the endothelium. In contrast to 
adiponectin, these all have a positive relationship with metabolic disease (Rasouli 
and Kern 2008, Sattar, Wannamethee et al. 2008).   
Hepatic Biomarkers 
As previously discussed (Lipotoxicity in obese women, 1.3.3.1, page 41), the storage 
capacity of adipose tissue is often exceeded in obesity. In turn promotion of ectopic 
fat deposition particularly in the liver occurs, affecting the secretion of hepatic 
derived biomarkers alanine transaminase (ALT), gamma-glutamyl transferase (GGT) 
and the acute phase protein, C-reactive protein (CRP), all associated with increased 




Maternal overweight and obesity 
Several reviews have described the relationship between aberrant adipokine 
secretion with adverse metabolic consequences in pregnancy, notably GDM and PET 
but published data in specifically obese pregnancies are few (Briana and Malamitsi-
Puchner 2009, Miehle, Stepan et al. 2012).  
Ramsay et al. highlighted important changes in measures of glucose and lipid 
metabolism in the 3rd trimester (see 1.3.3, page 39) and were one of the earliest 
groups to confirm significant differences in the concentration of a selection of 
adipokines (Ramsay, Ferrell et al. 2002).                                                                                                                          
A continuous relationship between maternal glucose concentrations, C-peptide and 
BMI with selected inflammatory mediators at 24-28 weeks’ gestation has now been 
confirmed by the authors of the HAPO study who examined a sub-set of 1481 
women (mean BMI 28.4±4.8kg/m2) (Lowe, Metzger et al. 2010). This unique and 
important study is the largest of its kind and shows an association between maternal 
glucose and inflammatory mediators in overweight women without diabetes. As FPG 
increased, mean adiponectin concentrations reduced, paralleled by rise in CRP and 
PAI-1; similar patterns were observed for 1 and 2 glucose values at OGTT for the 
same biomarkers, which remained significant following adjustment for BMI and C-
peptide. Resistin was the only adipokine measured that did follow a continuous 
upwards trend across the same glucose categories used in the main study  however 
the greatest mean concentration of resistin was found in the highest categories for 
BMI and C-peptide (The HAPO Study Cooperative Research Group 2008).                       
It has been proposed that the increase in inflammatory mediators in obese pregnant 
women may play a role in fetal growth regulation by modulation of placental 
nutrient transport in addition to maternal glucose homeostasis. In the HAPO cohort, 
adiponectin and CRP were inversely associated with birth weight, neonatal skin fold 
thickness and total body fat (estimated using anthropometry) and PAI-1 with sum of 
skinfolds only (p<0.05 for all) (Lowe, Metzger et al. 2010).  
The inclusion of neonatal adiposity measures extending into early childhood is 
required in the design of future large studies, to explore this hypothesis further.  
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The Placenta 
Rather than acting as a simple physiological conduit, the contributory role of the 
placenta in the overriding inflammatory state during an obese pregnancy is an area 
currently under investigation. Denison et al. measured the concentration and gene 
expression of a selection of pro-inflammatory cytokines such as IL-1b, IL-6, IL-8 
and TNF-α in the placenta and plasma of 80 obese and non-obese women (Roberts, 
Riley et al. 2011). Of the cytokines measured, only plasma concentrations of IL-1b 
(3.03pg/ml±0.38 v 1.77pg/ml±0.15, p=0.001) were greater for obese women with a 
trend towards significance for TNF-α (1.8pg/ml±0.59 v 0.8pg/ml±0.16, p=0.06) 
whereas in placentas from the same women, expression of receptor m-RNA was 
significantly greater for IL-1b, IL-8, and the chemokine MCP-1 in obese women. 
The immune cell population was similar between the two groups and the only 
structural difference found, was an increase in placental blood vessel wall muscle 
thickness for obese women with equivalent macro and microscopic findings.  It is 
unclear whether the vascular changes seen are a response or potential protective 
adaptation to the pro-inflammatory state in obesity. 
Subsequent studies of smaller number (n=24) have reported alterations in the 
expression of genes related to lipid and cytokine activity, in keeping with placental 
inflammation and suggestive of a lipotoxic environment with increased oxidative 
stress (Saben, Lindsey et al. 2014).  
1.4 Glucose homeostasis and mechanisms of insulin resistance 
in normal and obese pregnancies 
Dynamic alterations in glucose homeostasis and insulin sensitivity occur from early 
through to late pregnancy to match the energy demands of the developing feto-
placental unit. A 10-15% reduction in maternal fasting glucose is observed in the 
first trimester accompanied by changes in insulin secretion and increased peripheral 
sensitivity, particularly in skeletal muscle (Nelson, Matthews et al. 2010). Basal 
hepatic gluconeogenesis maintains normal glucose tolerance however with 
advancing gestation, a clear pattern of insulin resistance (IR) develops with a 50-
70% decrease in insulin sensitivity and 200% increase in insulin secretion observed 
in normal pregnancies (Catalano, Tyzbir et al. 1992). Multiple systems and 
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interactions underlie the overall state of insulin resistance although exact 
mechanisms are not fully understood.  
Normal adaptations to the hypothalamic-pituitary axis result in increased secretion of 
growth hormone and cortisol, paralleled by a rise in hepatic production of cortisol 
binding globulin (CBG) in response to placental oestrogens which serve to 
antagonise the effects of insulin (Karaca, Tanriverdi et al. 2010). Placental derived 
hormones particularly human placental lactogen (hPL) and human placental growth 
hormone (hPGH) have been shown to stimulate beta cell secretion of insulin in both 
animal and human islet studies (Brelje, Scharp et al. 1993) whilst maternal adipose 
tissue secretes multiple hormones and cytokines associated  with IR and impaired 
insulin signalling including adiponectin, TNF-α, interleukin-6, leptin and resistin 
(Barbour, McCurdy et al. 2007). Increasing adiposity correlates with increased 
plasma concentrations of many of these proinflammatory adipokines, with the 
exception of adiponectin, however the influence of the distribution and accretion of 
fat depots on insulin resistance in pregnancy remains unknown (Kershaw and Flier 
2004).  
Characterisation of normal glucose profiles in pregnancy has been established using 
intermittent venous or capillary glucose measurements. The advent of continuous 
glucose sensor (CGMS) devices has enabled more precise determination of the 
pregnancy related changes to glucose homeostasis in both lean and obese subjects. 
Using CGMS, an early study by Yogev et al. examined 57 pregnant subjects during 
habitual living with no dietary restrictions over 72 hours (mean pregravid BMI 
25.7±3.2 kg/m2, mean gestational age 29.7±6.2 weeks’). Fasting blood glucose was 
4.17mmol/l (SD 0.67) and mean blood glucose 6.11mmol/l (SD 0.89). Stratification 
of the group by BMI (obese n=15 and non obese n=42) revealed significant 
differences in glucose concentrations at defined time points. Obese women had a 
greater postprandial peak with increased time to achieve this and lower mean 
nocturnal glucose. No difference was observed for fasting and mean blood glucose 
concentrations (Yogev, Ben-Haroush et al. 2004). Harmon et al. furthered this work 
to evaluate patterns of glycaemia in early and late gestation in obese women without 
diabetes (early 15.7±2.0 and late 27.7±1.7 weeks gestation) but with significant 
differences observed between fasting as well as postprandial glucose values. Obese 
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women had significantly greater exposure to glucose from the 2nd trimester onwards 
and even with a small sample size (obese n=16 and lean n=22), they were able to 
demonstrate greater adiposity in infants born to obese mothers, measured by skin 
fold thickness which correlated strongly to late pregnancy concentrations of TG and 
free fatty acids (Harmon, Gerard et al. 2011). Irrespective of the diagnostic criteria 
used to diagnose GDM, obese women clearly have abnormal glucose tolerance in 
pregnancy compared to lean controls and remain at greatest risk of developing 
GDM.  
1.4.1 Continuous glucose monitoring sensors 
Continuous glucose sensors (CGMS) enable patients with diabetes on insulin therapy 
to improve self-management, avoid the undesirable effects of hypo and 
hyperglycaemia and enhance flexibility with daily activities and diet.  
CGMS has multiple advantages over traditional self-monitoring of glucose (SMBG) 
in pregnancy. Precise timing of the postprandial glucose peak has not been 
established and there is no consensus on the optimal time to measure CBG to assess 
peak insulin response. Current accepted clinical practice varies from testing 60-120 
minutes after a meal, on waking and prior to bed. Glucose fluctuations occur rapidly 
over 24 hours independent of mealtimes therefore periods of abnormal glucose 
concentration including nocturnal hypoglycaemia remain undetected by SMBG 
alone with potential clinical implications (Gardner, Wardle et al. 2011). 
 Further studies have demonstrated improved pregnancy outcomes with regards to 
lower birth weight, reduced risk of macrosomia and improved glycaemic control 
following changes in management as a result of CGMS intervention in women with 
T1DM (Murphy, Rayman et al. 2008). Using CGMS in research eliminates the errors 
observed by Mazze et al. of under and over reporting of glucose values, inclusion of 
phantom results and omission of data by subjects, identified when modified home 
glucometers with memory chips were used in parallel with traditional log-books 
(Mann, Beedie et al. 2013).  
Given the utility of these benefits over SMBG in pregnancy, we focused on using 
this technology in this thesis to gather continuous glucose data that SMBG would 
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conceivably fail to capture. The technical aspect of CGMS will now be discussed in 
more depth. 
Sensors provide data on the direction, magnitude, frequency and duration of glucose 
changes and using component software via a Bluetooth receiver, statistical reports 
are generated. Minimally invasive devices measure the glucose concentration of 
interstitial fluid (ISF) using subcutaneous electrochemical enzymatic coated sensors 
in place of capillary blood, which is used in conventional glucometers. Since glucose 
concentrations in the ISF are dependent on the rate of blood flow, change in blood 
glucose concentration and metabolic rate, a physiological mean lag time of 6.7 
minutes occurs between the two measurements (Oliver, Toumazou et al. 2009).  
The International Organization Standard (ISO) 15197 report states that for reference 
glucose values ≤4.2mmol/l the sensor should detect a concentration within 
0.83mmol/l and for values ≥4.2mmol/l within ±20% (Louie, Markovic et al. 2013).  
 
Figure 10 Clark error grid (mg/dl) (Oliver, Toumazou et al. 2009) 
Manufacturers use Clark error grids (Figure 10), developed over twenty years ago, to 
assess the accuracy of their sensors. By plotting the sensor glucose value on the y-
axis against reference glucose on the x-axis, a clinical risk score of five categories 
can be assigned to any glucose sensor error as follows: Zone A: clinically accurate, 
Zone B: benign, Zone C: overcorrect, Zone D: failure to detect and Zone E: 
erroneous (Oliver, Toumazou et al. 2009). The grid method assumes that target 
blood glucose is between 3.9-10.0mmol/l and values in zones A and B are deemed 
clinically acceptable.    
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Neither pregnancy with its associated hemodynamic changes nor sensor location 
(upper arm or abdomen) appear to affect the accuracy of sensor glucose 
concentrations measured, as demonstrated by Feldman et al. who reported 98% of 
readings in zones A or B using the FreeStyle® Navigator in subjects with T1DM 
(Abbott Diabetes, Alameda, California) (Feldman, Brazg et al. 2003). This sensor, 
which was selected for use in this thesis, can be worn for up to 5 days and requires 
five calibrations with capillary blood glucose (CBG) at 1, 2, 10, 24 and 72 hours post 
insertion.  
1.5 Approaches to interventions in obese pregnancies 
The majority of adverse complications of obese pregnancies are strongly associated 
with pre-pregnancy BMI (Nohr, Vaeth et al. 2008) therefore it would be reasonable 
to assume that pre-conception is the optimal time to intervene and reduce maternal 
weight however since a large proportion of pregnancies are unplanned, a significant 
proportion of women would potentially be missed. Pregnancy is perceived to be a 
time of high motivation for women not only to address and maximise their own 
health but that of their unborn child, creating a potential window of opportunity for 
long-standing lifestyle changes with a positive influence on future health.  
Various early pregnancy intervention strategies including dietary (Wolff, Legarth et 
al. 2008, Thornton, Smarkola et al. 2009, Quinlivan, Lam et al. 2011) or lifestyle 
advice (Phelan, Phipps et al. 2011), physical activity (Barakat, Cordero et al. 2012, 
Oostdam, van Poppel et al. 2012) and combinations of the two (Guelinckx, 
Devlieger et al. 2010, Dodd, Turnbull et al. 2011, Vinter, Jensen et al. 2011) have 
been investigated to date. Comparison of studies is limited due to differences in 
primary outcome measures, BMI inclusion criteria and varying intensities and 
duration of interventions. Moreover few have tried to evaluate the effect of the 
interventions on behavioural change. Attempts to determine the most effective 
intervention type have been made with no clear outcome but following a meta-
analysis by Gardner et al. of behavioural based interventions targeting diet and/or 
physical activity to reduce GWG, there is a suggestion that the most successful 
interventions are those started in early pregnancy and in women who do not smoke 
(Gardner, Wardle et al. 2011).  
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Furthermore, many studies to date have been considered to be of poor design and 
underpowered although several meta-analyses have sought to provide meaningful 
conclusions (Dodd, Grivell et al. 2010, Oteng-Ntim, Varma et al. 2012, 
Thangaratinam, Rogozińska et al. 2012) whilst large scale adequately powered RCTs 
with clinically relevant primary outcomes are currently in progress, using a variety 
of lifestyle (Dodd, Turnbull et al. 2011, Adamo, Ferraro et al. 2013, Poston, Briley et 
al. 2013) and pharmacological interventions (EMPOWaR ISRCTN 51279843 & 
MOP NCT01273584). 
1.5.1 Dietary, lifestyle and physical activity interventions  
Dietary and Lifestyle 
Many studies are small but some of the larger ones are summarised here. 
Dietary interventions have been developed to target various elements and patterns of 
food intake. Phelan et al. randomized 400 women from all BMI categories between 
10-16 weeks’ gestation to receive an intervention based upon reduction of high fat 
foods, increased exercise and self-monitoring of food intake until delivery (Phelan, 
Phipps et al. 2011). Education and reinforcement were made by an initial face to face 
visit with a health trainer who discussed appropriate weight gain within the 1990 
IOM guidelines, advised 30 minutes of walking per day and set calorie goals 
(20kcal/kg). Subjects received weekly mailed material promoting healthy living and 
telephone feedback. Data from self-recorded food diaries was used in addition to 
demography taken in clinic visits at 30 weeks’ and 6 months post partum. The 
intervention significantly reduced the number of healthy weight women who 
exceeded GWG recommendations compared to the control (40.2% v 52.1%, 
p=0.003) and whilst no such effect was observed in women who were overweight or 
obese, those in the intervention arm were twice as likely to return to pre-gravid 
weight or below at 6 months post partum irrespective of BMI (OR 2.1, 95% CI [1.3-
3.5] p=0.005).  
Similar reductions in GWG have been demonstrated following dietary intervention 
in two RCTs of comparable intensity for 132 and 360 obese women respectively 
(7.0kg v 13.8kg, p=0.04) (Quinlivan, Lam et al. 2011) (7.0kg v 8.6kg, p=0.01) 
(Vinter, Jensen et al. 2011). Results however are inconsistent, with no effect on 
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neonatal outcomes observed in the main (Thornton, Smarkola et al. 2009, Guelinckx, 
Devlieger et al. 2010, Quinlivan, Lam et al. 2011, Vinter, Jensen et al. 2011).  
Luoto et al. were able to demonstrate a significant reduction in neonatal birth weight 
and incidence of LGA in women identified as high risk for GDM (BMI≥25kg/m2, 
positive family history of T2DM, previous macrosomia and age ≥40yr) following a 
dietary and exercise intervention throughout pregnancy (8-12 to 37weeks’) (Luoto, 
Kinnunen et al. 2011). Women of all BMI categories were included but conclusions 
were limited as a consequence of being underpowered. Despite this, these early 
studies have shown significant positive changes to the overall eating habits and 
lifestyle choices of obese pregnant women including diet composition and calorie 
intake, reduction of saturated fats, increases in polyunsaturated fats, improvements in 
fibre consumption and exercise undertaken (Wolff, Legarth et al. 2008, Guelinckx, 
Devlieger et al. 2010, Luoto, Kinnunen et al. 2011).  
Exercise 
Exercise is an established method of improving insulin sensitivity and overall 
glycaemic control in addition to reducing cardiovascular risk by influencing multiple 
clinical and biochemical variables associated with adverse events including HbA1c, 
SBP, anthropometry and triglycerides in subjects with T2DM (Chudyk and Petrella 
2011).  The acute effects of exercise can increase insulin mediated uptake by skeletal 
muscle by up to 40% for 16 hours, with long term effects from sustained activity 
thought to be mediated via increased GLUT 4 production (Duncan, Perri et al. 2003).  
The progression to overt diabetes in high risk individuals including those who are 
obese with known glucose intolerance can be limited but the optimal mode, 
frequency, intensity and duration of exercise is yet to be identified (Eriksson and 
Lindgärde 1991, Tuomilehto, Lindstrom et al. 2001).  
Advancing gestation and physical restriction coupled with maternal anxiety is often 
considered a barrier to exercise in pregnancy.  Most exercise-only interventions 
centre around supervised exercise classes 2-3 times a week, adapted for pregnancy 
with a qualified trainer, with or without a home based element (Ong, Guelfi et al. 
2009, Oostdam, van Poppel et al. 2009, Callaway, Colditz et al. 2010, Nascimento, 
Surita et al. 2011, Barakat, Cordero et al. 2012).  
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Barakat et al. instituted a moderate aerobic exercise programme of 35-45 minute 
sessions three times a week in lean pregnant women (mean BMI 22.7±2.8 and 
23.3±2.9kg/m2 for control and exercise groups) from early pregnancy (6-9 weeks’ 
gestation) to term with an average of 85 sessions per women, assuming no preterm 
delivery. Group classes consisted of land and aquatic activities including light 
resistance training with full supervision and the support of an obstetrician (Barakat, 
Cordero et al. 2012). Maternal glucose screen at 24-28 weeks’ revealed a significant 
reduction in venous glucose measured 1 hour after a 50g oral glucose load in the 
exercise group (5.77 v 7.10mmol/l [103.82±20.4 v 126.93±29.9mg/dl]) with no 
difference in GWG and incidence of GDM between the two groups. Importantly, the 
exercise protocol was deemed safe and acceptable to women with good adherence 
(Barakat, Stirling et al. 2008).  
Conversely, the FitFor 2 programme found no significant differences in maternal 
FBG, fasting insulin, HbA1c, BMI or birth weight following a programme of similar 
intensity in women at high risk of GDM (BMI≥30 or >25kg/m2 plus one other risk 
factor) (Oostdam, van Poppel et al. 2012).  Lack of statistical power may have 
contributed to the results however compliance was poor with only 16.3% of women 
attending half of the total number of sessions (2/week) and as perhaps expected, 
compliance decreased with progression of pregnancy. No difference in the 
characteristics of compliant versus non-compliant women was noted from 15-24 
weeks’ but interestingly thereafter, compliant women were primarily Caucasian, 
nulliparous and educated to a higher level. Current evidence suggests that 
overweight and obese women may benefit the most from such exercise programmes 
in terms of greater reductions in GWG and measures of IR compared to lean women 
but translation into acceptable large scale RCTs is lacking (Ong, Guelfi et al. 2009, 
Nascimento, Surita et al. 2011).  
Summary and safety of interventions 
This current body of work has addressed potential concerns regarding the safety of 
such interventions. Thus far, no adverse effects of limiting gestational weight gain 
within recommended limits in obese pregnant women by dietary or exercise 
interventions have been reported (Barakat, Stirling et al. 2008, Thornton, Smarkola 
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et al. 2009, Vinter, Jensen et al. 2011, Stafne, Salvesen et al. 2012, Barakat, Pelaez et 
al. 2013).  
However, caution should be heeded, because observational studies have highlighted 
deleterious consequences for those who gain less than 5kg (the lowest gain advised 
by the IOM for BMI≥30kg/m2), including adverse effects on fetal growth. The 
largest review of data to address this issue is by Catalano et al., who performed a 
retrospective analysis of 1241 overweight and obese women who had previously 
participated in prospective studies (Catalano, Mele et al. 2014). The results suggest a 
greater risk of SGA in women who gained or lost <5kg during pregnancy (18/188 
[9.6%] versus 51/1053 [4.9%] for those who gained >5kg) although the actual 
incidence of 9.6% is comparable to the background population rate of 10%. Infants 
had significantly less total and lean fat mass with smaller head circumference and 
length reflecting skeletal growth (Table 7). The risk of SGA was independent of 
maternal glucose status and the exclusion of all women with GDM from secondary 
analysis did not alter results.  
Table 7 Comparison of neonatal measurements for restricted GWG (Catalano, Mele et al. 2014) 
 Weight loss/gain <5kg 
(n=188) 
Weight loss/gain >5kg 
(n=1053) 
P value 











Birth weight (g) 3258.4 (442.7) 3466.8 (491.5) <0.0001 
Length (cm) 49.3 (2.3) 50.0 (2.8) 0.001 
Head circumference (cm) 34.2 (1.7) 34.5 (1.7) 0.02 
Lean mass (g) 2855.1 (321.0) 2995.4 (346.9) <0.0001 
Fat mass (g) 403.4 (175.3) 471.4 (192.7) <0.0001 
Body fat (%) 12.0 (4.2) 13.2 (4.3) 0.0006 
LGA 14 (7.5%) 139 (13.2%) 0.03 
SGA 18 (9.6%) 51 (4.9%) 0.009 
Data presented are mean (SD) or n (%) 
It remains unclear whether limiting GWG further, causes undesired offspring 
changes as studies reporting a lack of potential harm have also been presented but 
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unlike the study by Catalano et al., detailed neonatal measures were not taken and 
results were presented for SGA and BW outcomes only (Blomberg 2011). The DALI 
study (ISRCTN70595832), a collaborative European RCT of a vitamin D and 
lifestyle intervention in different combinations for obese pregnant women is 
currently recruiting and may provide more insights into the effects of restricting 
GWG (target sample size 880).  Women receiving dietary advice are advised to gain 
less than 5kg to achieve the primary outcome of GWG reduction. Prenatal ultrasound 
scanning will enable detailed intrauterine dimensions to be made and within 48 hours 
of birth, neonates will have full anthropometric assessment (Jelsma, van Poppel et al. 
2013).  
The effect of this weight reduction on clinically relevant outcomes is highly variable. 
In a recent meta-analysis, Oteng–Ntim et al. reported a significant reduction of 
2.21kg in obese and overweight women with an associated lower incidence of GDM 
(OR 0.80, 95%CI [0.58-1.10]) but the strength of evidence was considered low.  It is 
clear however that the optimal time to intervene for women at greatest risk for GDM 
is pre or early pregnancy (Gardner, Wardle et al. 2011, Tobias, Zhang et al. 2011) 
and evidence suggests that pre-pregnancy BMI may contribute as much to adverse 
outcomes as excessive GWG (Nohr, Vaeth et al. 2008).  
 
1.5.2 Intervention studies aimed to improve glucose metabolism and reduce 
GDM incidence 
Maternal obesity and GDM compound the risk of adverse pregnancy and long-term 
metabolic outcomes, therefore studies designed to not only reduce GWG but also 
reduce the insulin resistance of pregnancy in high-risk women are required. 
However, determining causality in positive studies to understand whether changes in 
IR are a consequence or independent of reduced GWG remains difficult. In the 
absence of any weight loss, improvements in peripheral insulin sensitivity and 
activity of lipoprotein lipase (LPL), an enzyme involved in the catabolism of 
triglyceride rich lipoproteins and strongly associated with IR, have been reported in 
sedentary adults following a six month walking programme suggesting that even 
modest exercise in pregnancy may improve glucose homeostasis (Duncan, Perri et 
al. 2003).  
 64 
Considering the strong evidence to support lifestyle changes in reducing risk of 
T2DM (Tuomilehto, Lindstrom et al. 2001, Knowler, Barrett-Connor et al. 2002, 
Lindström, Louheranta et al. 2003), results of meta-analyses regarding interventions 
to reduce GDM are contradictory, with many unanswered questions (Tobias, Zhang 
et al. 2011, Yin, Li et al. 2013). 
 
A meta-analysis by Tobias et al. included data for 34, 929 subjects, collated from 
five prospective cohorts, two retrospective case-controlled studies and two cross-
sectional study designs with a total of 2855 cases of GDM. Strong inverse 
associations (25-55% reduced risk), between physical activity (PA) before or during 
early pregnancy and GDM were found, with the greatest magnitude of change 
observed for women engaging in the highest quantiles of activity before pregnancy 
(pooled OR 0.45 [95% CI 0.28 to 0.75], p=0.002) (Tobias, Zhang et al. 2011).  
 
In contrast, a recent meta-analysis by Yin et al. identified only six RCTs of PA with 
a total of 1278 subjects (Yin, Li et al. 2013). Results were insufficient to support the 
use of PA to prevent GDM (risk ratio 0.91 (95% CI 0.57 to 1.44], p=0.68) however 
studies, inadequately powered to examine for GDM outcome, were included in the 
analysis (Callaway, Colditz et al. 2010).  
 
Extending on earlier work, Barakat et al. completed the largest RCT of PA and GDM 
using the new international classification in 510 healthy Spanish women of normal 
BMI (24.1±4.1 kg/m2 exercise group v 23.7±3.8kg/m2 control, p=0.354) following 
the same protocol as detailed previously from 15 weeks’ onwards (Barakat, Pelaez et 
al. 2013). Using both the WHO (2006) and IADPSG criteria to diagnose GDM, no 
reduction of GDM was seen between the two groups for either definition in keeping 
with findings from a large Norwegian study (n=702) that adopted a less intense 
intervention (Stafne, Salvesen et al. 2012).  To ensure moderate exercise intensity 
was achieved, subjects used heart rate monitors and the Borg scale of perceived 
exertion however neither study measured the change in activity from enrolment to 
the endpoint, which would have provided information on potential behavioural 
change. 
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The normal pregnancy-associated rise in plasma insulin concentrations, can be 
attenuated by exercise, most likely via the same mechanisms observed in T2DM, at 
least in early gestation.  A dietary intervention, designed to restrict GWG to 6-7kg, 
adhering to the official Danish dietary recommendations (fat 30E%, protein 15-
20E% and carbohydrate 50-55E% [E%, % of total energy]) successfully limited 
GWG in obese pregnant women (6.6kg v 13.3kg, 95% CI [2.6-10.8], p=0.002) and 
reduced fasting plasma insulin concentrations from 15 weeks’ onwards (Wolff, 
Legarth et al. 2008). At 27 weeks’ a 20% reduction in plasma insulin was observed 
with a further 23% reduction at 36 weeks’ (Figure 11). Corresponding group 
differences for insulin concentration were -16pmol-1 (95% CI [-32 to -1], p=0.04) 
and - 25pmol-1 (95% CI [-47 to -40], p=0.022) at 27 and 36 weeks’ respectively. The 
intervention had no effect on FBG, 12 weeks’ into the programme and although a 
significant reduction of 8% was observed at 36 weeks’ (group difference -0.3g ml-1, 
95% CI [-0.6 to 0.0], p=0.03), translation of a relatively small glucose change into 
positive clinical outcomes in a larger sample size remains questionable since 
neonatal and maternal outcomes were the same for both groups including GDM.  
Two hour glucose values following OGTT were similar between the two groups 
throughout pregnancy.  
 
Figure 11 Changes in insulin concentration during pregnancy in obese women following a dietary 
intervention. Intervetion (■), Control (□) (Wolff, Legarth et al. 2008)  
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1.5.3 Targeted postprandial glucose interventions and the glycaemic index  
To minimise the risk of excessive fetal growth secondary to maternal 
hyperglycaemia, therapeutic strategies aimed at achieving near-normal glucose 
concentrations without the undesired effects of hypoglycaemia are required.  
Dietary advice remains the cornerstone of treatment for GDM, with increasing use of 
second line therapies particularly insulin and metformin for women who are unable 
to achieve adequate control with dietary changes alone (Dornhorst and Frost 2002, 
NICE 2015). Two seminal RCT’s have unequivocally demonstrated that treatment of 
mild glucose intolerance in pregnancy improves neonatal and maternal outcomes 
(Crowther, Hiller et al. 2005, Landon, Spong et al. 2009). In the Australian 
Carbohydrate Intolerance Study in Pregnant Women (ACHOIS), women with mild 
glucose intolerance randomised to the intervention group received dietary advice and 
only commenced insulin when fasting and/or postprandial blood glucose targets 
were exceeded on more than two occasions. A significant reduction in serious 
perinatal complications was achieved in the intervention arm and although 20% of 
women in this group were commenced on insulin to optimize glucose control, it is 
important to highlight that the majority of women were successfully managed with 
dietary advice alone (Crowther, Hiller et al. 2005).  Similarly in the Maternal-Fetal 
Medicine Unit (MFMU) study, treatment of mild GDM with diet and insulin (fasting 
BG<5.3mmol/l and 1-hr BG>10.0mmol/l, or 2-hr BG>8.6mmol/l, or 3-hr BG 
7.8mmol/l following 100 gram OGTT) reported significant reductions in multiple 
secondary outcomes including mean birth weight, shoulder dystocia, birth weight 
>4kg, incidence of LGA and cesarean delivery (Landon, Spong et al. 2009). 
The Low Glycaemic Index 
Otto and Niklas first highlighted the different glycaemic response to various foods in 
1980 with the subsequent concept of the glycaemic index (GI) food classification 
system developed by Jenkins in Toronto shortly thereafter (Jenkins, Wolever et al. 
1981). Initial studies compared a 50g portion of carbohydrate calculated from 
published food tables to a standard of 50g glucose. Following consumption of the 
carbohydrate, serial venous blood samples were taken up to 2 hours and glucose 
values plotted to determine the area under the curve (AUC). Similar methods are 
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adopted today however use of capillary blood glucose (CBG) is more frequently 
used against a standard of white bread. The AUC for each food is expressed as a 
percentage of the mean AUC for the standard, from a sample of ten subjects and 
used to calculate the GI (Wolever, Jenkins et al. 1991). The GI predicts the ranking 
of the glycaemic response of foods in an individual; foods that are digested and 
absorbed slowly raise blood glucose concentrations gradually and are thus given low 
GI (LGI) values. The division of GI values into three simple categories has 
facilitated a useable system for individuals and generated an additional tool for the 
delivery of dietary advice for healthcare professionals; high GI ≥70, medium GI 56-
69 and LGI <55.  
   
Figure 12 Schematic representation of the glycaemic response following consumption low and high 
GI food  
Inherent and important limitations of GI classification exist when applying the 
principles to the wider population and when interpreting individual responses to 
foods of different categories. Aberrations in methodology are known to affect the 
glycaemic index including food portion size and preparation, choice of standard, 
timing of test, frequency of blood sampling and the formula used to determine the 
AUC (Wolever, Jenkins et al. 1991). Subject characteristics such as age, sex, 
ethnicity, degree of glucose intolerance and co-existing disease that may influence 
glucose absorption are also confounders but attempts to standardise these factors 
would serve to limit the variability in glucose response and maintain consistencies 
across food groups tested therefore minimising the effect on overall GI (Pi-Sunyer 
2002). 
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Low GI and obesity 
The evidence for the use of LGI diets in clinical scenarios has been evaluated in a 
series of systematic reviews from the Cochrane Library (Thomas, Elliott et al. 2007, 
Tieu, Crowther et al. 2008, Thomas and Elliott 2009, Han, Crowther et al. 2013).   
The 2007 review for obesity (in non-pregnant subjects) included six eligible RCTs 
with a total of 202 subjects. The duration of LGI diet was wide, ranging from 5 
weeks’ to 6 months and with only 2 studies including a follow-up period, 
interpretation of results beyond the study duration is limited. Obese and overweight 
subjects who followed the LGI diet had significantly greater weight loss (weighted 
mean difference -1.1kg, 95% CI [-2.0 to -0.2]) and reductions in total cholesterol and 
LDL concentrations compared subjects on standard or high GI diets (WMD -0.22 
mmol/l, 95% CI [-0.43 to -0.02] and WMD -0.24 mmol/l, 95% CI [-0.44 to -0.05] 
for standard and high GI respectively) (Thomas, Elliott et al. 2007). Subsequently, 
Liu et al. demonstrated a significant reduction in serum glucose and insulin AUC 
(42% and 29% respectively) when comparing diets of LGI/low carbohydrate to high 
GI/high carbohydrate in overweight and obese people (Liu, Most et al. 2012). The 
reduction in glycaemia and insulinaemia was sustained over the course of the 12 
hour test day, following early morning test meal consumption, suggesting a 
prolonged effect of an LGI diet. 
Low GI and diabetes 
The Cochrane review of 2009 and an earlier meta-analysis both concluded that a 
modest, yet clinically useful, reduction in glycated hemoglobin (HbA1c) of 0.5% can 
be achieved with a LGI diet in the management diabetes, equivalent to the changes 
observed with single-agent pharmacotherapy (Brand-Miller, Hayne et al. 2003, 
Thomas and Elliott 2009). Similar limitations of small sample size and variation in 
duration of diet were reported and both papers included participants with T1 and 
T2DM, which differ significantly in their pathogenesis; the former mediated via 
autoimmune destruction of pancreatic islet cells and the latter via multiple altered 
pathways involving vascular, hepatic, inflammatory and adipose dysfunction, 
contributing to insulin resistance. The included studies did not detail changes to 
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weight or biomarkers associated with T2DM, which may have provided some 
mechanistic insight into how LGI carbohydrates influence glucose homeostasis.    
Low GI and pregnancy 
At present, data from two systematic reviews is inconclusive to support universal 
recommendation of LGI diets to prevent or treat GDM in pregnant women (Tieu, 
Crowther et al. 2008, Han, Crowther et al. 2013) however dietary GI is associated 
with maternal glucose metabolism and fetal outcomes for all women and not just 
those with GDM.  
The Camden study was a prospective analysis of dietary GI calculated from three 24 
hour recall questionnaires over the course of pregnancy, to explore associations 
between GI, glucose metabolism and fetal outcomes in 1082 women. A positive and 
significant relationship between GI, maternal HbA1c and plasma glucose 1 hour 
following 50g GCT was observed at 24-28 weeks’ gestation. Using co-efficients 
from regression analysis, the authors calculated expected glucose values for the top 
and bottom quintiles of GI and found reductions for both in favour of an LGI diet: a 
difference of 2.2% and 4.2% for HbA1c and plasma glucose respectively was 
observed (Scholl, Chen et al. 2004). Similarly, GI was positively related to fetal 
growth. Following adjustment for GA only, a GI in the lowest quintile was 
associated with a 100g reduction in BW that increased to 116g when all possible 
confounders were included.  
For women with established GDM, the adoption of an LGI diet following 
unsuccessful attempts to control glycaemia with generalised dietary advice can 
significantly reduce the progression to insulin therapy, without compromise to 
pregnancy outcomes (Moses, Barker et al. 2009).  
Louie et al. conducted a systematic review of LGI diets in pregnancy for women of 
all BMI categories including three studies complicated by GDM (Louie, Brand-
Miller et al. 2010). Of the eight studies included, half showed positive influence of a 
LGI diet on pregnancy outcomes, with a reduction in LGA reported in two but a 
moderate increase in the delivery of an SGA infant in one. A study by the same 
authors, included in the review, compared the effects of a LGI versus moderate-high 
GI (HGI) diet from 12 weeks gestation in a fairly low intensity study of 5 face-to 
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face consultations with no inclusion BMI restriction (n=70) (Moses, Luebcke et al. 
2006). Both diets were in line with Australian guidelines for nutrition in pregnancy 
(dietary intake of fat 30% and carbohydrate 55%) and no specific requirements were 
made about total energy, fat or fibre intake. Women in the LGI arm, had infants with 
significantly lower birth weight, birth centile and ponderal index but rates of SGA 
for both arms were the same. The positive reductions in fetal size were independent 
of GWG and insulin resistance (HOMA-IR and fasting insulin), which were similar 
between the two groups at 36 weeks’ and although women in the HGI were 
statistically heavier at enrollment, the actual difference in BMI was small (BMI: LGI 
24.4±0.7 kg/m2 and HGI 26.6±0.9kg/m2, p=0.04).  
In the main, LGI diets have been shown to be safe in pregnancy with no adverse 
maternal effects reported but issues regarding restricted fetal growth have been 
identified in the previously discussed Camden study. A small but increased risk of 
SGA for women with a dietary GI in the lowest quintile (GI <50) compared to those 
in the third quintile (GI 54-56) was observed with no change to the incidence of 
LGA with increasing GI. These concerns surrounding birth weight, identified by this 
prospective study, have not been reproduced in subsequent studies and will continue 
to be addressed by ongoing larger intervention trials.  
 
1.5.3.1  Randomised controlled trials of LGI interventions in high risk 
pregnant women 
The three largest RCTs aimed at lowering the GI of the diet, in conjunction with 
supporting a healthy lifestyle in high risk pregnant women have completed 
recruitment (Walsh, McGowan et al. 2012, Briley, Barr et al. 2014, Dodd, Turnbull 
et al. 2014) and two have published the outcomes (Walsh, McGowan et al. 2012, 
Dodd, Turnbull et al. 2014). Whilst the Pregnancy and Glycaemic Index Outcomes 
Study (PREGGIO) from Australia did not specifically recruit obese women and 
included those with NGT, the results are nonetheless relevant and merit discussion 
(Moses, Casey et al. 2014). The study evaluated the effect of LGI dietary advice 
compared to routine healthy eating with both arms receiving equivalent support and 
contact from the research team and dietician from 20 weeks’ onwards. In contrast to 
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an earlier but smaller study from the same group (Moses, Luebcke et al. 2006) (see 
1.5.3, page 66), no significant differences were observed for the primary outcomes of 
birth weight, birth centile or ponderal index. The failure to replicate the findings in 
the larger cohort with women of similar characteristics, is perhaps unsurprising since 
the control in PREGGIO was a healthy diet, re-enforced with dietary counselling, in 
contrast to the high GI diet, reflective of habitual diet, used in the earlier study.  
 
ROLO (ISRCTN 54392969) 
The ROLO study hypothesized that an LGI diet would reduce recurrence of 
macrosomia in subsequent pregnancies for women who had previously delivered an 
infant >4000g versus standard antenatal care with no dietary advice (n=781, mean 
BMI 26.8kg/m2) (Walsh, Mahony et al. 2010). No difference in the primary outcome 
was observed but positive findings were noted for those following the LGI diet in 
relation to reduction of GWG and improvements in glucose tolerance. At 40 weeks’ 
gestation, women following the LGI diet gained 1.5kg less weight than controls 
(mean difference -1.3, 95% CI [-2.4 to -0.2], p=0.01) and fewer exceeded the 2009 
IOM guidelines for GWG  (38% v 48% for LGI and control respectively). Both FPG 
and 1 hour glucose following 50g glucose challenge test were significantly lower in 
the LGI group although the incidence of GDM following 100g glucose load was no 
different (Walsh, McGowan et al. 2012).     
 
LIMIT (ACTRN12607000161426) 
LIMIT was the first adequately powered lifestyle intervention RCT for obese and 
overweight pregnant women with 2212 participants recruited to a combined 
programme of dietary and exercise advice, in conjunction with behavioral strategies. 
This was delivered over three visits with a research dietician and reinforced by 3 
additional telephone consultations with trained assistants (Dodd, Turnbull et al. 
2014). Dietary advice was not principally centered on LGI principles but 
incorporated food exchanges, increased fibre and fruit consumption and reduction of 
refined sugars to maintain a eucaloric diet and a global effect of lowering overall GI 
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(Dodd, Turnbull et al. 2011). The primary outcome of a reduction in LGA incidence 
(birth weight ≥90th centile for gestational age and sex) was not met against the 
control of routine antenatal care. Pregnancy outcomes including diagnosis of GDM 
and GWG were the same apart from a small reduction in risk for the secondary 
outcome of macrosomia in the intervention group (15% v 19%, RR 0.83, 95% CI 
[0.68-0.99], p=0.04).  
 
UPBEAT (ISRCTN 89971375) 
The (UK Pregnancies Better Eating and Activity Trial) UPBEAT, which has recently 
completed recruitment and will soon report on clinical outcomes, is multi-center 
RCT of a complex dietary and physical activity intervention aimed at improving 
glucose homeostasis in obese pregnant women (n=1555). Following randomisation 
at 15+0-17+6 weeks’ gestation to intervention or standard antenatal care, the 
programme is delivered over eight weekly group sessions with a health trainer until 
OGTT at 27+0 – 28+6 weeks’ gestation. The objective of the dietary recommendation 
is to reduce the GI and glycaemic load (GL= GI x carbohydrates (g)/100) using food 
swaps and to exchange saturated fatty acids (SFA) for monounsaturated (MUFA) 
and polyunsaturated fats (PUFA).  Women maintain contact with the research team 
with three further structured visits until delivery where dietary data, blood samples 
and anthropometry are obtained. Within 72 hours of birth, a detailed anthropometric 
assessment of the baby is made which is repeated at the 6 month postnatal review.    
The study endpoints include maternal and neonatal primary outcomes of GDM 
diagnosed by 75g OGTT using the recommendations of the IADPSG (IADPSG 
2010) and LGA delivery defined as adjusted birth weight >90th centile for gestational 
age using customised centiles, where adjustment is made for maternal height, weight, 
ethnicity, parity, and infant sex (Gardosi, Figueras et al. 2011). 
Extended details of the intervention and protocol will be discussed in methods 
(Chapter 3, page 78) and are available on the trial web site 
(http://www.medscinet.net/upbeat/about.aspx). 
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A pilot trial was undertaken in 183 women in four urban UK hospitals, to evaluate 
changes in dietary and physical activity behaviours in response to the intervention, to 
trial all aspects of the protocol and to undertake process evaluation (Poston, Briley et 
al. 2013). Baseline habitual diets for all women were similar with no differences in 
the following; total energy intake, GI, GL and macronutrient composition.  





Difference (95% CI) P Value 
Energy intake 
(MJ/d) 
7.71 (2.30)     6.75 (2.57) -0.94 (-1.72 to -0.18) 0.016 
Dietary GI (%) 60 (26) 53 (13) -7 (-15 to 0) 0.054 
Dietary GL (g/d) 146 (55) 111 (39) -33 (-47 to -20) <0.001 
GL (%E) 31.3 (13.3) 26.6 (8.0) -4.8 (-8.5 to -1.0) 0.013 
Carbohydrate 
(%E) 
48.2 (8.0) 50.0 (8.2) 1.7 (-1.0 to 4.4) 0.207 
Protein (%E) 15.5 (3.2) 17.1 (4.9) 1.5 (0.1 to 2.8) 0.034 
Protein (g) 70.6 (24.0) 66.5 (23.5) -4.8 (-12.3 to 2.6) 0.204 
Total fat (g) 35.9 (7.7) 32.5 (7.4) -3.2 (-5.6 to -0.8) 0.010 
SFA (%E) 12.9 (3.9) 11.1 (3.8) -1.6 (-2.8 to -0.3) 0.015 
MUFA (%E) 11.6 (4.0) 10.4 (3.2) -1.0 (-2.2 to 0.2) 0.088 
PUFA (%E) 5.9 (2.8) 6.0 (2.7) 0.13 (-0.8 to 1.1) 0.774 
P:S ratio 0.51 (0.35) 0.64 (0.52) 0.13 (-0.01 to 0.28) 0.075 
NSP (g) 10.5 (4.2) 12.0 (6.0) 1.77 (0.08 to 3.47) 0.040 
Abbreviations: GI glycaemic index, GL glycaemic load, MUFA monounsaturated fatty acid, NSP 
non-starch polysaccharide, P:S ratio polyunsaturated fatty acid: saturated fatty acid ratio, PUFA 
polyunsaturated fatty acid, SFA saturated fatty acids, %E percentage energy 
Results are given as mean (SD) for variables at 28 weeks gestation. Comparisons are adjusted for 
baseline levels throughout.  
At 28 weeks gestation, there was a significant reduction in total energy intake, GL, 
total fat and SFA with an increase in fibre consumption (non-starch polysaccharides, 
NSP) for the intervention group (Table 8). Groups entered the study with a medium 
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GI diet (58) but after 8 weeks of adherence to the programme, a borderline 
significant 7-point reduction in the GI was achieved, with the intervention group diet 
reclassified as LGI (difference -7 [95% CI -15 to 0], p=0.054).  On completion of the 
study, analysis will determine if these positive dietary changes are maintained 
throughout pregnancy and beyond and whether they translate into favourable clinical 
outcomes.  
 
In summary, for all the pregnancy interventions discussed, the additional 
commitment over and above the time required for routine antenatal care is a severe 
limitation. Poor compliance and high dropout rates are greatest in women from 
ethnic minorities and those who have not received higher education (Callaway, 
Colditz et al. 2010, Vinter, Jensen et al. 2011, Oostdam, van Poppel et al. 2012). 
Authors have attempted to facilitate participation by various means including local 
delivery, provision of transport to research centres and regular phone, postal and 
email contact but greater understanding of barriers particularly to increased PA is 
needed.                                                                                                                          
 
Adequately powered RCTs are required to determine if sole or combination 
interventions are successful in improving maternal, obstetric and offspring outcomes 
and whether they have real translational potential as a therapeutic option for obese 
pregnant women. Pragmatic study designs that encourage and support pregnant 
women, which can adapt to meet the cultural requirements of the local population, 
are essential.  
 
1.5.4 Prediction of GDM 
Not all obese women develop GDM, however this heterogeneity poses a burden on 
limited resources with all women with a BMI≥30kg/m2 currently managed as if at 
risk, often resulting in sub-optimal management. Accurate and early identification of 
pregnant obese women who will subsequently develop GDM women would enable 
early risk stratification, more appropriate use of health care resources and targeting 
of potential intervention strategies.  
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Currently, the UK National Institute for Health and Care Excellence (NICE) 
recommend selected rather than universal GDM screening, according to risk factors, 
which include obesity. Women who have previously delivered a macrosomic infant, 
have had previous GDM, or who have a first degree relative with diabetes and high-
risk ethnicity are also screened. A systematic review of screening for GDM 
undertaken for a health technology assessment (HTA) reported low sensitivities (50–
69%) and specificities (58–68%; eight studies) when traditional methods of risk 
factor screening were used (Scott, Loveman et al. 2002).  
In this thesis, a preliminary investigation was undertaken to determine whether the 
addition of a panel biomarkers to routine clinical measurements further improves 
prediction of GDM. For this purpose we studied 117 women participating in a pilot 
trial for the UPBEAT study and sixteen biomarkers frequently implicated in the 
pathogenesis and prediction of GDM and/or type 2 diabetes. These reflect 
inflammatory pathways, markers of adipose tissue function, hepatic fat accumulation 
and vascular dysfunction (Sattar, Wannamethee et al. 2008, Savvidou, Nelson et al. 
2010, Ferreira, Rezende et al. 2011). Prediction models were then developed 






The changes in fat distribution in obese pregnant women who develop GDM differ 
from those with normal glucose tolerance in pregnancy, with a preference for central 
and upper body accumulation and subsequent alterations in the secretion of 
adipokines. Using this information in conjunction with differences in clinical 
measures, more accurate prediction of GDM in obese women, than current strategies 
yield, can be made. 
Specific aims: 
In the UPBEAT pilot study:  
1. Examine longitudinal changes in maternal biochemistry and adiposity.  
2. Assess any effect of the intervention on maternal biochemistry, including non 
esterified fatty acids  (NEFA) and adiposity. 
3. Develop a prediction model to identify those at greatest risk of GDM, which 
shall be repeated on completion of the whole study. 
 
2.2 Improving glycaemic profiles in obese pregnant women 
(IGPOP) 
Hypothesis 
The consumption of a slow digesting, low glycaemic index (SD-LGI) nutritional 
supplement in obese pregnant women will attenuate the postprandial glycaemic 
response compared to a eucaloric supplement of equal macronutrient composition 
with a corresponding reduction in plasma concentrations of insulin and C-peptide. 
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Specific Aims  
 
1. To obtain data on glucose, insulin and C-peptide response in obese pregnant 
women following administration of a nutritional supplement compared to control 
supplement. 
2. To examine the immediate and prolonged effects of consumption of a SD-LGI 
supplement on blood glucose concentration and further investigate the glucose 
lowering effect of the supplement when consumed as part of a mixed meal or in 
isolation as a snack. 
3. To determine the normal glycaemic profile of obese pregnant women following 
habitual diet using continuous glucose monitoring.  
4. To inform the design of a large scale RCT to demonstrate the benefits of the 
nutritional supplement on maternal and infant outcomes.  
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3 METHODS: UK PREGNANCIES BETTER 
EATING AND ACTIVITY TRIAL (UPBEAT) 
The pilot study for UPBEAT was performed at 4 urban centres in the UK: Guy’s and 
St.Thomas’ NHS Foundation Trust (London), King’s College Hospital Foundation 
Trust (London), The Southern General and Princess Royal Maternity Hospitals 
(Glasgow) and The Royal Victoria Infirmary (Newcastle), between March 2010 and 
April 2011.  
Ethical Approval: NHS Research Ethics Committee approval was obtained in all 
contributing centres (UK IRAS integrated research application system; reference 
09/H0802/5).  
3.1 Recruitment 
Eligible subjects were identified using maternal demographics used for outpatient 
clinic lists and were approached by a research assistant at the first antenatal 
ultrasound scanning appointment. Verbal and printed information was provided and 
followed up with a call from a research midwife (RMW) after a minimum of 24 
hours. For those who were willing to participate, the 1st study visit was scheduled a 
week later between 15+0-17+6 weeks’ gestation and for those who declined, consent 
was sought to record basic demography including BMI. Active screening for 
undiagnosed T2DM in those with previous GDM with HbA1c or FBG was not 
performed. If available, postnatal data on diabetes status was used.  
Inclusion criteria: Obese women, BMI≥30kg/m2, with a singleton pregnancy 
between 15+0-17+6 weeks’ gestation and no history of GDM or glucose intolerance in 
the index pregnancy.  
Exclusion criteria: pre-existing diabetes, metformin therapy, coeliac disease, pre-
existing renal disease or essential hypertension, systemic lupus erythematosus (SLE), 
antiphospholipid syndrome, sickle cell disease or thalassemia and current psychosis. 
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A flowchart summarizing the study protocol and principle research visits, together 
with a brief description of data obtained at each visit in the UPBEAT pilot study is 
given below.   
3.2 Protocol 
Recruitment (15+0-17+6 weeks’ gestation) 
Following informed consent, information was obtained on demography, maternal 
and family history and current pregnancy health. Randomisation to the intervention 
or control arms, which consists of standard antenatal care, occurred at the second 
appointment, approximately one week later (7-10 days) between 16+0 and 18+6 
weeks’ gestation by a secure internet based data management system 
(MedSciNet™). The randomisation schedule was minimised according to ethnicity, 
parity (0 vs >= 1), age and BMI (30-34.9kg/m2 vs 35-39.9kg/m2 and >40kg/m2). For 
all centres, study visits and data collection took place in a clinical research facility or 
the antenatal outpatients department with a dedicated RMW. 
Pre-pregnancy BMI was confirmed from patient hand-held antenatal notes 
documented at the first routine antennal visit with a midwife at approximately 8-12 
weeks’ gestation and measured at the first study visit to ensure eligibility. Height 
was measured using the free standing Leicester Measure® stadiometer and weight 
with the Marsden® digital scales in light clothing, without footwear. If BMI was 
<30kg/m2 at this visit, subjects were excluded.  
Blood pressure was recorded using the Microlife® BP3BT0-A automated blood 
pressure monitor which is validated for use in pregnancy and following appropriate 
training, maternal skinfold thickness (triceps, biceps, subscapular and supra-iliac) 
were measured in triplicate with Harpenden skinfold calipers (validated for values 
≤80mm) (Holtain Ltd, Wales, UK) in addition to the following circumferences: 
waist, mid arm, thigh and hip. Total sum of skinfolds was calculated at four sites 


























Potentially eligible women contacted by research midwife 
Agrees to take part 
First appointment (15+0-17+6 weeks’ gestation)                          
Consent, BMI, eligibility check, demography and socioeconomic status, 
dietary assessment, attitudinal assessment questionnaire, accelerometer 
provided 
Second Appointment (1 week later)         
Randomisation, dietary assessment, accelerometer data downloaded, 
EPDS, EQ-5D, RPAQ questionnaires, anthropometry, weight, blood 
samples 
Control Arm: Standard antenatal care Intervention Arm 
8 weekly sessions with health trainer 
 
Third Appointment (27+0-28+6 weeks’ gestation)      
OGTT, dietary assessment, attitudinal assessment, EPDS, 
EQ-5D questionnaires, weight, anthropometry, blood 
samples, accelerometer provided 
Declines participation    
Confirm permission to collect 
outcome data 
Fourth Appointment (1 week later)                                                 
Dietary assessment, accelerometer data downloaded, RPAQ 
questionnaire, weight 
Fifth Appointment (34+0-35+6 weeks’ gestation)                
As 3rd appointment (no OGTT) 
 
Sixth Appointment (1 week later)                         
As 4th appointment 
 
Maternal and neonatal outcome data 
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Blood and urine samples were obtained from 117 women in the three centres that 
had facilities for sample handling and storage. Serum and plasma was stored at -
80°C for future analysis. Details of sample collection and processing are discussed in 
3.7, page 84. 
A series of questionnaires were completed to obtain data on behavioral and 
psychological well being; the EuroQuol Quality of life (EQ-5D), the Edinburgh 
Postnatal Depression Scale (EPDS), and the International Physical Activity 
Questionnaire (IPAQ). Detailed dietary data was collected using the triple-pass 24 
hour recall method and the validated food frequency questionnaire (FFQ) at the start 
and end of the appointed week. Calculation of GI and macro/micronutrient 
composition was made using WISP Tinuviel software®. Physical activity (PA) was 
measured in all participants by accelerometry over two separate weeks prior to 
randomisation and post intervention at 27+0-28+6 weeks’.  
Post Intervention (27+0-28+6 weeks’ gestation) 
At 28 weeks’ gestation, following the 8 week intervention programme, all subjects 
underwent a 75g oral glucose tolerance test (OGTT) with GDM diagnosed according 
to the International Association of the Diabetes Pregnancy Study Groups (IADPSG) 
criteria (fasting blood glucose ≥5.1mmol/l or 1 hour glucose ≥10.0mmol/l or 2 hour 
glucose ≥8.5mmol/l)(IADPSG 2010). Women with GDM were referred to routine 
antenatal NHS care. At Guy’s and St.Thomas’ NHS Foundation trust, women with 
IADPSG GDM were only referred to routine NHS care if they met the local trust 
criteria for GDM. For those that did not meet these glucose thresholds, ongoing 
clinical care was provided by myself in a separate clinic with referral access to the 
main diabetes antenatal service if required.     
Late pregnancy study visits 
A further three structured visits were scheduled for the duration of the pregnancy at 
29+0-30+6, 34+0-35+6 and 36+0-37+6 weeks’ gestation for the purposes of assessing diet 
and physical activity (PA) over the period of one week. Blood samples were 
collected and maternal anthropometry measured at visit five only yielding three-time 
points for biochemical and anthropometric data in total: 
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1. Visit 2 (V2): randomisation [15+0-17+6 weeks’]  
2. Visit 3 (V3): post intervention and OGTT [27+0-28+6 weeks’] 
3. Visit 5 (V5): late pregnancy [34+0-35+6 weeks’] 
Maternal and neonatal outcome data was recorded at delivery and at the 6 months 
postnatal review.  
It should be noted that in keeping with pragmatic study design of UPBEAT, women 
only attended in the fasted state for the OGTT post intervention at visit 3 (27+0-28+6 
weeks’). Therefore all biochemistry analyses are measured on a random sample with 
only those at visit 3 fasted.  
Primary and secondary outcomes 
In this thesis the primary outcome was concentration of a panel of biomarkers 
measured at 28 weeks’ gestation following the 8-week intervention (see 3.7.3.1, page 
85 for table of 16 biomarkers). 
Secondary outcome was the development of a prediction model for GDM.   
3.3 Data collection 
All data was imputed directly into a secure, password protected online database 
system developed and maintained by Medscinet® 
(http://www.medscinet.net/upbeat/about.aspx). Information for each centre was 
available for authorised persons to review and the clinical trial manager performed 
quality control on a regular basis.  
On completion of the pilot, Microsoft® excel spread sheets of blood sample 
locations for each centre were generated using the online data export facility to 
minimize transcribing error and used to coordinate sample collection for analysis. 
All raw data used in the main analysis was exported in a similar way.  
3.4 Intervention 
The intervention was delivered in group sessions by health trainers over an 8 week 
period from 19 to 27+0-28+6 weeks’ gestation when OGTT was performed. For 
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subjects unable to attend all group sessions, contact was made via phone or email.  
Health trainers received appropriate training from the study dietician and Weight 
Concern, a registered charity (Number 1059686), with ongoing peer support 
provided throughout, in the form of educational away days for all research staff.  
 
Figure 13 Component parts of the intervention adopted in the UPBEAT pilot study 
Using the SMART model of behavioural change (specific, measurable, achievable, 
relevant and time specific) with positive feedback rather than setting predefined 
goals, women were encouraged to change their eating and PA behaviours with the 
aid of a log book (Doran 1981).  
At the initial one-to-one visit, women were given the following; pedometer, log book 
for weekly SMART goals, DVD of pregnancy specific exercises and a participant 
handbook detailing the content and theory behind the health trainer (HT) sessions. At 
each group session, different elements of dietary and PA interventions were covered 
with a review of the previous week’s SMART goals and new ones set for the future. 
Personal barriers to behavioural change were discussed amongst the group with 
potential solutions as to how these may be overcome generated.  
Dietary advice 
Specified dietary targets included a decrease in overall GI, glycaemic load (GL) and 
consumption of SFAs. A reduction in total energy intake was not a specific aim but 
this was an anticipated outcome of the dietary changes. Women were encouraged to 
exchange high GI for LGI foods, switch from drinks containing sugar to those 
Intervention  
x8 1.5hr weekly sessions with HT  
Pedometer & log book 
Exercise DVD Participant handbook 
SMART goals 
Dietary exchanges 
Low GI/GL diet,  
Reduction in free sugar & 
SFA 
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flavoured with LGI alternatives and replace saturated fats with monounsaturated and 
polyunsaturated fats. Dietary changes were discussed in the HT facilitated group 
sessions, supported by the use of visual aids and the participant handbook.  
Physical activity 
Women were advised to increase their PA by gradually increasing the time spent 
walking at a moderate level, using the pedometer as a tool to record and titrate up the 
number of steps taken.   
3.5 Control 
Women in the control arm followed standard antenatal care within each centre. They 
attended study visits at the 4 defined time points following randomisation for 
anthropometry, blood sampling and completion of questionnaires. Those diagnosed 
with GDM were seen by their hospital diabetes team according to local protocol.   
3.6 Power Calculation 
A power calculation to meet the specific aims of this thesis, that is to assess to effect 
of the intervention on the panel of biomarkers at 28 weeks’ gestation and 
subsequently develop a prediction model for GDM, was not performed. Limitations 
surrounding this are raised in the discussion.  
The total sample size (n=183) was obtained from the already completed UPBEAT 
pilot study, which was powered for a change in dietary and physical activity 
behaviours at 28 weeks’ within a predefined time limit.   
 
3.7 Blood Samples 
3.7.1 Collection 
Four venous blood samples (6ml each) were taken using standard draw procedure by 
the RMW at randomisation (visit 2), post intervention (visit 3) and late pregnancy 
(visit 5) using the Vacuette® system: 
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1. 1 plain tube with clot activator for serum 
2. 2 tubes with EDTA 
3. 1 tube with lithium heparin  
3.7.2 Processing 
Samples were retrieved within 30 minutes and centrifuged for 10 minutes 
(Eppendorf centrifuge, 10minutes, 1400g, 4oC). The serum sample was stored at 
room temperature for 30 minutes to allow for clotting, prior to being spun under the 
same conditions, followed by a further 10 minutes at 2500g.  
Up to 20 aliquots were prepared for freezing from the EDTA and lithium heparin 
samples and ≤10 for the serum, all of 250ul. The buffy coat was removed with a 3ml 
Pasteur pipette, transferred to a microtube and spun for an additional 10 minutes at 
1400g.   
Barcoded samples were scanned onto the study database prior to freezing at -80oC 
and remained on ice until such time.  
3.7.3 Biochemistry 
3.7.3.1 Biomarker selection 
The choice of biomarkers analysed in the pilot study was made upon a review of the 
current evidence discussed in section 1.3.3.2 Mechanisms of insulin resistance (page 
42).   
In this thesis biomarkers implicated in the pathogenesis of GDM which also provide 
an indirect measure of IR and lipid metabolism were analysed: plasma insulin, 
plasma total cholesterol, triglycerides, high-density lipoprotein (HDL-c), low-density 
lipoprotein (LDL-c) and high-sensitivity C-reactive protein (hs-CRP). Additional 
calculations were made for very-low-density lipoprotein (VLDL) and the following 
ratios; cholesterol: HDL and LDL: HDL. Because of the high cost of directly 
measuring HDL and LDL, the surrogate markers HDL-C and LDL-c were used, 
representing cholesterol associated with apolipoprotein A1/HDL particles. 
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Furthermore we explored to predictive ability of more novel biomarkers for GDM 
which have been used in pregnancy studies and reflect a range of inflammatory 
pathways, adipose tissue function, hepatic fat accumulation and vascular dysfunction 
(Savvidou, Nelson et al. 2010, Ferreira, Rezende et al. 2011, Lacroix, Battista et al. 
2013).  
In total 16 biomarkers were measured in this thesis as listed below and 18 reported 
including the two ratios cholesterol:HDL and LDL:HDL (Table 9).  
Table 9 Biomarkers measured in the UPBEAT pilot study 
Insulin (mU/l) Fructosamine (umol/l) 
Cholesterol (mmol/l) ALT (U/L) 
Triglycerides (mmol/l) AST (U/L) 
HDL (mmol/l) Ferritin (ng/ml) 
LDL (mmol/l) Adiponectin (µg/ml) 
VLDL (mmol/l) tPA (ng/ml) 
Cholesterol:HDL IL-6 (pg/ml) 
LDL:HDL Leptin (pg/ml) 
CRP (mg/l) Visfatin (ng/ml) 
To the best of our knowledge no other work exploring the prediction of GDM using 
these biomarkers in a specifically obese pregnant population has been performed. 
3.7.3.2 Analysis 
Plasma total cholesterol, HDL-cholesterol triglycerides, ALT, AST, hs-CRP, 
fructosamine (c311, Roche Diagnostics, Burgess Hill, UK) and ferritin (elecsys 
2010, Roche Diagnostics, Burgess Hill, UK) were measured on clinically validated 
automated platforms using the manufacturers’ quality controls and calibration 
materials. Coefficients of variation (CVs) were <6%.  
Plasma insulin was measured by an enzyme linked immunosorbent assay (ELISA) 
(Mercodia, Uppsala, Sweden) that does not cross-react with proinsulin, with an 
interassay CV <7%.  
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Baseline plasma adiponectin, IL-6, leptin (R&D Systems, Abingdon, U.K.), t-PA 
(Stago, Theale, UK) and visfatin (Phoenix peptide, Karlsruhe, Germany) were 
measured by enzyme-linked immunosorbent assay. These methods had inter-assay 
CV’s <10%.  
All analyses were performed on previously unthawed EDTA and serum samples at 
the British Heart Foundation Laboratory at the University of Glasgow.  
 
Plasma NEFA and fatty acids were measured on samples obtained after fasting for 
12 hours at 27+0-28+6 week’s gestation in the KCL Division of Nutritional Sciences.  
 
NEFA was measured on a clinically validated automated platform (Clinical Analyser 
ILab 650, Instrumentation Laboratories, Warrington, UK) using the Randox (FA115) 
kit with quality control (QC) performed after each 60 sample batch at the upper and 
lower range of the assay with the following CVs: 
 
NEFA 
QC1 target 1.24 mmol/l, %CV 0.95 
QC2 target 0.58 mmol/l, %CV 0.97 
Plasma fatty acids were measured by gas-liquid Chromatography (GC) (Bondia, 
Castellote et al. 1994). Esterified and non-esterified fatty acid methyl esters 
(FAMEs) were analysed using the one-step transesterification direct method (Lepage 
and Roy 1984). Main fatty acids peaks (C16:0, C18:0, C18:1(n-9), C18:2(n-6), 
C18:3(n-3), and C20:4(n-6) were recognised by referring to standard retention times 
(Sigma-Aldrich Co. Ltd, Gillingham, UK). C20:5(n-3) and C22:6(n-3) were 
determined by cod liver oil FAME standards (Sigma-Aldrich Co. Ltd (Gillingham, 
UK). The remaining FAs were measured by GC mass spectrophotometry (GC-MS). 
Each plasma FA concentration was determined as the area under the peak matched 
with the known standard (Sun, Ma et al. 2007). 
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3.8 Statistical analysis 
3.8.1 Analysis of the UPBEAT pilot data 
Data are presented by GDM status (GDM versus non GDM) in keeping with the 
theme of this thesis and where relevant by randomised treatment (control versus 
intervention) for the following categories: demography, maternal anthropometry, 
biomarker and NEFA analysis with baseline measurements taken at randomisation 
(15+0-17+6 weeks’).  
It is important to note that analysis comparing the overall difference for each 
biomarker as shown in Table 18 included data from all three visits. In contrast, the 
development of a prediction model for GDM using biochemical and clinical 
variables, discussed in 5.5 Prediction model for GDM (page 128), included data 
obtained at randomisation only (16+0-18+6).  
Log transformations were made for all biochemical variables following standard 
distribution checks and parametric tests, described in standard methodology, were 
used where appropriate (Altman 1990).  
The effect of randomised treatment was estimated by random effects Generalised 
Least Squares (GLS) multiple regression clustering by patient with robust standard 
errors and adjustment for visit and GDM status. GLS is a technique for estimating 
the unknown parameters in a linear regression model. The GLS is applied when the 
variance of the observations are unequal, or when there is a certain degree of 
correlation between observations as would occur during time series analyses. This 
would include measurements recorded over the course of pregnancy as in UPBEAT. 
For a comparison between women who developed GDM and those who did not, the 
same method was used but with adjustment for visit and randomised intervention 
(Arellano 1987).  
Differences between patient groups are reported as arithmetic means (SD) with 95% 
confidence intervals. Statistical significance was  <0.05.  
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3.8.2 Prediction of GDM  
The analysis was exploratory with the aim of identifying potentially useful 
combinations of clinical and biochemical predictors of maternal GDM with an aim to 
develop a multivariable prediction model. Therefore, potentially useful biomarkers 
were not excluded and no adjustment was made for multiple testing. Standard 
distributional checks (BoxCox regression and Normal distribution plots) were 
carried out, and separate decisions made on the appropriate transformation. Based on 
these findings, log transformation was made for all biochemical variables. 
Differences between patient groups are reported as geometric means and ratios of 
geometric means, with 95% confidence intervals.  
Customised birth centiles were calculated using the GROW calculator (version 6.7) 
(http://www.gestation.net/birthweight_centiles/birthweight_centiles.htm) which 
adjusts for gestational age, sex, maternal BMI, height and ethnicity, for analysis of 
the predictive power of the biomarkers on secondary clinical outcomes SGA, LGA 
and macrosomia (Gardosi, Chang et al. 1992).   
The association of clinical indicators with GDM was established using linear or 
logistic regression as appropriate, with robust standard errors.  Biochemical 
indicators were assessed as predictors of GDM, adjusting for significant clinical 
indicators.  Following univariate analysis, those variables which were identified as 
independent predictors of GDM were included in the model.  
Table 10 Summary of clinical and biochemical variables used in the development of a prediction 
model for GDM  
Clinical Measures  Biomarkers  
Age (years) Smoking status Insulin (mU/l) Fructosamine 
(umol/l) 
Height (m) Material circumference 
(cm) 
Waist, mid-arm, hip, thigh 
Cholesterol (mmol/l) ALT (U/L) 







BMI (kg/m2)  HDL (mmol/l) Ferritin (ng/ml) 
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Parity ≥2  LDL (mmol/l) Adiponectin (µg/ml) 
Ethnicity  VLDL (mmol/l) tPA (ng/ml) 
Deprivation score   Cholesterol:HDL IL-6 (pg/ml) 
Systolic BP (mmHg)  LDL:HDL Leptin (pg/ml) 
Diastolic BP 
(mmHg) 
 CRP (mg/l) Visfatin (ng/ml) 
Internal validation using discrimination to assess the overall performance of the 
markers as predictors of GDM was assessed by comparison of ROC areas.  
Calibration was not performed. Where necessary, composite predictors were derived 
using multiple logistic regression.  
All data analysis was carried out using the statistical package Stata, version 11.2 
(StataCorp, College Station, Texas). 
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4 METHODS: IMPROVING GLYCAEMIC 
PROFILES IN OBESE PREGNANCIES (IGPOP) 
The IG-POP study was designed to evaluate the glycaemic response of two 
nutritional supplements A and B, developed by Abbott Nutrition with the aim of 
blunting PPG in obese pregnant women (OP). This was the first study to trial 
palatability of the products in pregnant women and to test this hypothesis.  
Three supplements were initially developed, A, B and C with a control D.  However 
following concerns regarding palatability in the early stage of phase 1, C was 
excluded from the study. For this thesis, only A, B and D will be discussed which 
were all banana flavoured.  
For stage 2, B was redeveloped due to issues of excess sediment and the composition 
of D was modified based on stage 1 results with an increase in total fat content to 
match B. Both supplements were therefore assigned new identification codes (Table 
11). 
All study visits took place in the dedicated clinical research facility (CRF) at St. 
Thomas’ Hospital, London with a member of the IGPOP team, consisting of a 
clinical research fellow and part-time dietician.  
Ethical approval: NHS approval was granted by the Riverside South West Research 
Ethics Committee (Reference number 12/LO/0307).  
 
4.1 Dietary composition of nutritional supplements  
The detailed macro and micronutrient composition of all products used in the IG-
POP study are summarised in Table 11.  
Supplements were produced by Abbott Nutrition, Columbus, Ohio and exported to 
the UK in 8oz (237ml) ready-to-drink cartons.  
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Table 11 Detailed macro and micro nutrient composition of products used in IGPOP stages 1 and 2 











Volume of serving (oz) 8 4 8 4 4 
Frequency of serving - - - Twice a day Twice a day 
Macronutrients per 8oz    
Calories (kcal) 149 303 152 303 303 
Protein (g) 











Total Fat (g) 











Saturated fat (g) - - - - - 
Trans fat (g) - - - - - 
DHA (mg) 50 100 50 100 100 
Carbohydrate (g) 











MD 9-16 (g) 







































































Fiber (g) - - - 3.1 0 
Sugars (g) - - - 33 46 
Maltodextrin (DE20-23) 













Micronutrients per 8oz 12501RF(A) 
Low fat 
12500RF(B)







Vitamin A                (IU)  











Vitamin C (mg) 70 70 - 70 70 
Vitamin D                (IU)  











Vitamin E                 (IU)  











Vitamin K (mcg) 16.2 16.2 - 16.2 16.2 
Calcium (mg) 500 500 - 500 500 
Iron (mg) 6.1 6.1 - 6.1 6.1 
Thiamin (B1)(mg) 0.8 0.8 - 0.8 0.8 
Riboflavin (B2)(mg) 0.8 0.8 - 0.8 0.8 
Niacin (mg) 5.2 5.2 - 5.2 5.2 
Vitamin B6 (mg) 1 1 - 1 1 
Folic acid (mcg) 300 300 - 300 300 
Vitamin B12 (mcg) 2.2 2.2 - 2.2 2.2 
Biotin (mcg) 4.4 4.4 - 4.4 4.4 
Pantothenic acid (mg) 3 3 - 3 3 
Sodium (mg) 102 102 - 102 102 
Potassium (mg) 419 419 - 419 419 
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Phosphorus (mg) 476 476 - 476 476 
Iodine (mcg) 22 22 - 22 22 
Magnesium (mg) 115 115 - 115 115 
Zinc (mg) 10 10 - 10 10 
Selenium (mcg) 32 32 - 32 32 
Copper (mg) 0.5 0.5 - 0.5 0.5 
Manganese (mg) 0.6 0.6 - 0.6 0.6 
Comium (mcg) 30 30 - 30 30 
Chloride (mg) 254 254 - 254 254 
Choline (mg) 120 120 - 120 120 
 
4.1.1 Stage 2 
The macronutrient composition was equivalent for both supplements in stage two but 
the concentration of CHO sub-groups, known to affect absorption differed 
significantly, with the intervention product composed of more slow-digesting, low-
GI carbohydrates (SG-LGI) (Table 12). Supplements were produced in similar 8oz 
(237ml) cartons however subjects were required to consume 4oz twice a day with 
breakfast and as an afternoon snack at 1500hr to make up the total daily dose; 
marked measuring cups were provided for ease.  Table 11 details the breakdown of 
CHO content for both supplements per 24 hours of each test day.  
Table 12 Detailed carbohydrate breakdown of supplements used in stage 2 per 24 hours for each test 
day  
Carton size 8oz* (total daily dose) Intervention (12539RF) 
B 
Control (12551RF) D 
Glycaemic load (GL) 730 1124 
Calories (Kcal) 303 303 
Total fat (g) 











Carbohydrate (CHO) (g)        
% calories from CHO 
Rapid digesting (%) 
Slow digesting (%) 
Resistant starch (%) 













*one whole 8oz carton was consumed over each test day in two divided 4oz servings 
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4.2 Data collection and database development 
An online secure database was designed specifically for the IGPOP study and 
developed with Medscinet® (http://www.medscinet.net/igpop). This ensured paper 
free data collection since everything was recorded directly onto the database to 
minimise transcription error.  
Randomisation was programmed into the database software using the SQL Server 
randomization function that randomly selects a drink each time. Therefore the final 
supplement drink was not random since simple elimination was adopted following 
each test.  
All data including CGMS outputs was backed up in a secure encrypted file on the 
university network.  
4.3 Stage 1 
Stage 1 was single blinded and sub-divided into 1a and 1b.  
In stage 1a, the glycaemic response of A, B and D was evaluated in four categories 
of women (n=10 per group) following a standard meal tolerance test (MTT) with 
capillary blood glucose (CBG) measured at 9 defined time points, up to 240 minutes. 
Each woman was required to attend the CRF on 3 separate occasions with a 
minimum 2 day washout period between visits.  
1. Lean non-pregnant [LP] (BMI ≥18.5-≤24.9kg/m2) 
2. Obese non-pregnant [ONP] (BMI ≥30kg/m2) 
3. Lean pregnant [LP] (BMI ≥18.5-≤24.9kg/m2 – self reported pre-pregnancy 
BMI) 
4. Obese pregnant [OP] (BMI ≥30kg/m2 -self reported pre-pregnancy BMI) 
In stage 1b, the GI of the drink with the lowest AUC from stage 1a was 
calculated. Ten healthy, lean women (BMI ≥18.5-≤24.9kg/m2) attended the CRF 
on two separate occasions for a MTT for the test drink and a 50g glucose 
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standard. Standard GI methodology was followed and is detailed in the protocol 
(Brouns, Bjorck et al. 2005). 
 
4.3.1 Recruitment  
Non-pregnant participants were recruited through a local advert distributed to all 
students and staff of King’s College London’s via the university email service.  
Pregnant women were approached by a member of the IGPOP team at routine 
antenatal and fetal scanning clinics at Guy’s and St Thomas’ NHS Foundation Trust 
(GSTT) at 12 or 20 weeks gestation. Pre-pregnancy BMI was ascertained in advance 
from data held on the Terranova® heath ware system uploaded by community 
midwives at the 1st antenatal visit.  
Following the initial contact a patient information sheet was provided to all 
interested women and after a minimum of 48 hours, a follow-up telephone call made 
to discuss participation and arrange the first visit if verbal consent was given. 
Written consent was obtained by all women at the 1st face to face appointment with 
the study team.   
Participants were offered complimentary taxi transport for all appointments.   
Inclusion criteria for stages 1a and 1b 
• Minimum age 18-40 years including age at conception                                                        
• Able to understand and write English (to enable written informed consent 
including pregnancy testing for those in the non-pregnant groups in 1a and 
1b)                                      
• Able to attend CRF on at least four occasions for stage 1a and two for stage 
1b               
• Appropriate BMI for each category (early pregnancy BMI, confirmed from 
antenatal booking notes for obese and lean subjects)                                                                                            
• 24-28 weeks’ gestation at first study visit for those in the pregnant groups 
(LP & OP) 
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Exclusion criteria for stages 1a and 1b 
• Multiple pregnancy                  
• Suffering from any medical condition known to independently influence 
weight, body composition or biochemistry including, but not limited to, 
thyroid disturbances, lupus, autoimmune polyglandular syndrome (APS), 
treated hypertension, Cushing’s disease, cancer, HIV/AIDS, renal disease, 
liver disease, familial hyperlipidaemia, past history of diabetes (Type 1, 2, 
and gestational) and polycystic ovary syndrome (PCOS). 
• Gestational diabetes in index pregnancy diagnosed by local clinical trust 
guidelines (fasting blood glucose ≥6.1mmol or 2 hour glucose ≥7.8mmol 
following a 75g OGTT).  
• Lactose, gluten or wheat intolerant 
• Receiving treatment or currently suffering from an untreated eating disorder 
• Currently following a modified diet 
4.3.2 Sample size 
Sample size in stage 1 complies with standard published GI testing methodology, 
which recommends a sample size of ten subjects to generate clinically useful GI 
values with 80% power at a level of p<0.05 (two tailed) (Brouns, Bjorck et al. 2005).  
4.3.3 Protocol 
Stage 1a 
Preparation and arrival 
Women attended the CRF at 0830hr fasted for all 3 (instead of the original 4) visits, 
following the withdrawal of drink C. 
Detailed instructions for study day preparation were sent in advance (Appendix 1: 
IGPOP Supplementary documents, page 191). The overnight fast commenced at 
2200hr following a 30-50g CHO meal (example meals were included) and avoidance 
of strenuous activity and caffeine was advised.  
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Height was measured using the free standing Leicester Measure® stadiometer and 
weight with the Marsden® digital scales in light clothing, without footwear. Non-
pregnant women were excluded if BMI did not meet the inclusion criteria for the 
group and for pregnant women, pre-pregnancy BMI was re-confirmed from antenatal 
notes.  
Blood pressure was recorded using an appropriate cuff with the Microlife® BP3BT0 
automated device, validated for use in pregnancy. A medical and drug history 
including vitamin supplements was taken and urinary pregnancy testing performed to 
confirm status of the non-pregnant women.  
Supplement Drinks 
For the MTT, each supplement drink provided the equivalent of 46g of carbohydrate 
in a total volume of 500ml. Owing to the different CHO composition of the 
supplements per 8oz carton (237ml) (Table 11), preparation was slightly different to 
ensure standardisation:  
1. Drink A-x2 8oz cartons (474ml) mixed with water to a final volume of 500ml 
2. Drink B-x1 8oz carton (237ml) mixed with water to a final volume of 500ml 
3. Drink D-x2 8oz cartons (474ml) mixed with water to a final volume of 500ml  
Following baseline measurement of CBG at 0 minutes, the drink was consumed over 
a maximum of 5 minutes and subjects were free to drink water over the next 240 
minutes. If the 0min CBG test was ≥6.1mmol, in keeping with impaired fasting 
glycaemia (IFG), subjects were excluded from the study.  
CBG Measurements 
Capillary blood glucose was measured at 9 time points using a calibrated Abbott 
FreeStyle® Navigator glucometer assigned to each women for the study. 




Completion of test 
During the test participants were asked to complete an online palatability 
questionnaire. At the end, concerns regarding any aspect of the test were discussed 
and participants were given a snack prior to leaving the CRF. 
Primary and secondary outcomes  
The primary outcome of stage 1a was capillary blood glucose concentration 
measured at 9 time points to determine AUC for each drink in each of the 4 
categories of obese and lean pregnant women. The secondary outcome was to 
identify any issues regarding palatability for supplements A and B particularly in the 
pregnant groups to inform the study design of stage 2.  
 
Figure 14 Flow chart for stage 1a for the 4 different groups (total n=40) 
Stage 1b 
Following the analysis of stage 1a data, a decision was made by the research team 
with Abbott Nutrition to use drink B in stage 2. Therefore in stage 1b, the GI value 
of drink B was determined in 10 healthy women.  
The recruitment process and inclusion/exclusion criteria were identical to the 
selection of non-pregnant women in 1a who were invited to participate again.  
Visit 1 
• Arrive fasted 0830hr 
• CBG at 0 minutes 
• consume drink A , B or D 
(control) 
• CBG measured at 8 time points: 
• 15,30,45,60,90,120,180 & 240 
minutes 
Visit 2 
• Arrive fasted 0830hr 
• CBG at 0 minutes 
• consume drink A , B or D 
• CBG measured at 8 time points: 
•  15,30,45,60,90,120,180 & 240 
minutes 
Visit 3 
• Arrive fasted 0830hr 
• CBG at 0 minutes 
• consume drink A , B or D 





Standard published methodology for GI testing was used (Brouns, Bjorck et al. 
2005). For this, a minimum of 10 subjects with no significant past medical history 
are required to consume a 50g CHO serving of the test food and 50g of glucose as 
the standard. Serial CBG are measured over 120 minutes to calculate the AUC which 
is then expressed as a percentage of the mean AUC for the standard (Wolever, 
Jenkins et al. 1991).  
Preparation and arrival 
This was the same as for stage 1a. Participants were required to attend the CRF for 2 
test days with a minimum 2 day washout. 
To provide 50g CHO of supplement drink and standard, the following volumes were 
given: 
1. Drink B: 257ml 
2. Standard: 273ml of Lucozade Original® (70kcal/100ml) 
After the baseline CBG was taken (0min), supplements were consumed within 5 
minutes and once again water was permitted.  
CBG Measurements 
Capillary blood glucose was measured at 7 time points up to 2 hours using a 
calibrated Abbott FreeStyle® Navigator glucometer assigned to each women for the 
study. 
Timing of CBG measurements: 0, 15, 30, 45, 60, 90 and 120 minutes 
Completion of test 
A snack was given prior to going home and any concerns addressed.  
Primary outcome  
The primary outcome measure was glucose AUC following 50g CHO of drink B and 
the standard (Lucozade Original®).  
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4.4 Stage 2 
Stage 2 was a single blinded randomised crossover design in obese pregnant women. 
The aim was to evaluate the immediate and extended effects on glucose and insulin 
concentrations, following consumption of the control or intervention (drink B) as 
part of a controlled diet using CGMS. The study was divided into three distinct 48 
hour periods (intervention/control, washout and intervention/control) and subjects 
were required to attend the CRF twice, on the 1st day of each test phase. 
4.4.1 Recruitment 
Recruitment was the same as for pregnant women in stage 1. As these women were 
naive to CGMS, all were invited to attend a screening visit to assess competency 
using the system and offered a trial wearing the sensor at home.   
Participants were offered complimentary taxi transport for all appointments.   
Inclusion criteria 
• Singleton pregnancy with minimum age at conception of 18-40 years 
• Early-pregnancy BMI ≥ 30 kg/m2 
• 24+0 -28+6 weeks’ gestation at 1st study visit 
• Able to understand and write English and give informed consent 
• Able to attend the CRF on a Thursday and consecutive Monday according to 
the protocol 
Exclusion criteria 
Exclusion criteria were the same as those used in stage 1. Following randomisation, 
participants were excluded if GDM was diagnosed in the time window between 
consent and the 1st test day or suspected during the course of the study. In this 
circumstance, women were referred to the local diabetes department for a 75g 
OGTT.   
4.4.2 Sample Size 
The study was a randomised crossover design of intervention versus control in obese 
pregnant women. In the protocol development phase, the power calculation detailed 
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below was based on the assumption that the analysis would be performed using the 
mean glucose concentrations derived from CGMS (AUC).  
Preliminary analysis of raw CGMS data by Dr Garcia at Seplin Solutions revealed 
high intra-day variability with 13 women randomised to sequence 1 
(intervention/control) and 9 to sequence 2 (control/intervention), which was shown 
to have introduced substantial bias in using the mean CGMS data. To correct for 
this, a random subsample of 16 patients (n=8 for sequences 1 and 2) was selected for 
analysis using linear regression with mixed modelling. This is expanded in section 
4.5.2 Statistical analysis for IGPOP page 110. 
The findings of previous studies in obese pregnant women informed the power 
calculation.  Harmon and Yogev, found the SD for glucose measurements in obese 
pregnant women to be 13 or 12 mg/dl respectively (Yogev, Ben-Haroush et al. 2004, 
Harmon, Gerard et al. 2011). It is felt that a difference of 0.5mmol/l (9mg/dl) in 
glucose measurement when comparing standard diet versus intervention diet is likely 
to be clinically and scientifically important. This 9 mg/dl is also similar to the 
differences found under various conditions between obese and normal weight 
women (Harmon, Gerard et al. 2011). We know of no robust data on correlations 
between repeated measures of serum glucose in diabetic subjects and therefore 
considered a range of plausible values (correlation coefficients: 0.1, 0.3, 0.5, and 
0.7), with a mean of 9mg/dl and SD of 12.5mg/dl based on values (12 and 13) from 
the two papers.    
 
Correlation coefficient (r) 0.1 0.1 0.1 0.3 0.3 0.3 0.5 0.5 0.5 0.7 0.7 0.7 
Sample size (n) 15 20 22 15 20 22 15 20 22 15 20 22 
Power (%) 54.7 67.0 71.7 65.4 77.7 81.4 79.6 89.6 92.2 95.0 98.6 99.2 
Table 13 Summary of power calculation for Stage 2 
 
Previous studies using a similar LGI product by Abbott Nutrition, known as 
Glucerna® in T2DM (n=15 and mean participant BMI 30kg/m2), demonstrated 
significant improvements to postprandial glycaemia (data courtesy, Abbott 
Nutrition). This suggested that a study of 22 subjects would be adequate even for 
very low correlation coefficients (e.g. < 0.5 commonly found in biochemical 
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measurements, repeated over short time intervals). Taking into consideration 
participant drop out and incomplete data we aimed to recruit 25 women.  
4.4.3 Protocol 
A flow chat outlining the key features of stage 2 is shown below (Figure 15).  
Pre-study visit 
All women were required to have a visit 1-2 weeks’ prior to the study with the 
clinical research fellow. The aim was to give women the opportunity to handle the 
CGMS device and learn how to perform a calibration with a CBG test using the in-
built glucometer. This was also an opportunity for the women to ask any questions 
about the sensor and explain the relevant additional features, particularly the alarm 
systems. Information sheets on how to care for the device including precautionary 
everyday measures e.g. around water, were also provided. By the end of the 
appointment, a joint decision based on competency and confidence was made 
regarding progression to the study.  
Menu options for the controlled diet were discussed and meal choices selected. All 
dietary preferences and allergies were documented on the database.  
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Figure 15 Summary of IGPOP Stage 2 by individual day 
 
CGMS: Abbott FreeStyle® Navigator 
The Abbott FreeStyle® Navigator was used which has 3 components (Table 16):  
1. The subcutaneous sensor coated with glucose oxidase (GOx).  
2. The transmitter connecting to the sensor and worn over the skin. 
3. The receiver unit, which links wirelessly to the transmitter using bluetooth™ 
technology within a 3m range.  
 
Interstitial glucose concentration is measured via a concentration-dependent current 
generated by the movement of electrons from an oxidation reaction between ISF 
glucose and GOx. In the FreeStyle® Navigator, glucose oxidase is cross-linked with 
an osmium mediator to directly capture the electrons from the initial oxidation 
reaction in contrast to other commercially available devices which measure electron 
movement from the indirect production of hydrogen peroxide. The addition of this 
mediator enables the sensor to operate at very low voltage potentials (40mV) thus 
preventing interference from other ISF constituents (Oliver, Toumazou et al. 2009).  
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The system requires calibration with CBG using the in-built glucometer at five 
specific time points: 1, 2, 10, 24 and 72 hours. The receiver alarms prompts the user 
to perform a CBG test on each occasion and only begins to record glucose following 
a successful 1 hour calibration initially. 
The system allows for meal markers to be set by the user for analysis of post-
prandial glucose changes. Women were taught how to use this feature at the pre-
study visit and encouraged to demonstrate this again under supervision again during 
CRF test days.  
The sensor is approximately the size of a penny and made from a plastic material. A 
spring-loaded device was used to insert the sensor under aseptic technique into the 
subcutaneous fat to a depth of approximately 5mm and width <1mm. Although 
studies have demonstrated no difference in the performance and accuracy of the 
system when sited on the upper arm or abdomen, all women preferred the upper arm.  
Data collected from participants was uploaded from the receiver via Bluetooth™ 
onto the CoPilot® Health Management System designed specifically for the 
FreeStyle® Navigator.  
a)                                                                      b) 
            
Figure 16 a) The Abbott FreeStyle® Navigator system components and b) Subcutaneous position of 
the CGMS sensor 
Dietary intake 
A standardised diet with a low residue and medium to high dietary GI reflecting the 
“average UK diet” (National Diet and Nutrition Survey 2008/2009, Food Standards 
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Agency:http://tna.europarchive.org/20110116113217/http://www.food.gov.uk/multi
media/pdfs/publication/ndnsreport0809.pdf) (Aston, Gambell et al. 2008) was 
provided for the two 48 hour test periods (days 1 and 2 [Thursday, Friday] and day 5 
and 6 [Monday, Tuesday]). On days 1 and 5, breakfast and lunch were provided in 
the CRF with the remaining food and supplement drinks measured out by research 
staff and packed to take home. Women were advised to eat at similar times on each 
test day and asked to return all empty drink cartons.  
A half carton (4oz) of the intervention/control drink was to be consumed twice a day 
and a marked measuring cup was provided: 
1. At breakfast (0830hr)-with cereal instead of milk 
2. As an afternoon snack at 1500hr 
A copy of the menu choices developed by a research dietician is included in the 
appendix (12.5 Meal Choices For IGPOP Stage 2, page 208). An example menu for 
the CRF test days with composition, calculated using standard food tables and WISP 
dietary software is shown below (Table 14). Unlimited water and black tea/coffee 
without sugar were permitted and a daily milk allowance was included.  
 
Table 14 Example of Menu A consumed on CRF test days (days 1 and 5). Alternative food choices 
are given in the appendix 













09.30 Breakfast               
Cornflakes (17g variety pack)  61 14 1 2 0 1 93 
Test or control supplement  152 23 17 7 4 2 27* 
Meal total 212 37 18 9 4 2 
 13.00 Lunch               
Branston macaroni cheese (395g) 376 55 6 13 11 2 35 
Cheddar cheese (60g) 219 0 0 14 18 0 34 
Nature's Finest Tropical Fruit Salad 
pot (in juice) 113g 67 14 13 3 0 1 50 
Meal total 662 69 19 30 29 2 
 15.00 AFTERNOON               
Test or control supplement  152 23 17 7 4 2 27 
18.30 DINNER                
Sainsbury’s spinach and ricotta 
cannelloni (400g)  595 55 12 20 31 7 
 Ambrosia chocolate custard (150g) 171 28 22 5 4 1 38 
Meal total 766 83 34 25 35 8 
 20.30 SUPPER & MISC               
Philadelphia tub (35g) snack 55 1 1 3 4 0 34 
Philadelphia tub (35g) snack 55 1 1 3 4 0 34 
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Poppy and sesame thin crackers x 4 80 10 0 2 4 1 65 
Sainsbury’s grape pack (80g) 53 12 12 0 0 1 46 
Meal total 243 25 16 8 12 2 
 
        Meal total excluding supplements 1883 214 86 71 80 14 
 Total  2035 237 102 78 84 15   
Dietary data were generated using the WISP dietary data software  
*Estimation of GI. For test supplement, GI given is calculated form Stage 1b IGPOP.   
Preparation and arrival 
Preparation and arrival for study days was identical to stage 1. A participant’s 
handbook was designed which contained “handy hints” on how to calibrate the 
sensor, manage alarms or warning symbols and reconnect with the transmitter if 
connection was lost (i.e. >3m range is exceeded) (hard copy enclosed in appendix). 
It also included healthy dietary advice, a food diary to record all intake during the 
study and full contact details of the research group.  
Before each study day, the date and time on each paired receiver/transmitter were 
checked, all batteries replaced and any previous glucose data from preceding 
participants uploaded onto Co-pilot® and deleted from the receiver. 
The sensor was inserted on day 1 (Thursday) by the research team who encouraged 
all women to perform the 1 hour calibration themselves under supervision to ensure 
correct initialisation. On day 5 (Monday) the old sensor containing data from the 1st 
test phase and weekend habitual period was removed on arrival and a new one sited. 
As a result, there was a time gap of missing data prior to the 1st 1 hour calibration of 
the new sensor.  During the hour wait before calibration, a venous cannula was 
inserted in the antecubital vein and the randomised drink prepared. 
Meal Test 
Blood samples were taken every fifteen minutes from 0-210 minutes and glucose 
was measured on the YSI 2300 STAT Plus™ glucose and lactate analyser (Yellow 
Springs Instrument, Ohio, USA) in the CRF on each occasion prior to processing.  
Sample time points were: 0, 15, 30, 45, 60, 75, 90, 105, 120, 135, 150, 165, 180, 195 
and 210 minutes. 
 107 
Following confirmation that the sensor was working correctly, the 0min blood 
sample was taken and the intervention/control drink consumed within 5 minutes. 
During the meal test women were shown how to complete the food diary and any 
queries were discussed.  The 2 hour sensor calibration was also performed in the 
CRF and all sensors checked to be working correctly at regular intervals.  
Completion of test 
The pre-measured food was provided with the appropriate number of supplements 
prior to departure. The research dietician explained the menus again, stressing the 
importance of adherence to the controlled diet until midnight on the Friday (day 2) 
when habitual diet could be followed until fasting on Sunday night in preparation for 
the next study day on Monday; non-adherence to the controlled diet was identifiable 
from CGMS readings and data for such subjects was excluded from analysis. All 
consumables such as glucose test strips, lancets and a sharps bin plus a CGMS quick 
reference guide including contact telephone numbers were provided.  
Primary and secondary outcomes  
The primary outcome of stage 2 was measurement of plasma glucose, insulin and C-
peptide concentrations following ingestion of a SD-LGI drink to evaluate the acute 
response (up to 210 minutes) in a controlled environment compared to a drink of 
rapidly digesting CHO.  
Secondary outcomes included measurement of the prolonged effects of the SD-LGI 
drink on glucose concentrations (up to 48 hours) and evaluation of habitual glucose 
profiles in obese pregnant women at 24-28 weeks’, using CGMS for both.  
4.4.4 Blood samples 
Fifteen venous blood samples were taken on each of the two study days at the CRF 
to provide an immediate measure of the plasma glucose concentration, and a sample 
for later measurement of C-peptide, insulin, NEFA and triglyceride concentrations. 
Insulin, C-peptide and glucose were measured at all 15 time points, and TG and 
NEFA at 5 time points: 0, 60, 120, 180 and 210 minutes. 
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4.4.4.1 Collection and processing 
Using aseptic technique, an initial 1ml of blood representing the “dead space” within 
the cannula was aspirated and discarded. A further 2ml was then aspirated for 
analysis and divided into 3 tubes:  
1. 0.75ml-EDTA (red) for TG and NEFA  
2. 0.5ml-Lithium heparin (orange) for YSI glucose assay. 
3. 0.75ml-Sodium heparin plasma (yellow) for insulin and C-peptide 
Lithium heparin samples were analysed directly from whole blood at room 
temperature on the YSI analyser. Regular maintenance of the instrument was 
performed by the clinical research fellow in accordance with manufacturer’s 
guidelines, following appropriate training.  
The remaining samples were processed within 5 minutes and centrifuged for 10 
minutes (Eppendorf centrifuge, 10minutes, 1400g, 4oC). Single aliquots were 
prepared and barcoded samples were scanned onto the study database prior to 
freezing at -80oC.  
4.4.4.2 Analysis 
Plasma TG and NEFA were measured on a clinically validated automated platform 
(Clinical Analyser ILab 650, Instrumentation Laboratories, Warrington, UK) using 
the IL Triglyceride and Randox (FA115) kits in the KCL Division of Nutritional 
Sciences. Quality control (QC) was performed after each 60 sample batch at the 
upper and lower range of the assay with the following CVs: 
 
Triglycerides NEFA 
QC1 target 1.10 mmol/l, %CV 2.39 QC1 target 1.24 mmol/l, %CV 0.95 
QC2 target 3.00 mmol/l, %CV 1.12 QC2 target 0.58 mmol/l, %CV 0.97 
 
Plasma insulin and C-peptide were measured using manual ELISA kits (Mercodia, 
Uppsala, Sweden) at the MS2 SAS Peptide Hormone Laboratory, Royal Surrey 
County Hospital, Guildford, UK.  All standards, controls and samples were assayed 
in duplicate and for any sample yielding a result above the top standard, repeated 
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analysis in dilution using the zero standard from the appropriate kit was re-run. All 
controls were performed at both front and back of each ELISA plate. 
4.4.5 Criteria for downloading and cleaning CGMS data 
CGMS data was uploaded into the Abbott software, Co-pilot® (version 3.0) and 
exported into Microsoft Excel®, immediately following sensor removal at the last 
visit.  
A strategy for reviewing and cleaning data using clinically relevant and accepted 
methods, was agreed by the research team, which included Dr Helen Murphy 
(University of Cambridge), a consultant diabetologist with extensive experience of 
using CGMS, particularly the FreeStyle® Navigator, in pregnancy. Marianna 
Nodale, a research mathematician with an interest in CGMS from Dr Murphy’s 
group, provided additional support. A summary of the consensus is detailed below: 
 
Table 15 Process used for cleaning CGMS data for analysis 
Two clinicians (including myself), blinded to the randomisation order, independently reviewed and 
later crosschecked all CGMS data. The following points were reviewed: 
Missing time points 
ACTION: coded as missing data 
Data out of sensor (i.e. <1.1mmol/l) and manufacturer’s temperature range 
ACTION: data point excluded plus data within 30 minutes (i.e. 3 data points) either side 
Identification of obvious erroneous results  (i.e. large variability in glucose readings out of keeping 
with glucose trend (drop of ≥+/-2mmol) 
ACTION:  data point excluded plus data within 30 minutes (i.e. 3 data points) either side 
Sensor failure 
ACTION:  omit data 30 minutes prior to failure and 30 minutes (i.e. 3 data points) after resumption of 
sensor function 
ACTION: data previously coded as out of sensor range and/or out of temperature range was excluded-
data point excluded plus data 30 minutes either side 
Hypoglycaemia  
ACTION: This was defined CGMS glucose <3.3mmol/l* 
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Hyperglycaemia  
ACTION: preprandial glucose ≥5.27mmol/l, 1-hour post meal glucose ≥7.78mmol/l, 2-hour post meal 
≥6.67mmol/l 
Meal Markers 
ACTION: Meal markers at the start of meal/snack were identified from CGMS (patient meal 
markers). For missing meal markers, we used meal/snack times recorded in the CRF and confirmed 
appropriate changes in CGMS blood glucose levels which were agreed between the two project leads 
(RM and NP).   
*A clinical definition was agreed using relevant studies and clinical guidelines for hypoglycaemia in 
subjects with diabetes (Gangji, Cukierman et al. 2007, Seaquist, Anderson et al. 2013) 
4.5 Statistical analysis for IGPOP 
4.5.1 Stage 1 
Raw data extracted from the online IGPOP database was transferred into GraphPad 
Prism®, software for analysis (San Diego, California, USA, version 5.01 for 
windows). Using the mean glucose concentration (n=10 per group), the incremental 
area under the curve (iAUC) was calculated to adjust for differences in fasting blood 
glucose concentrations at baseline. One-way ANOVA test with Tukey’s multiple 
comparison analysis, using the mean difference between iAUC of the three 
supplements per participant, allowed for comparison of the supplements.  
4.5.2 Stage 2 
Preliminary analysis using the mean CGMS value per 10 minute time point, revealed 
high intra-day variability (expectantly around meal times) with a non-linear 
structure, giving unpredictable results (GraphPad Prism®). Consequently variation 
was large relative to the difference in treatment groups, making it difficult to capture 
the differences between the groups appropriately using standardised techniques.  
Linear regression with mixed modelling was therefore used and a linear mixed 
model (LMM) assuming a normally distributed error term was fitted to the data. 
LMMs are an appropriate statistical tool for repeated measures over time (West, 
Welch et al. 2007, West 2009). They take into account the interrelationships of the 
responses within subjects and are robust against dropouts. Alternative models with 
and without effects for period (hospital v home) and treatment were checked and 
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discarded as appropriate, based on the goodness of fit measures such as likelihood 
ratio test. When comparing LMMs with other statistical tools to model repeated data, 
such as Generalised Estimation Equations (GEE), it was preferable to use LMM 
(Gardiner, Luo et al. 2009). 
Two models were plotted: 
1. Main effects model (M1) – The predicted individual observations were 
plotted, allowing for straightforward overall interpretation. 
2. Full model (M2) – This model was to gain a better understanding of the 
structure of the overlying data (extending from the previous model) by 
including the relevant interactions between variables, i.e. sequencing effects 
and period (hospital versus home).  
Simple randomisation was adopted which did not take into account the order of the 
drink consumed; sequence 1=intervention/control and sequence 
2=control/intervention.  This led to an unbalanced allocation sequence for the 22 
women included in the preliminary analysis with 13 women randomised to sequence 
1 and 9 to sequence 2 which in the primary analysis was shown to have introduced 
substantial bias in the CGMS data (Schulz and Grimes 2002). To correct for the 
unbalanced design, a random subsample of 16 patients who had been allocated 
equally to sequence 1 and sequence 2 at the first visit was therefore selected for 
analysis and is presented in this thesis.   
Parameter estimates of fixed effects are shown which were derived from fitting the 
linear mixed model to the observed data (i.e. actual CGMS data) point every ten 
minutes. Thus, no summary measure such as the mean is taken as a response. This is 
because the individual observations were modelled and therefore results are based 
purely on individual patient responses. Two sided t-test and estimates were obtained 
with 95% confidence intervals. 
There was no difference when raw or cleaned CGMS data was used and results are 
presented for cleaned data only.  
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The analysis for the subsample of 16 subjects using SPSS version 19 was carried out 
in by Dr Llenalia Garcia Fernandez (SEPLIN statistical solutions), in close 
collaboration with myself.  
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5 RESULTS: UPBEAT 
 
5.1 Participant characteristics  
Four urban centres participated in the UPBEAT pilot study (n=183). For the purpose 
of this thesis, only data from three sites was included since blood sampling was not 
performed at King’s College Hospital Foundation Trust (London).  
One hundred and seventeen women were identified from three centres: 
1. Guy’s and St.Thomas’ NHS Foundation Trust (London), n=66 
2. The Southern General and Princess Royal Maternity Hospitals (Glasgow), 
n=24 
3. The Royal Victoria Infirmary (Newcastle), n=27 
Fifty-eight women were randomised to the control and 57 to the intervention. 
Baseline demography was equivalent between the two arms with a mean age and 
BMI of 30.8(5.4) years and 36.9(4.76) kg/m2 respectively with full details listed in 
Appendix 2: UPBEAT pilot results, page 211).   
Eleven subjects were excluded from all analysis by GDM status due to incomplete 
OGTT data (n=107). For evaluation of the intervention, all 117 women were 
included. In the main, results of comparisons by GDM status are presented with 
accompanying data by treatment group included in Appendix 2: UPBEAT pilot 
results, page 211.  
Twenty-nine women were diagnosed with GDM (27.4%). Demographic and clinical 
characteristics of women who developed GDM compared to those who did not are 
summarised in Table 16.  In general, women with GDM were older (p=0.001), more 
often of higher parity (≥2), had increased systolic and diastolic blood pressure and 
were more likely to be black. BMI was not significantly different between the two 
groups, although skinfold thicknesses were greater in women who developed GDM 
(triceps skinfolds, p=0.003) and total sum of skinfolds thickness (p=0.03).  
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No GDM (n=78) GDM 
(n=29) 
Comparison** P  
Age (years)  
 






17 (21.8%)   
21 (26.9%) 
26 (33.3%) 




4 (13.8%)   
10 (34.5%) 
13 (44.8%) 
3.3 (1.3 to 5.3) 
 
--- Reference --- 
1.6 (0.3 to 9.9) 
3.3 (0.6 to 16.8)    
7.9 (1.5 to 41.0) 
0.001 
0.03 
Height (m)  
Weight (kg) 








0.00 (-0.03 to 0.03) 
-2.11 (-7.82 to 3.60)   










1.6 (-2.0 to 5.3) 





Mid arm  
Hip  












0.4 (-3.2 to 4.1) 
0.6 (-1.1 to 2.4) 
-2.4 (-6.7 to 1.9) 




























6.2 (2.1 to 10.3) 
3.6 (-0.3 to 7.5) 
3.8 (0.1 to 7.4) 
0.3 (-3.3 to 3.9) 
 




















16 (55.2%)   
0 (0.0%)   
2 (6.9%) 
 
--- Reference --- 
3.7 (1.5 to 9.4)   
0.0 (0.0 to ∞)    







≥2       
 








--- Reference --- 
1.4 (0.5 to 3.8)       









History of GDM 
(multiparous only) 
 
39 (50.0%)   
38 (48.7%)  
0 (0.0%)    
1 (1.3%)   
 
1/40 (2.5%)  
 
17 (58.6%)   
38 (48.7%)      
2 (6.9%) 





















2/78 (2.6%)   
16/78 (20.5%)   
 












21 (72.4%)   
6 (20.7%)    
2 (6.9%) 
 
--- Reference --- 
0.5 (0.2 to 1.3)     
0.9 (0.2 to 4.8)   
0.33 
*Results are given as n (%) or mean (SD) 
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** Comparisons are differences in the mean, median differences or odds ratios as appropriate. Values 
are left blank where there are insufficient data. Comparisons are adjusted for baseline levels 
throughout.  
The randomised treatment allocation is balanced by minimisation on maternal age, centre, ethnicity 
and parity 
 
5.2 Maternal anthropometry and biochemistry by 
randomisation group 
5.2.1 Anthropometry 
No significant difference in skinfold thickness (triceps, biceps, subscapular and 
suprailiac) including sum of skinfolds was observed following the intervention 
(Table 17Error! Reference source not found.) and gestational weight gain in the 
two groups was equivalent (Ch2(1)=2.23, p=0.33). 





Treatment effect: Difference 
















0.6 (-2.4 to 3.5) 



















0.3 (-2.8 to 3.3) 



















0.3 (-2.9 to 3.6) 



















4.1 (1.2 to 6.9) 



















4.5 (-1.5 to 10.5) 





Data are presented as n=arithmetic mean (SD) 
1n=59, 2n=53, 3n=46, 4n=58, 5n=54, 6n=44, 7n=57 
Baseline (15+0-17+6 weeks’), Post-intervention (27+0-28+6) weeks, late gestation (34+0-35+6) 
* Effect of randomised treatment estimated by random effects Generalised Least Squares (GLS) 
regression clustering by patient with robust standard errors and adjustment for visit and GDM status 
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Similarly there were no differences in circumference measurements (neck, waist, 
mid-arm, wrist, hip and thigh) see Appendix 2: UPBEAT pilot results, page 211. 
5.2.2 Biochemistry 
Following completion of the dietary and physical intervention at 27+0-28+6 weeks’ 
gestation, no differences were observed between the two arms. In late gestation 
however (34+0-35+6 weeks’), the concentration of cholesterol, LDL and visfatin were 
lower in the intervention arm (Table 18). Treatment effects were estimated using 
multiple regression, with an adjustment for baseline measurements. 





Treatment effect:  
Ratio of geometric 
















0.99 (0.96 to 1.02) 



















1.07 (0.91 to 1.26) 



















1.09 (0.91 to 1.32) 



















1.03 (0.79 to 1.33) 



















1.07 (0.89 to 1.29) 



















1.05 (0.90 to 1.24) 



















1.06 (0.75 to 1.48) 














 55.11 (1.49)7 
 60.37 (1.43)7 
 50.35 (1.51)12 
 
- 
0.91 (0.76 to 1.09) 
















5.15 (1.52)10   
 
- 
0.97 (0.86 to 1.08) 




















Treatment effect:  
Ratio of geometric 








0.96 (0.60 to 1.53) 

















0.98 (0.94 to 1.02) 



















1.03 (0.94 to 1.14) 



















0.95 (0.90 to 1.01) 



















0.84 (0.67 to 1.05) 



















1.05 (0.95 to 1.15) 



















0.99 (0.89 to 1.09) 



















1.03 (0.98 to 1.09) 



















1.04 (0.93 to 1.17) 





Data are presented as geometric mean (geometric SD; defined as exponent of SD of logged value) 
Baseline (15+0-17+6 weeks’), Post-intervention (27+0-28+6 weeks’), Late gestation (34+0-35+6 weeks’) 
1n=59. 2n=52, 3n=43, 4n=51, 5n=40, 6n=57. 7n=53, 8n=45, 9n=55, 10n=41, 11n=49, 12n=42, 13n=56 
* Effect of randomised treatment estimated by random effects Generalised Least Squares (GLS) 
regression clustering by patient with robust standard errors and adjustment for visit and GDM status. 
Comparisons are adjusted for baseline levels throughout.  
 
1. Mean plasma cholesterol concentration was significantly lower in the 
intervention group in late pregnancy (34+0-35+6 weeks’) (5.93mmol/l v 
6.63mmol/l, ratio 0.94 [95% CI 0.89 to 0.99] or -6% change [CI -11 to -1%], 
p=0.03) (Figure 17). 
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Figure 17 Longitudinal changes in plasma cholesterol concentration by randomisation. Error bars 
represent geometric mean±SEM on the log scale. 
 
2. Mean plasma LDL concentration was 2.90mmol/l v 3.65mmol/l, for 
intervention and control respectively at visit 5 (ratio 0.89 [95% CI 0.81 to 
0.98], p=0.02), representing an 11% reduction (-11% change, [95% CI -18.9 








































Figure 18a) Longitudinal changes in plasma LDL concentration and in plasma visfatin (b) 
concentration by randomisation. Error bars represent geometric mean±SEM on the log scale.  
 
3. Plasma visfatin concentrations were highly variable. Values were higher at 
recruitment in the intervention arm and remained stable until completion of 
the programme (27+0-28+6 weeks’ gestation) when a progressive decline was 
observed. This is in contrast to the control arm, which demonstrated a linear 
increase (Figure 18).  
 
5.3 Maternal anthropometry and biochemistry by GDM status 
Data for 11 women was excluded from all analysis of the biomarkers by GDM status 
due to incomplete OGTT results. Of the 107 women included, 29 (27.4%) developed 
GDM defined by the IADPSG criteria. For the 16 biomarkers measured, including 
two clinically relevant ratios (cholesterol: HDL and LDL: HDL), comparisons were 
made for each study visit between women with and without GDM following 

















At baseline (15+0-17+6 weeks’), women who developed GDM had significantly 
greater triceps skinfolds (p=0.003) and total sum of skinfold measures (37.4 v 
31.2mm, p=0.03). Following analysis of the data for all visits combined, only triceps 
remained significant (35.1 v 32.0mm, p=0.045) (Error! Reference source not 
found.). 
Table 19 Summaries of skinfold thickness (mm) by GDM status 
 GDM (n=29) No GDM (n=78) Overall comparison 
between groups:  
Mean difference (95% CI), 
Significance test* 




















































-0.99 (-4.0 to 2.0), 0.52  
Sum of skinfolds 
Baseline 
Post-intervention 
Late gestation  
 
93.9 (16.5)1 






5.0 (-1.4 to 11.4), 0.13  
Data are presented as n=arithmetic mean (SD) 
1n=29, 2n=26, 3n=78, 4n=64, 5n=77 
Visit 2: randomisation (16+0-18+6), visit 3: post intervention (27+0-28+6), visit 5: late gestation (34+0-
35+6)  
*Comparison between GDM & non-GDM women by random effects Generalised Least Squares 
(GLS) regression clustering by patient with robust standard errors and adjustment for visit and 
randomised intervention (Arellano 1987). 
No differences were observed between circumference measures see Appendix 2: 
UPBEAT pilot results, page 211.   
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5.3.2 Biochemistry 
Details of the mean concentration at each study visit for individual biomarkers are 
shown in Table 20.  
Table 20 Summaries of biomarker concentration by GDM status 
Biomarker GDM  
(n=29) 
No GDM      
(n=78) 
Comparison between 
groups: Ratio of 
geometric means 
(95% CI) 
Overall comparison between 
groups: Ratio of geometric 















1.04 (1.00 to 1.09) 
1.08 (1.03 to 1.12) 
1.05 (1.01 to 1.10) 















1.13 (0.89 to 1.44) 
0.98 (0.83 to 1.15) 
1.08 (0.88 to 1.33) 














25.30 (1.32)9   
 
1.23 (1.03 to 1.46) 
1.16 (0.97 to 1.38) 
1.15 (1.00 to 1.33) 















1.05 (0.74 to 1.49) 
1.18 (0.85 to 1.63) 
1.16 (0.88 to 1.54) 












6.12 (2.01)10   
6.45 (1.80)9 
 
0.66 (0.52 to 0.84) 
0.74 (0.58 to 0.95) 
0.83 (0.66 to 1.04) 















1.14 (0.96 to 1.35) 
1.22 (1.02 to 1.47) 
0.98 (0.83 to 1.17) 













1.25 (2.31)13   
 
1.03 (0.73 to 1.46) 
1.02 (0.70 to 1.48) 
0.88 (0.64 to 1.21) 















0.91 (0.76 to 1.07) 
0.91 (0.75 to 1.10) 
0.69 (0.56 to 0.86) 
















0.93 (0.80 to 1.07) 
0.97 (0.84 to 1.13) 
0.98 (0.85 to 1.14) 















1.28 (0.80 to 2.04) 
1.10 (0.82 to 1.49) 
1.71 (1.05 to 2.79) 















0.98 (0.91 to 1.05) 
0.93 (0.86 to 1.01) 
0.89 (0.81 to 0.98) 





 1.67 (1.42)2 
 
 1.53 (1.38)7 
 
1.09 (0.94 to 1.26) 
1.05 (0.91 to 1.21) 
0.51 
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Biomarker GDM  
(n=29) 
No GDM      
(n=78) 
Comparison between 
groups: Ratio of 
geometric means 
(95% CI) 
Overall comparison between 
groups: Ratio of geometric 




 2.05 (1.48)2 
 2.39 (1.44)6 
 1.87 (1.42)7 
 2.56 (1.46)14 
1.10 (0.93 to 1.29) 














0.96 (0.86 to 1.07) 
0.94 (0.82 to 1.07) 
0.98 (0.85 to 1.12) 















1.19 (0.88 to 1.63) 
1.11 (0.84 to 1.47) 
0.87 (0.62 to 1.21) 















1.08 (0.93 to 1.25) 
1.10 (0.93 to 1.29) 
0.96 (0.81 to 1.13) 















0.93 (0.82 to 1.07) 
0.90 (0.77 to 1.04) 
0.84 (0.72 to 0.98) 












3.42 (1.32)7  
3.81 (1.39)14 
 
1.02 (0.92 to 1.13) 
0.99 (0.87 to 1.13) 
0.91 (0.79 to 1.05) 















0.97 (0.82 to 1.16) 
0.96 (0.79 to 1.16) 
0.86 (0.70 to 1.05) 
0.93 (0.78 to 1.10) 
0.41 
Results given as geometric means (SD) 
Baseline (15+0-17+6 weeks’), Post-intervention (27+0-28+6 weeks’), Late gestation (34+0-35+6 weeks’) 
1n=28, 2n=29, 3n=25, 4n=27, 5n=24, 6n=26, 7n=77, 8n=74, 9n=59, 10n=75, 11n=58, 12n=72, 13n=56, 
14n=60, 15n=76 
*Mean difference across all visits.  
**Comparison between GDM & non-GDM women by random effects Generalised Least Squares 
(GLS) regression clustering by patient with robust standard errors and adjustment for visit and 
randomised intervention.  
 
1. Concentrations of plasma fructosamine, were significantly greater in women 
who developed GDM, (6% difference; 95% CI 1.9 to 9.6%) over the duration 
of the study (ratio 1.06 [95% CI 1.02 to 1.10], p=0.003). There was a steady 
decline in fructosamine concentrations from early pregnancy in both GDM 
and non GDM (Figure 19).  
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Figure 19 Longitudinal changes in plasma fructosamine concentration by GDM status. Error bars 
represent geometric mean±SEM on the log scale.  
 
2. Plasma concentrations of AST were significantly greater in women with 
GDM representing an overall 18% increase (95% CI 3.9 to 34.1) across the 
study (ratio 1.18, [95% CI 1.04 to 1.43], p=0.01).  
 
Figure 20 Longitudinal changes in plasma AST concentration by GDM status. Error bars represent 
geometric mean±SEM on the log scale. 
 
3. In both groups of women, adiponectin concentrations declined from visits 2 
to 3, followed by a small rise in late gestation, without a return to baseline 
(Figure 21). Women with GDM had lower concentrations of adiponectin 
throughout the study. At randomisation, a -34% difference was observed for 


































to 0.84], p=0.001), which reduced to -17% by visit 3 (ratio 0.83, [95%CI 0.66 
to 1.04]). The difference across all visits was -27% (95%CI 9.1 to 40.7%) 
(Table 20).  
 
Figure 21 Longitudinal changes in plasma adiponectin concentration by GDM status. Error bars 
represent geometric mean±SEM on the log scale. 
 
4. Women who developed GDM tended to have lower concentrations of plasma 
leptin throughout pregnancy. At late gestation, a significant 31% difference 
between those with and without GDM was observed (ratio 0.69 [95%CI 0.85 
to 1.14], p=0.001) (Figure 22). This difference resulted mainly from a 
reduction in leptin levels in the GDM group, while the levels in the controls 
remained relatively stable. 
 
Figure 22 Longitudinal changes in plasma leptin concentration by GDM status. Error bars 




































5. Plasma insulin concentrations decreased from randomisation to post 
intervention in both groups and then increased thereafter. Insulin 
concentrations were similar at these time periods whereas in late gestation, 
concentrations were significantly greater in women with GDM compared to 
those without (ratio 1.71 [95%CI 1.05 to 2.79], p=0.03 at visit 3) (Figure 23). 
 
Figure 23 Longitudinal changes in plasma insulin concentration by GDM status. Error bars represent 
geometric mean±SEM on the log scale.  
 
5.4 NEFA and fatty acids 
Total fasting plasma NEFA and fatty acid composition were measured on post 
intervention samples only obtained during the OGTT at visit 3 (27+0-28+6 weeks’ 
gestation). 
 
5.4.1 Comparison of NEFA and fatty acid composition by randomisation 
Since abnormal fatty acids (FAs) are associated with insulin resistance and fetal 
macrosomia and because significant differences were found in the dietary intake of 
saturated fatty acids and the ratio of PUFA:SFA, a detailed analysis of fatty acids 
was undertaken (Poston, Briley et al. 2013). 
A significant 13% reduction was observed for the intervention arm compared to the 
















Greater concentrations of the SFA stearic acid (C18:0) (p=0.006) and a borderline 
significance reduction of MUFA oleic acid (C18:3n-6) (p=0.06) were found in the 
intervention group. 
All other plasma FAs were equivalent between the randomised groups (Table 20). 
Table 21 Summary of NEFA concentration and composition of fatty acids by randomisation at 27+0-
28+6 week’s gestation 








in arithmetic means 
(95% CI)* 
P 
NEFA (mmol/L) 0.31 (0.17)  0.33 (0.17) 0.02 (-0.05 to 0.09) 0.56 
Plasma 14:0 0.92 (0.35) 0.79 (0.25) -0.13 (-0.25 to -0.02) 0.027 
Plasma 16:0 23.18 (2.00)  22.92 (1.85) -0.25 (-1.00 to 0.50) 0.50 
Plasma 16:1 1.89 (0.76) 1.69 (0.71) -0.21 (-0.49 to 0.08) 0.15 
Plasma 18:0 5.29 (0.46) 5.56 (0.52) 0.27 (0.08 to 0.46) 0.006 
Plasma 18:1n-9 22.65 (2.84) 22.47 (2.69) -0.18 (-1.25 to 0.90) 0.74 
Plasma 18:1n-7 1.62 (0.27)  1.61 (0.22) -0.01 (-0.11 to 0.08) 0.78 
Plasma 18:2n-6 25.98 (3.81) 26.28 (3.51) 0.30 (-1.12 to 1.73) 0.68 
Plasma 18:3n-3 0.74 (0.20) 0.68 (0.22) -0.05 (-0.13 to 0.03) 0.20 
Plasma 18:3n-6 0.25 (0.09) 0.22 (0.07) -0.03 (-0.06 to 0.00) 0.06 
Plasma 20:3n-6 1.80 (0.41) 1.69 (0.37) -0.12 (-0.27 to 0.04) 0.14 
Plasma 20:4n-6 6.42 (1.25) 6.85 (1.26) 0.43 (-0.06 to 0.91) 0.09 
Plasma 20:5n-3 * 0.66 (0.84) 0.66 (0.54) -0.00 (-0.27 to 0.27) 0.996 
Plasma 22:4n-6 0.24 (0.07) 0.23 (0.06) -0.01 (-0.03 to 0.02) 0.50 
Plasma 22:5n-6 0.63 (0.20) 0.63 (0.17) 0.01 (-0.07 to 0.08) 0.86 
Plasma 22:5n-3 0.36 (0.08) 0.37 (0.12) 0.02 (-0.02 to 0.05) 0.43 
Plasma 22:6n-3 2.82 (0.78) 2.95 (0.79) 0.13 (-0.18 to 0.43) 0.42 
Other plasma fatty 
acids 
4.55 (0.62) 4.40 (0.60) -0.15 (-0.39 to 0.09) 0.21 
Results given as arithmetic mean (SD). Comparison between control and intervention was by simple 
linear regression with robust standard errors. 
* For plasma 20:5n-3, results are confirmed by a non-parametric Wilcoxon rank-sum test 
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5.4.2 Comparison of NEFA and fatty acid composition by GDM status 
Plasma NEFA was significantly greater in subjects with GDM (p=0.037) and 
although not significant, concentrations of the PUFA eicosapentaenoic acid (EPA, 
plasma 20:5n-3), an omega-3, were 25% higher in GDM (p=0.28).  
Women without GDM had greater concentrations of the naturally occurring trans 
vaccenic acid from the omega 7 group (C18:1n-7) (p=0.01) and dihomo-γ-linolenic 
acid (DGLA, C20:3n-6) (p=0.016) (Table 22).  
Table 22 Summary of NEFA concentration and composition of fatty acids by GDM status at 27+0-





No GDM (n=75)  GDM (n=29) Comparison: difference in 
arithmetic means (95% CI)* 
P 
NEFA 0.30 (0.16) 0.38 (0.19) 0.08 (0.01 to 0.16) 0.037 
Plasma 14:0 0.85 (0.26) 0.87 (0.41) 0.02 (-0.14 to 0.19) 0.77 
Plasma 16:0 22.81 (1.69)  23.66 (2.34) 0.85 (-0.09 to 1.79) 0.08 
Plasma 16:1 1.82 (0.66) 1.72 (0.92) -0.10 (-0.47 to 0.27) 0.593 
Plasma 18:0 5.40 (0.46) 5.50 (0.62) 0.09 (-0.16 to 0.34) 0.46 
Plasma 
18:1n-9 
22.59 (2.75) 22.49 (2.79) -0.10 (-1.30 to 1.10) 0.87 
Plasma 
18:1n-7 
1.65 (0.25)  1.52 (0.21) -0.13 (-0.23 to -0.03) 0.01 
Plasma 
18:2n-6 
26.22 (3.23) 25.89 (4.62) -0.33 (-2.18 to 1.51) 0.72 
Plasma 
18:3n-3 
0.73 (0.20) 0.65 (0.23) -0.09 (-0.18 to 0.01) 0.07 
Plasma 
18:3n-6 
0.23 (0.08) 0.23 (0.07) -0.01 (-0.04 to 0.02) 0.64 
Plasma 
20:3n-6 
1.80 (0.41) 1.61 (0.33) -0.19 (-0.34 to -0.04) 0.016 
Plasma 
20:4n-6 
6.66 (1.33) 6.56 (1.11) -0.10 (-0.61 to 0.41) 0.69 
Plasma 
20:5n-3 
0.62 (0.73) 0.77 (0.61) 0.15 (-0.13 to 0.43) 0.28 





0.63 (0.19) 0.63 (0.17) -0.00 (-0.08 to 0.07) 0.95 
Plasma 
22:5n-3 
0.36 (0.11) 0.37 (0.08) 0.01 (-0.03 to 0.04) 0.77 
Plasma 
22:6n-3 
2.84 (0.77)  3.00 (0.81) 0.16 (-0.18 to 0.51) 0.36 
Other plasma 
fatty acids 
4.54 (0.56) 4.30 (0.71) -0.24 (-0.53 to 0.05)  0.10 
Results given as arithmetic mean (SD). Comparison between GDM and no GDM was by simple 
linear regression with robust standard errors. 
* For plasma 20:5n-3, results are confirmed by a non-parametric Wilcoxon rank-sum test. 
5.5 Prediction model for GDM 
5.5.1 Biomarker analysis  
Univariate biomarker analysis and development of the initial prediction model, 
included adjustment for maternal anthropometry (triceps skinfold and total sum of 
skinfolds) in addition to age, parity ≥2, black ethnicity, DBP and SBP as significant 
clinical predictors of GDM.   
Plasma concentrations of AST at randomisation were significantly greater in women 
with GDM (ratio 1.23, 95% CI [10.01 to 1.50], p=0.042). Using clinically relevant 
categories of AST, (<20, 20-29.9 and ≥30U/L), the incidence of having GDM 
increased from 15.5% to 24.4% and 36.8% respectively. Odds ratios for 
development of GDM are shown in Table 23. These categories were not used in 
analysis for the prediction model however and as such the data was treated as 
continuous.   
Table 23 Association of GDM with early pregnancy concentrations of plasma AST (16+0-18+6 weeks’ 
gestation) 




Comparison (adjusted odds ratio, 95% 
CI) 
<20 4/26 (15.4%) 22/26 (84.6%) [Reference group] 
20-29.9 10/41 (24.4%) 31/41 (75.6%) 2.53 (0.43 to 17.79) 
≥30 14/38 (36.8%) 24/38 (63.2%) 4.01 (0.71 to 22.52) 
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Results are given as n (row %). Comparisons are adjusted for triceps skinfold, total sum of skinfolds, 
age, parity ≥2, black ethnicity, DBP and SBP. 
Plasma concentrations of adiponectin were 32% lower at baseline in subjects who 
subsequently developed GDM (ratio 0.68, 95% CI [0.54 to 0.85], p=0.001). When 
divided into 5 categories (<5, 5-9.9, 10-14.9, 15-19.9 and ≥20µg/ml), the risk of 
GDM was inversely associated with increasing concentrations of adiponectin. For 
concentrations ≥20µg/ml, there were no women with GDM but 3 women without 
(Table 24).  
Table 24 Association of GDM with early pregnancy concentrations of adiponectin (16+0-18+6 weeks’ 
gestation).   
Adiponectin (ug/ml) GDM (n=28/105) No GDM (n=77/105) Comparison (adjusted odds ratio, 95%CI) 
<5 12/32 (37.5%) 20/32 (62.5%) [Reference group] 
5-9.9 13/47 (27.7%) 34/47 (72.3%) 0.39 (0.11 to 1.44) 
10-14.9 2/12 (16.7%) 12/12 (83.3%) 0.12 (0.01 to 1.92) 
15-19.9 1/9 (11.1%) 8/9 (88.9%) 0.04 (0.00 to 1.67) 
≥20 0/3 (0%) 3/3 (100%) 0 
Results are given as n (row %) and adjusted for triceps skinfold, total sum of skinfolds, age, parity ≥2, 
black ethnicity, DBP and SBP 
 
The distribution of AST and adiponectin by GDM status are illustrated below in a 
boxplot. 
   
Figure 24 Box and whisker plot of the distribution of AST and adiponectin concentrations by GDM 
status. Boxes show median and quartiles; whiskers extend to the lowest value within 1.5 times the 
inter-quartile range (IQR) of the lower quartile, and the highest value within 1.5 IQR of the upper 
































In logistic regression, adiponectin (OR 0.18, 95%CI [0.05 to 0.67], p=0.01) and 
maternal age (OR 1.15, 95%CI [1.0 to 1.3], p=0.035) were consistently predictive of 
GDM. Black ethnicity (BE) ceased to be predictive (p=0.74) (Table 25).  
Table 25 Combined logistic regression using biomarkers and all significant clinical risk factors 
(triceps and total sum of skinfolds, age, parity [≥2], Black ethnicity, SBP, DBP and adiponectin)     
 Odds Ratio 95% Confidence Interval P 
AST 4.53 0.93 to 22.1 0.06 
Log adiponectin 0.18 0.05 to 0.67 0.01 
Age (for each additional year) 1.15  1.0 to 1.31 0.035 
Parity ≥2 3.38 0.75 to 15.23 0.11 
Black ethnicity 0.80 0.21 to 3.04 0.74 
SBP 1.0 0.91 to 1.10 0.93 
DBP 1.09 0.98 to 1.21 0.10 
Triceps skinfolds 1.07 0.98 to 1.17 0.11 
Total sum of skinfolds 1.0 0.96 to 1.05 0.82 
 
Further analysis to explore why BE was no longer significant in the model found that 
BE was predictive of a high AST and low adiponectin in this cohort (p<0.001), 
which are both stronger predictors of GDM (Table 26).  
Table 26 Comparison of early pregnancy concentrations of AST and adiponectin (16+0-18+6 weeks’ 





Comparison between groups: Ratio of 
geometric means (95% CI) 
P 
AST (U/L) 32.5 (1.4) 23.8 (1.4) 1.38 (1.20 to 1.57)  0.00 
Adiponectin (ug/ml) 4.8 (1.8) 7.8 (1.7) 0.61 (0.49 to 0.77) 0.00 
Data are presented as geometric mean (geometric SD; defined as exponent of SD of logged value) 
5.5.1.1 Area under the curve-receiver operating curve (AUC-ROC) 
The prediction model demonstrated an AUC-ROC of 0.796 (95% CI [0.692 to 
0.898], p=0.073) for clinical predictors alone which increased to 0.857 (95% CI 
[0.777 to 0.938]) with the addition of adiponectin. The addition of AST resulted in a 




Figure 25 Receiver-operating curve and summaries using the basic model (including age, parity, 
ethnicity, blood pressure and maternal anthropometry), with the addition of adiponectin and AST. 
AUC, area under the receiver-operating curve. 
 
5.5.2 Biomarker analysis excluding anthropometry 
The role of maternal anthropometry in standard antenatal care has not been 
established. Therefore a decision was made by the UPBEAT study group to retain 
routine clinical measures and exclude anthropometry from further analyses to 
generate a more pragmatic model. 
 Table 27 summarises baseline comparisons of biomarkers in women with and 
without GDM following adjustment for age, parity [≥2], Black ethnicity, SBP and 
DBP.  
Significant differences were observed for adiponectin only, with plasma 
concentrations 34% lower in women with GDM (95% CI [-47% to -19%], p<0.001). 
There was a trend towards significance for fructosamine in the GDM group 
(p=0.05), which did not persist after adjustment (p=0.82). No other biochemical 
markers were associated with GDM.  
Plasma concentrations of AST and CRP were greater in the GDM group, although 










0.00 0.25 0.50 0.75 1.00
1−Specificity
Basic model (clinical variables only) AUC = 0.7955
Basic model + adiponectin AUC = 0.8571
Basic model + adiponectin + AST AUC = 0.8660
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Table 27 Comparison of biomarkers by GDM status (adjusted for routinely used clinical predictors: 
age, parity [≥2], Black ethnicity, SBP and DBP) 
Biomarker* GDM (n=29) No GDM (n=77) Comparison (95% CI)        P value 
Fructosamine (umol/l) §200.87 (1.10)     192.90 (1.09)      1.00 (0.97 to 1.04) 0.82 
ALT (U/L) §21.41 (1.79)      19.00 (1.57)       1.12 (0.84 to 1.50) 0.42 
AST (U/L) §30.63 (1.53)      25.07 (1.41)       1.17 (0.96 to 1.43) 0.11 
Ferritin (ng/ml) §42.06 (2.27)      39.48 (2.29)       0.95 (0.64 to 1.41) 0.79 
Adiponectin (µg/ml) §4.97 (1.72)       7.34 (1.76) 0.66 (0.53 to 0.81) <0.001 
tPA (ng/ml) §10.35 (1.49)      9.00 (1.47)        1.05 (0.86 to 1.28) 0.64 
IL-6 (pg/ml) ¶1.01 (2.08)       ●0.95 (2.54)        0.91 (0.66 to 1.24) 0.55 
Leptin (pg/ml) §53.82 (1.49)      ○59.36 (1.52)       0.92 (0.76 to 1.13) 0.44 
Visfatin (ng/ml) §4.94 (1.40)       ○5.28 (1.42)        0.93 (0.77 to 1.12) 0.42 
Insulin (mU/l) 26.00 (2.99)      20.20 (2.78)       1.33 (0.80 to 2.21) 0.27 
Cholesterol (mmol/l) 5.31 (1.18)       5.42 (1.21)        1.01 (0.93 to 1.10) 0.80 
Triglycerides (mmol/l) 1.67 (1.42)       1.53 (1.38)        1.13 (0.96 to 1.32) 0.13 
HDL (mmol/l) 1.64 (1.32)       1.71 (1.26)        0.94 (0.82 to 1.08) 0.39 
CRP (mg/l) 9.18 (1.93)       7.77 (2.30)        1.28 (0.89 to 1.83) 0.18 
VLDL (mmol/l) 0.76 (1.42) 0.71 (1.38)        1.13 (0.97 to 1.32) 0.12 
LDL (mmol/l) 2.74 (1.39)       2.93 (1.34)        0.99 (0.86 to 1.14) 0.86 
Cholesterol:HDL 3.23 (1.31 3.17 (1.27)        1.07 (0.95 to 1.21) 0.27 
LDL:HDL 1.67 (1.56)       1.71 (1.45)        1.05 (0.87 to 1.27) 0.63 
* indicates geometric means and ratios of geometric means 
§n=28 and ¶n=27     ●n=75 and ○n=74 
Only adiponectin predictive after allowing for major clinical variables. 
In a combined logistic regression model including adiponectin and 5 clinical risk 
factors, the only consistent predictive variables were adiponectin (OR for a halving 
in adiponectin concentration 4.04 [95% CI 1.69 to 9.64], p=0.002) and maternal age 
(OR per additional year 1.18, [95% CI 1.04 to 1.34], p=0.01) (Table 28). Black 
ethnicity ceased to be predictive for the same reasons discussed in 5.5.1 Biomarker 
analysis, page 128.  
 
Table 28 Combined logistic regression using significant biomarkers and routine clinical risk factors 
(age, parity [≥2], Black ethnicity, SBP, DBP and adiponectin)     
 Odds Ratio 95% Confidence Interval P value 
Log adiponectin 0.13 0.04 to 0.47 0.002 
Age (for each additional year) 1.18     1.04 to 1.34 0.01 
Parity ≥2 2.09   0.50 to 8.73 0.31 
 133 
Black ethnicity 1.35    0.42 to 4.33 0.62 
SBP 1.04      0.95 to 1.13 0.41 
DBP 1.08    0.98 to 1.19 0.15 
5.5.2.1 Area under the curve-receiver operating curve (AUC-ROC) 
An AUC-ROC of 0.760 [95% CI 0.645 to 0.875] for prediction of GDM was 
achieved with clinical predictors (age, parity, ethnicity and blood pressure) alone. 
The AUC-ROC increased significantly to 0.834 [95% CI 0.742 to 0.927] 
(Ch2(1)=4.00, p=0.046) with addition of adiponectin (Figure 26).  
  
Figure 26 Receiver-operating curve and summaries using the basic model (including age, parity, 
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6 RESULTS: IGPOP, A PILOT STUDY OF A SD-
LGI DIETARY INTERVENTION 
The increases in infant adiposity and metabolic complications following maternal 
obesity are in part a consequence of maternal insulin resistance and subsequent 
hyperglycaemia and dyslipidaemia (Dabelea, Hanson et al. 2000, Reynolds, Allan et 
al. 2013).  
The ACHOIS and MFMU randomised controlled trials clearly demonstrated that 
treating IGT in pregnancy with dietary advice and insulin when needed, improves 
maternal and neonatal outcomes (Crowther, Hiller et al. 2005, Landon, Spong et al. 
2009). It should be noted that although lowering the dietary glycaemic index (GI) of 
women in the intervention group in the Australian Carbohydrate Intolerance Study in 
Pregnant Women (ACHOIS) study was not a specific aim, it is likely that the overall 
GI was lowered as a result of the routine dietary advice given. For lean women with 
NGT in pregnancy, current evidence suggests potential benefits of LGI diets but the 
PREGGIO study (Moses, Casey et al. 2014) did not meet its primary aim of 
improving pregnancy outcome when diets of LGI and healthy eating were compared.  
Nonetheless for obese pregnant women who have greater postprandial glycaemia 
(1hour and 2 hour) and reach a greater glucose peak (Yogev, Ben-Haroush et al. 
2004, Harmon, Gerard et al. 2011), dietary modifications to reduce this exposure, 
when transfer of maternal glucose to the fetus is maximal, may yield favourable 
physiological and clinical outcomes.  
Lowering the dietary GI and improving the quality of CHO consumed can blunt the 
postprandial glycaemic response and improve insulin sensitivity (Kwak, Paik et al. 
2012). This includes switching from rapid to slow digesting carbohydrates and 
increasing the percentage contribution of resistant starch and indigestible fibres.                                            
In this thesis, two nutritional supplement products (A and B) developed by Abbott 
Nutrition with the primary aim of blunting postprandial glycaemia were evaluated in 
obese pregnant women. 
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In stage one of the study the glycaemic response following a meal tolerance test 
(MTT) was determined, and the glycaemic index of prototype B in non pregnant lean 
women calculated following standard GI testing methodology (Brouns, Bjorck et al. 
2005). In stage two, the prototype that displayed superior glucose lowering effects in 
stage 1 was tested to assess if the addition of a nutritional supplement in obese 
pregnant women improves glucose and insulin profiles when incorporated within a 
balanced diet. Methods are described in detail in Chapter 4, Methods: Improving 
Glycaemic Profiles in Obese Pregnancies (IGPOP), page 91. 
6.1 Stage 1a 
Stage 1a investigated the effects of 2 slow-digesting LGI (SD-LGI) nutritional 
supplements (A and B) on postprandial glycaemia versus a control (D) in 4 
categories of women. Capillary blood glucose was measured at 9 time points up to 
240 minutes and the incremental area under the curve (iAUC) calculated.   
The nutritional composition of the three products is detailed in Dietary composition 
of nutritional supplements, page 91.  
Ten women were recruited to each of the 4 groups: lean non-pregnant (LNP), lean 
pregnant (LP), obese non-pregnant (ONP) and obese pregnant (OP).  Gestational age 
was 24+0-28+6 weeks’ for the pregnant women. The mean BMI with ethnicity for 
each group is given below. 
Table 29 Demographic details of the four groups of women participating in stage 1a 
Category (n=10) Mean BMI (kg/m2) Age (years) Ethnicity  
Lean non-pregnant (LNP) 22.5 (1.5) 25.6 (4.1) European: 7  
Indian: 1  
Chinese: 2 
Lean pregnant (LP) 22.1 (1.6) 27.9 (3.8) European: 4 
Black: 6 
Obese non-pregnant (ONP) 35.3 (4.9) 28.4 (5.4) European: 6 
Black: 3 
Mixed: 1 
Obese pregnant (OP) 38.5 (6.7) 32.5 (4.9) European: 4  
Black: 6 
*BMI and age given as mean (SD), ethnicity given as (n). 
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Table 30 summarises the FBG and iAUC for all three supplements in the four 
categories of women.  For each group, B yielded the lowest iAUC when compared to 
A and D respectively. 
With equivalent caloric value and carbohydrate content, the only difference in 
macronutrient composition between A and B was fat concentration with B 
containing a high fat load (14g v 1g per 16oz serving).   
Table 30 Fasting blood glucose concentration and iAUC for the three test supplements in all subjects 
Study group A B D 
Lean non-pregnant: LNP    
FBG  4.10 (0.15) 4.41 (0.19) 4.65 (0.21) 
iAUC  166.7 (20.4) 72.5 (12.3) 200.4 (28.8) 
Lean pregnant: LP    
FBG  4.32 (0.12) 4.14 (0.10) 4.11 (0.09) 
iAUC 101.5 (10.2) 95.8 (14.1) 253.2(14.7) 
Obese non-pregnant: ONP    
FBG 4.69 (0.11) 4.74 (0.09) 4.75 (0.09) 
iAUC  130.1 (26.8) 103.9 (12.3) 226.0 (40.4) 
Obese pregnant: OP    
FBG 4.47 (0.14) 4.62 (0.12) 4.69 (0.17) 
iAUC  184.3 (23.7) 181.5 (23.0) 259.1 (30.8) 
FBG: fasting blood glucose given as mean (SEM) in mmol/l. iAUC: incremental area under the curve 
given as mean (SEM) in mmol/l/240min 
 
In keeping with IR of pregnancy, compounded by obesity, LNP women had the 
lowest iAUC (72.5 mmol/l/240min), which progressively increased in the order of 
LP, ONP and OP to a maximum of 181.5mmol/l/240min following consumption of 
B. This pattern was less consistent for A and D. 
One-way ANOVA test with Tukey’s multiple comparison analysis confirmed a 
consistent reduction in iAUC for B versus D (control) across all groups notably in 
the obese pregnant group. No significant differences were found between the iAUC 
for A and B (Table 31).  
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Table 31 Comparison between A, B and D within each study group 
One way ANOVA 
(Tukey’s multiple comparison test) 
Mean Difference of 
iAUC per participant 
P value  95% CI of difference 
Lean non-pregnant (LNP)    
A vs B 0.42 0.08 -0.04 to 0.87 
A vs D -0.18 0.06 -0.63 to 0.28 
B vs D -0.59 0.002 -1.05 to -0.14 
Lean pregnant (LP)    
A vs B -0.06 0.56 -0.67 to 0.55 
A vs D -0.79 0.004 -1.39 to -0.18 
B vs D -0.73 0.004 -1.33 to -0.12 
Obese non-pregnant (ONP)    
A vs B 0.06 0.38 -0.44 to 0.55 
A vs D -0.44 0.03 -0.94 to 0.05 
B vs D -0.50 0.01 -0.99 to -0.00 
Obese pregnant (OP)    
A vs B 0.25 0.38 -0.18 to 0.67 
A vs D -0.26 0.08 -0.69 to 0.17 
B vs D -0.51 0.03 -0.93 to -0.08 
When comparing the glucose response of supplement B across the four categories of 
women, the iAUC was greatest in the obese pregnant group compared to lean and 
non-pregnant women.  
The timing of the post-prandial peak for all supplements was comparable at 
approximately 60 minutes with the greatest increment recorded for D on each 








a)      b) 
        
Figure 27 a) Line graph and b) box plot of glucose iAUC lean non pregnant (LNP) women for A, B 
& D (n=10). Error bars represent mean± SEM 
 
a)      b) 
 
Figure 28 a) Line graph and b) box plot of glucose iAUC for lean pregnant (LP) women for A, B & 
D (n=10). Error bars represent mean± SEM.  
 
 
a)      b) 
   
Figure 29 a) Line graph and b) box plot of glucose iAUC for obese non pregnant (ONP) women for 




























































































































a)      b)  
   
Figure 30 a) Line graph and b) box plot of glucose iAUC for obese pregnant (OP) women for A, B & 
D (n=10). Error bars represent mean± SEM. 
 
6.1.1 Stage 1a palatability  
All participants completed online palatability questionnaires during each of the three 
tests. Overall satisfaction for B was high with 17 women stating that they “liked it” 
compared to 7 and 14 positive replies for supplements A and D respectively. 
Dissatisfaction was greatest for A as shown in Figure 31.  
 
Figure 31 Summary of stage 1a palatability findings for all women combined (LNP, LP, ONP, and 
OP)  
There was no difference in terms of general acceptability in pregnant women when 
asked the question “how likely are you to drink the product?” There was however a 
clear indication that women would be prepared to consume a nutritional drink during 
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Figure 32 Histogram of responses to the question “how likely are you to drink the product?” in lean 
and obese pregnant women combined 
Furthermore, pregnant women were more likely to consider consuming more 
servings per day compared to non-pregnant women: (A) 2.47 v 1.81, (B) 2.75 v 2.0 
and (D) 2.53 v 1.83 (pregnant versus non-pregnant).      
 
6.1.2 Summary of Stage 1a 
In summary, B led to the lowest iAUC compared to A and D in all categories of 
women. This was associated with high scores for palatability particularly in pregnant 
women who would consider consuming the drink during pregnancy if recommended. 
On the basis of these findings, it was concluded that supplement B was most likely 
to confer benefit in terms postprandial glucose excursions and was therefore 
investigated in stage 2 which focussed on obese pregnant women.  
 
6.2 Stage 1b 
To determine the GI of B, two 50g glucose challenge tests were performed, in 10 
lean women. CBG was measured at 7 time points up to 120 minutes (0, 15, 30, 45, 
60, 90 and 120 minutes), to provide 50g CHO, the following volumes were given:  
1) Supplement B: 257ml and  
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Incremental AUC for Lucozade and B was 13.00 and 3.56 respectively. Using the 
standard formula shown below, the GI of B was 27.38, confirming its low GI 
classification (low ≤50, medium 56-69 and high ≥70) (Wolever, Jenkins et al. 1991).  
 
Table 32 Summary of outcome measures for stage 1b. Data is presented a mean (SD) for baseline and 
peak glucose concentration. *SD not available for iAUC 
 Lucozade (n=10)  B (n=10) GI value of the supplement 
Baseline glucose (mmol/l) 4.54 (0.54) 4.27 (0.50) =(iAUC B/iAUC standard)*100 
Peak glucose (mmol/l) 8.09 (1.05) 5.42 (0.59) = (66.22/237.5)*100 
iAUC (mmol/l/min)* 237.5  66.22   =27.38 
 
Figure 33 Line graph of mean capillary glucose concentrations in stage 1b for lean non pregnant 
women (n=10) following consumption of  supplement B (!) and the standard glucose control 
Lucozade ("). Error bars represent mean± SEM. 
     



















7 RESULTS: IGPOP STAGE 2 
Stage 2 was a single blinded randomised crossover design in obese pregnant women. 
The aim was to evaluate the immediate and extended effects on glucose and insulin 
concentrations, following consumption of the control (D) or intervention (B) 
nutritional supplements as part of a controlled diet using CGMS.  
Macronutrient content of the two products was equivalent (CHO 60.7%, fat 20.8% 
and protein 18.5%) with differences in CHO composition of the two supplements 
summarised below.  Detailed composition is provided in Chapter 4.1, page 91. 
Table 33 Macronutrient composition of intervention supplement (B) and control (D) per 16oz serving 
used in Stage 2 
Macronutrient B (intervention) D (control) 
Slow digesting carbohydrates (%) 68 - 
Rapid digesting carbohydrates (%) 5 100 
Resistant starch (%) 15.5 - 
Indigestible fibre (g) 3.5 - 
Fat (g) 14.0 14.0 
Calories per 16oz (474ml) serving (Kcal) 303 303 
The study was divided into three distinct 48hour periods following randomisation to 
the intervention or control on the 1st visit to the CRF: 
1. Thursday* and Friday●: intervention or control  
2. Saturday and Sunday: washout with habitual diet   
3. Monday* and Tuesday●: intervention or control 
*Denotes study day at CRF and ● study day at home with ongoing CGMS 
Of the 25 women recruited 3 were excluded. Two had multiple problems with sensor 
failure despite re-insertion of new devices and one was excluded following 
preliminary review of the CGMS data, which confirmed non-compliance with the 
prescribed diet.  
As described in detail below, sixteen women were randomly selected from the 
sample of 22 (ID numbers 2, 3, 4, 5, 7, 8, 9, 10, 11, 12, 13, 15, 16, 18, 19 and 21) 
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with 8 subjects for each sequence of treatment as described in Chapter 4.5.2, page 
110. 
The mean age of the sample was 31 years (range 21-39, SD 4.8) and BMI 37kg/m2 
(range 31-46, SD 4.7). Three quarters of women were of black ethnic origin.  
 
Figure 34 Pie chart of ethnicity of the selected sample (n=16) 
   
7.1 CGMS 
A model based on individual observations instead of summary statistics, was fitted to 
the data. The effect of treatment over time was then analysed using linear mixed 
models adjusted by period and day.  
The following tables show the parameter estimates from fitting the linear mixed 
model (LMM) to the observed data points every ten minutes.  
7.1.1 24hr glucose estimates  
1. When considering the overall performance of the supplement treatment 
throughout the study (over 2 days and one night) the glucose curve derived 
from the LMM was lower than both habitual and control as shown in Figure 
35. Furthermore the glucose estimates for the habitual diet and control days 
were significantly greater with values of 0.27mmol/l and 0.23mmol/l 









 Estimates of fixed effects 
Parameter Estimate (mmol/l) Standard error P Value 95% CI 
Habitual v treatment 0.27 0.03 <0.001 0.21 to 0.32 
Control v treatment 0.23 0.04 <0.001 0.16 to 0.31 
Hospital v home -0.02 0.03 0.39 -0.07 to 0.03 
Figure 35 Graph with summary of estimates showing the overall effect in glucose concentration for 
the intervention supplement compared to the control and habitual period (2 days and 1 night) 
following LMM. Estimated glucose concentrations in mmol/l. The x-axis represents 24 hours 
following consumption of the intervention/control supplement using combined data for each 2-day 
test period following LMM.  
 
2. A direct comparison between control and intervention is shown in Figure 36. 
Greater differences were noted on hospital research days (Thursday and 
Monday) compared to those at home (Friday and Tuesday). However the 
differences remained significant between intervention and control excluding 




 Treatment (mmol/l) Control (mmol/) P Value 
Thursday 4.56 (4.51-4.61) 4.68 (4.63-4.72) <0.001 
Friday 4.75 (4.71-4.79) 4.84 (4.81-4.88) 0.001 
Weekend    
Monday 4.47 (4.43-4.51) 4.73 (4.68-4.77) <0.001  
Tuesday 4.74 (4.71-4.78) 4.78 (4.74-4.82) 0.51 
Figure 36 Graph and estimates of glucose concentrations for each study day showing direct 
comparison between intervention and control. Data presented as mean glucose (mmol/l [range]) and 
bars represent the 95% confidence interval. 
 
7.1.2 Daytime glucose observations 
The overall comparison of the treatment compared to the control is shown in Figure 
37 with corresponding estimates plotted for daytime observations only.  
Predicted mean blood glucose concentrations were consistently lower for the 
treatment throughout the day with significantly greater estimates for habitual and 
control diets (p<0.001 for comparison of treatment with habitual and control). No 
difference was observed between hospital versus home study days. 
 
Thursday Friday Weekend-Habitual Monday Tuesday 
Treatment 4.556 4.753 4.750 4.470 4.742 



























 Estimates of fixed effects 
Parameter Estimate (mmol/l) Standard error P Value 95% CI 
Habitual v treatment 0.25 0.03 <0.001 0.19 to 0.31 
Control v treatment 0.26 0.04 <0.001 0.18 to 0.34 
Hospital v home -0.02 0.03 0.54 -0.08 to 0.04 
Figure 37 Graph with summary of estimates for nocturnal glucose concentrations in mmol/l 
following LMM for the intervention, control and habitual periods. The x-axis represents 24 hours 
following consumption of the intervention/control supplement using combined data for each 2-day 
test period following LMM.  
 
7.1.3 Nocturnal glucose observations 
Data for the second night was discarded for clinical reasons, therefore analysis 
included the first night for each two-day period.  
The overall response curve was lower following the intervention supplement 
compared to the control but no significant difference was found (p=0.09). Glucose 
estimates during the habitual period however were significantly greater when 
compared to the intervention (p<0.001) (Figure 38). 
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 Estimates of fixed effects 
Parameter Estimate (mmol/l) Standard error P Value 95% CI 
Habitual v treatment 0.36 0.03 <0.001 0.29 to 0.42 
Control v treatment 0.05 0.04 0.09 -0.01 to 0.11 
 
Figure 38 Graph with summary of estimates for nocturnal glucose concentrations in mmol/l 
following LMM for the intervention, control and habitual periods.  
7.1.4  Fasting blood glucose 
A LMM was fitted to the 6 consecutive glucose measures recorded between 0600hr 
and 0650hr with data included from one day of each phase. A reduction in glucose 
concentration was seen in all groups until approximately 0620hr followed a 
progressive rise thereafter.  
Glucose concentrations for the treatment were significantly lower compared to 
habitual data (p<0.001) but no different to the control (p=0.22) (Figure 39).  
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 Estimates of fixed effects 
Parameter Estimate (mmol/l) Standard error P Value 95% CI 
Habitual v treatment 0.41 0.07 <0.001 0.28 to 0.55 
Control v treatment 0.08 0.06 0.22 -0.04 to 0.19 
Figure 39 Graph with summary of estimates for fasting glucose concentrations in mmol/l following 
LMM for the intervention, control and habitual periods. 
 
7.1.5 Postprandial glucose 
Postprandial data for treatment and control (30 minutes pre-meal to 180 minutes 
post) was analysed for study days only. During the habitual period, women were not 
requested to record meal markers.  
Breakfast was the only meal where a significant difference in postprandial glycaemia 
was observed with greater glucose concentrations following the control (p=0.03, 
0.34 and 0.71 for breakfast, lunch and dinner respectively).    
Postprandial glucose concentrations were generally lower on hospital days compared 
to the second day at home for all meals in both arms (breakfast p<0.001, lunch 
p=0.80 and dinner p=0.43).  
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Graphs representing the postprandial glycaemic response for each meal with 
summaries of estimates for glucose concentrations following LMM are shown 
(Figure 40 to Figure 42). 
 
 Estimates of fixed effects 
Parameter Estimate (mmol/l) Standard error P Value 95% CI 
Control v treatment 0.09 0.04 0.03 0.01 to 0.18 
Interaction: home v hospital -0.58 0.05 <0.001 -0.68 to -0.49 
Figure 40 Graph with summary of estimates for breakfast postprandial glucose concentrations 
(180minutes) in mmol/l following LMM for the intervention versus control. 
  
 Estimates of fixed effects 
Parameter Estimate (mmol/l) Standard error P Value 95% CI 
Control v treatment -0.20 0.21 0.34 -0.62 to 0.22 
Interaction: home v hospital 0.06 0.21 0.80 -0.37 to 0.48 
Figure 41 Graph with summary of estimates for lunch postprandial glucose concentrations 
(180minutes) in mmol/l following LMM for the intervention versus control. 
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 Estimates of fixed effects 
Parameter Estimate (mmol/l) Standard error P Value 95% CI 
Control v treatment -0.20 0.06 0.71 -0.13 to 0.09 
Interaction: home v hospital -0.05 0.06 0.43 -0.16 to 0.07 
Figure 42 Graph with summary of estimates for dinner postprandial glucose concentrations 
(180minutes) in mmol/l following LMM for the intervention versus control.  
 
7.2 IGPOP biochemistry: Insulin, C-Peptide, NEFA and 
Triglycerides 
Samples were obtained up to 210 minutes following consumption of the intervention 
(B) and control (D) supplements for all subjects participating in the study but only 
data for the same 16 women included in the CGMS analysis was used. Results were 
recorded at 5 and 15 time points for NEFA/triglycerides and insulin/C-peptide 
respectively with logarithmic transformation performed for insulin and C-peptide 
only, following standard distributional checks. Tables reporting the mean 
concentration of each biomarker at each time point with 95% CI are included in 
Appendix 3: IGPOP Biochemistry Results, page 214.  
For all biomarkers, a difference was observed between women depending on the 
sequence order they were allocated to, following simple randomisation on day 1 
(sequence 1 intervention/control and sequence 2 control/intervention). After 
adjustment for repeated measures, this difference was not significant however and 
the patterns of response were attributed to chance alone. Figures for each biomarker 
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are presented below initially by study visit number to illustrate the influence of the 
sequence order, followed by a line graph of combined data, summarising potential 
differences between the intervention and control over the duration of the study 
(Figure 43 to Figure 50).  
Linear regression analysis found no detectable effect of the intervention supplement 
(B) when compared to the control for insulin, C-peptide and triglycerides (Table 34). 
A borderline significant trend towards greater concentrations of plasma NEFA 
following the intervention supplement was observed (p=0.049).  
Table 34 Results of linear regression analysis to examine for any effect or difference in plasma 
concentrations of insulin, C-peptide, NEFA and triglycerides following consumption of the test (B) 
compared to the control (D) in obese pregnant women (n=16) 
 
Biomarker Treatment effect 95% CI P value 
 Ratio of geometric means   
Insulin 0.98 0.88 to 1.09 0.68 
C-peptide 0.97 0.92 to 1.02 0.29 
 Difference in arithmetic mean    
NEFA 0.05 0.00 to 0.10 0.049 
Triglycerides 0.04 -0.01 to 0.10 0.15 
 
a) b)  
 
Figure 43 Plasma concentration of insulin (mU/L) 210 minutes post consumption of intervention (B) 
and control (D) on a) visit 1 and b) visit 2 to the CRF for n=16 obese pregnant women. Data presented 





Figure 44 Combined data of visits 1 and 2 for plasma insulin concentration (mU/L) measured 210 
minutes post consumption of intervention (B) and control (D) in 16 obese pregnant women. Data 
presented as geometric mean±SEM. 
 
a)                                                          b)          
 
Figure 45 Plasma concentration of C-peptide (pmol/L) 210 minutes post consumption of intervention 
(B) and control (D) on a) visit 1 and b) visit 2 to the CRF for n=16 obese pregnant women. Data 




Figure 46 Combined data of visits 1 and 2 for plasma C-peptide concentration (pmol/L) measured 
210 minutes post consumption of intervention (B) and control (D) in 16 obese pregnant women. Data 
presented as geometric mean±SEM. 
a)              b) 
Figure 47 Plasma concentration of NEFA (mmol/L) 210 minutes post consumption of intervention 
(B) and control (D) on a) visit 1 and b) visit 2 to the CRF for n=16 obese pregnant women. Data 




Figure 48 Combined data of visits 1 and 2 for plasma NEFA concentration (mmol/L) measured 210 
minutes post consumption of intervention (B) and control (D) in 16 obese pregnant women. Data 
presented as mean±SEM. 
 
 
a)                                                                             b) 
 
Figure 49 Plasma concentration of triglycerides (mmol/L) 210 minutes post consumption of 
intervention (B) and control (D) on a) visit 1 and b) visit 2 to the CRF for n=16 obese pregnant 




Figure 50 Combined data of visits 1 and 2 for plasma triglyceride concentration (mmol/L) measured 
210 minutes post consumption of intervention (B) and control (D) in 16 obese pregnant women. Data 
presented as geometric mean±SEM. 
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8 DISCUSSION 
The importance of lifestyle modifications before pregnancy to improve clinical 
outcomes, particularly GDM, cannot be underestimated as demonstrated by Zhang et 
al. who studied a prospective cohort of 14, 437 nurses participating in the Nurses’ 
Health Study II (Zhang, Tobias et al. 2014).  All factors (BMI, diet, activity and 
smoking status) were independently associated with GDM but BMI was the 
strongest risk factor following adjustment. Conversely the combination of 4 risk 
factors deemed to be of lowest risk (BMI<25kg/m2, non-smoker, healthy eating and 
adequate exercise) was associated with a 52% reduced risk of GDM.   
CGMS technology has revealed important aberrations in glucose homeostasis, 
notably a delayed and greater post prandial peak glucose concentration, specifically 
in obese women who may not meet current criteria for GDM, (Yogev, Ben-Haroush 
et al. 2004). Furthermore, positive associations between greater fasting and 
postprandial glucose concentrations and increased fetal fat mass have been identified 
in these “non-GDM” women (Harmon, Gerard et al. 2011).  Considering the CGMS 
data, together with confirmation of abnormal pregnancy outcomes at lower glucose 
thresholds, targeting glycaemic control and evaluating influences of interventions on 
markers of insulin resistance and adipocyte function in obese pregnant women at risk 
of GDM as in UPBEAT are obviously justifiable. This is the rationale which has 
underpinned the studies in this thesis. 
8.1 The influence of the UPBEAT intervention on biomarkers 
of insulin resistance and biomarkers of adipocyte function: 
a pilot study 
The first study in the thesis was to address the influence of the dietary and physical 
activity intervention of UPBEAT on a range of biomarkers implicated in insulin 
resistance and obesity for women participating in the pilot study.  
Whilst no lean control group was assessed, the results at 28 weeks’ gestation in the 
control group were similar to those reported for obese pregnant women in previous 
observational studies, which described an elevation of LDL, total cholesterol, 
 157 
triglycerides, CRP and Il-6 compared to lean controls (Stewart, Freeman et al. 2007, 
Meyer, Stewart et al. 2013).  To the best of our knowledge only two recently 
published studies of smaller size (n=27 and 42 respectively and n=58 for UPBEAT 
controls), have included longitudinal measurement of adiponectin in obese pregnant 
women (Meyer, Stewart et al. 2013; Ramirez, Miller et al. 2014). In both studies, 
concentrations of plasma adiponectin were not only comparable to values observed 
in this thesis but also significantly lower in obese women compared to lean controls 
(Meyer, Stewart et al. 2013, Ramirez, Miller et al. 2014).  
The participants in this thesis therefore share some similarities in terms of 
biomarkers compared to previously published data in obese pregnant women. A 
detailed description of results obtained following an overnight fast in the 2nd 
trimester in the two previous similar studies is given below (Table 35) compared to 
data collected in this thesis (control subjects only who received standard antenatal 
care). The most notable differences are observed for plasma insulin and leptin. 
Table 35 A comparison of observational longitudinal studies in obese pregnant women, measuring a 
similar panel of biomarkers to those included in this thesis. Data is reported for the 2nd trimester only 
and the control arm of the UPBEAT pilot study (Stewart, Freeman et al. 2007, Meyer, Stewart et al. 
2013).   
 This Thesis*  Meyer et al* Stewart et al** 












Total cholesterol (mmol/l) 6.07 (1.21) 5.82 (1.06) - 
LDL (mmol/l) 3.21 (1.38) 3.79 (0.97) - 
Triglycerides (mmol/l) 1.92 (1.48) 2.45 (0.94) - 
Insulin (mU/l) 14.62 (1.99) 58 (41) - 
Leptin  60.37 (1.43)! 44 (20)# - 
Adiponectin (µg/ml) 5.39 (2.08) 6.3 (2.8)  - 
NEFA (mmol/l) 0.31 (0.17)  0.24 (0.34) - 
IL-6 (pg/ml) 1.13 (2.35) - 1.80 (1.10-3.13)  
CRP (mg/l) 8.20 (1.87) - 8.58 (4.23-12.6)  
Data is reported as *mean (SD) and  **median (IQR) 
Leptin reported in !pg/ml and #ng/ml 
All blood samples taken following an overnight fast at equivalent gestational age: 27+0-28+6 weeks’ 
(UPBEAT), 24-28 weeks’ (Meyer et al.) and 2nd trimester (Stewart et al., actual GA not reported) 
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Despite changes in a ‘healthy direction’ in the diet as evaluated in the pilot study, it 
was found that there were no differences in biomarkers between randomised groups 
on completion of the intervention at 28 weeks’. However by late gestation, women in 
the intervention arm had significantly lower concentrations of cholesterol, LDL and 
visfatin. Very few intervention studies in obese pregnant women have previously 
determined the effect of the intervention on relevant biomarkers, and none as 
comprehensively as this study in the range of the biomarkers assessed.  
A study in 50 obese Caucasian women (mean BMI 34kg/m2), of a very intensive 
dietary intervention demonstrated significant improvements in serum insulin, leptin 
and blood glucose concentrations, compared to the control group who received no 
dietary support. The intervention of ten 1-hour sessions with a research dietician, 
was principally designed to limit GWG to 6-7kg, adopting official Danish dietary 
recommendations (total energy from fat 30%E, protein 15-20%E, carbohydrate 50-
55%E), individualised for each subject from 15 weeks’ (Wolff, Legarth et al. 2008). 
The primary outcome was achieved with a 6.7kg difference in GWG observed 
between the two groups in the absence of any adverse effects on fetal growth or 
pregnancy outcomes. At 27 weeks’ a significant 20% reduction in fasting serum 
leptin (p=0.004) and insulin (p=0.04) was observed in the intervention arm, with no 
difference in glucose concentrations following a 50gram OGTT. By late gestation 
however, this divergence was limited to insulin with a further 23% reduction 
(p=0.022, leptin p=0.201), accompanied by an 8% reduction in fasting plasma 
glucose only (p=0.03) with no difference in glucose at 2 hours post OGTT. For the 3 
women diagnosed with GDM in the control arm (10%), compared to none in 
intervention, data was excluded from analysis since standard treatment included 
dietary advice.  
This is in contrast to findings from the LiP study from Denmark the largest 
comparable RCT in obese pregnant women (n=304, mean BMI 33kg/m2) which 
found no difference in the concentration of fasting total cholesterol, HDL, LDL and 
triglycerides in each trimester, despite achieving significantly lower GWG of -1.6kg 
in the intervention group (Vinter, Jorgensen et al. 2014). Nonetheless a small 
improvement in insulin resistance, defined by a significantly smaller change in 
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HOMA-IR from baseline to 28 weeks’ was reported although by late gestation, this 
was no longer significant. 
In comparison to the study by Wolff and colleagues (n=50), LiP (n=304) was a 
hybrid intervention of 4 individual dietary sessions plus 20 1-hour aerobic exercise 
sessions with free gym membership (Wolff, Legarth et al. 2008, Vinter, Jensen et al. 
2011). Adherence to the dietary component was high at 92% but low for the exercise 
classes with mean attendance of 10.4 hours out of a maximum of twenty. 
Populations from both studies were exclusively Caucasian and comparable at 
baseline (mean age 29 years and BMI 35v33kg/m2) with fasted samples obtained 
throughout. This was in contrast to UPBEAT where fasted samples were measured 
following OGTT at 27-28 weeks’. Both studies were successful in their aim to limit 
GWG to 6-7kg but a much greater reduction in GWG between study arms was 
achieved by subjects in the Wolff study (6.7kg v 1.2kg in LiP), yielding a possible 
explanation for the significant improvements in plasma insulin and leptin 
concentrations, not observed in LiP. Although the detailed composition of the 
reduced GWG was not defined to confirm if this was isolated to adipose mass, these 
results do highlight the potentially important role of adipose tissue as a secretary 
organ in the pathogenesis of insulin resistance in pregnancy.   
Further explanations for the positive findings observed by Wolff et al., might lie 
within the high intensity study design of 10 compared to 4 dietary consultations, 
which appear to have greater compliance than physical activity sessions, following 
review of the data (Luoto, Kinnunen et al. 2011, Oostdam, van Poppel et al. 2012). 
Consistently reported barriers to greater physical activity in pregnancy include 
movement restriction associated with advancing gestation and unsupported fears of 
harm from additional exercise, together with work and childcare commitments. 
Current evidence suggests that overweight and obese women may benefit the most 
from diet and exercise programmes in terms of greater reductions in GWG and 
measures of insulin resistance compared to lean women but translation into 
acceptable large scale RCTs is lacking (Ong, Guelfi et al. 2009, Nascimento, Surita 
et al. 2011). Following on from this, it is important to note that unlike the LiP 
protocol where pre-existing diabetes was excluded at enrolment by OGTT, women in 
the Wolff study may have had undiagnosed IGT or T2DM. It is therefore plausible 
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that the degree of insulin resistance was greater overall, providing a greater scope for 
change (Wolff, Legarth et al. 2008).  
The most recent feasibility study of a dietary intervention in obese pregnant women 
has focused specifically on Hispanic women who form the largest ethnic minority 
group in the United States (Hawkins, Hosker et al. 2015) 
(http://www.census.gov/prod/2007pubs/acs-03.pdf). With the highest birth rates and 
almost 2-fold increased risk of developing GDM compared to White European 
women of equivalent BMI (Bardenheier, Elixhauser et al. 2013), understanding if 
targeted interventions are successful in the most at-risk groups is essential. The 
importance of this is particularly pressing since the risk of T2DM following GDM is 
greatest in the initial 5 years for all women, during which time almost 50% of 
Hispanic women will have had a diagnosis confirmed (Kjos, Peters et al. 1995). 
In this small study (n=68), women with pre-pregnancy of ≥25kg/m2 were 
randomised to standard care or a 6-month programme of monthly individual 
consultations supported by 5 telephone sessions, delivered by a healthcare trainer 
(Hawkins, Hosker et al. 2015). The aims were to achieve American College of 
Obstetricians and Gynaecologists recommended levels of activity in pregnancy, 
reduce saturated fat and increase fibre intake via a programme modified to meet the 
cultural and linguistic needs of this group. Whilst there was no significant effects of 
the intervention on surrogate measures of insulin resistance or diet at 24-28 weeks’ 
(fasted plasma glucose, insulin, leptin, adiponectin, resistin, TNFα, CRP, total 
caloric intake, %E fat and fibre consumption), retention in this hard to reach group 
was high in both arms at 97%. Compared to non-Hispanic White counterparts, the 
same research group have shown that Hispanic women are less likely to engage in 
vigorous physical activity in pregnancy (Lynch, Landsbaugh et al. 2012). Therefore 
and perhaps more importantly, this study demonstrated increased levels of vigorous-
intensity activity together with an attenuation of pregnancy associated reductions in 
moderate physical activity following the intervention.  
In terms of modifying biomarkers associated with the development of GDM and 
subsequent T2DM, in a favourable direction, results from the UPBEAT pilot are 
promising. Significant reductions not previously reported in comparable studies, 
were achieved for cholesterol, HDL and visfatin in late pregnancy (34+0-35+6 
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weeks’), suggesting a late and sustained effect of the intervention not apparent on 
completion of the intervention at 27+0-28+6 weeks’. Biochemical data from the 
LIMIT study which included overweight and obese women (n=2012 with 56.8% 
BMI≥30kg/m2) is awaited but in keeping with published dietary data from the 
UPBEAT pilot (Poston, Briley et al. 2013), a reduction in percentage dietary intake 
from saturated fats has been reported, although of a lower magnitude (p=0.04) 
(Dodd, Cramp et al. 2014). When compared to similar RCT’s, the UPBEAT cohort 
detailed in this thesis, could be considered as “high risk” for GDM. Using the LiP 
study as an example, our population was slightly older (30.18 v 29 years), more 
obese (36.0 v 33.4kg/m2) and heterogeneous with almost a third of women from 
black ethnic minorities (Vinter, Jensen et al. 2011). Until recently, obese pregnant 
women participating in lifestyle RCTs have predominantly come from lower-risk 
Caucasian groups (Wolff, Legarth et al. 2008, Luoto, Kinnunen et al. 2011, 
Oostdam, van Poppel et al. 2012, Walsh, McGowan et al. 2012, Dodd, Turnbull et 
al. 2014).  
With limited resources to provide lifestyle programmes to all obese women in 
pregnancy, stratification to identify those at greatest risk of pregnancy related 
morbidity and heightened lifetime risk of metabolic dysfunction, is required to 
determine who would benefit most from such approaches. Data for the most 
successful and acceptable strategies, modified to meet the changing needs of 
pregnant women are now beginning to emerge for these specific groups.  
HDL/LDL Cholesterol 
The difference in LDL cholesterol between the intervention and control group at 36 
weeks’ gestation (p=0.02) may reflect an improvement in cardiovascular and 
metabolic risk in the trial participants. It might be anticipated that we would have 
observed a similar fall to that in LDL in the inflammatory mediators measured but 
none was observed. However there was a non significant reduction in CRP (p=0.08) 
which will be of interest to assess in the full UPBEAT cohort. 
 
Strong positive associations between total cholesterol and LDL with inflammation, 
hepatic dysfunction and T2DM have been consistently reported (Sattar, 
Wannamethee et al. 2008). In early pregnancy obese women present with greater 
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concentrations of total cholesterol, LDL cholesterol, triglycerides (Ramsay, Ferrell et 
al. 2002, Scifres, Catov et al. 2014, Farias, Franco-Sena et al. 2015) and CRP 
(Stewart, Freeman et al. 2007) compared to lean controls. In contrast, explorative 
analysis of all participants in the UPBEAT pilot to examine for associations between 
BMI and the panel of biomarkers measured did not yield significant correlations for 
any measures of lipid metabolism but at baseline, significant associations were found 
for Il-6, insulin, leptin and CRP (Table 36).  
 
Table 36 Summary of Pearson’s correlation analysis for the control and intervention arms combined 
of BMI against lipid, inflammatory and hormonal biomarkers measured in the UPBEAT pilot study at 
baseline and post intervention.  
 Baseline (15+0-17+6 weeks’)* Post Intervention (27+0-28+6 weeks’)** 
Correlation Coefficient (r) P Value Correlation Coefficient (r) P Value 
Total cholesterol -0.11 0.25 -0.09 0.33 
Triglycerides -0.06 0.50 -0.10 0.30 
LDL -0.02 0.81 -0.01 0.84 
HDL -0.18 0.06 -0.15 0.12 
VLDL -0.07 0.49 -0.10 0.30 
Cholesterol:HDL 
Ratio 
0.10 0.33 0.07 0.46 
LDL:HDL Ratio 0.09 0.34 0.08 0.44 
     
Il-6 0.30 0.002 0.30 0.002 
tPA - - -0.24 0.02 
Insulin 0.28 0.003 - - 
Leptin 0.41 <0.001 0.35 0.0002 
CRP 0.28 0.004 0.26 0.007 
Combined data for women in the control and intervention arm is presented (BMI≥30kg/m2 for all) 
Only significant associations are presented for inflammatory and hormonal biomarkers 
*Non-fasted samples measured at randomisation 
**Fasted samples measured during OGTT 
 
In a smaller study of 55 women (n=27 obese), a significant association between 
maternal BMI was identified for triglycerides only (p=0.03) but nonetheless, 
subfraction analysis of LDL cholesterol revealed important differences related to 
adverse clinical risk for obese women (Meyer, Stewart et al. 2013). A high 
concentration of small dense LDL-III particles (>50%), termed “Pattern B”, is 
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associated with a pro-atherogenic profile and characterises conditions related to 
ectopic hepatic fat such as T2DM (Dallmeier and Koenig 2014) and non-alcoholic 
steatohepatitis (Sugino, Kuboki et al. 2011). Due to the size and density of LDL-III, 
it has been postulated that invasion of the endothelial wall is facilitated and oxidation 
occurs more readily with a deleterious effect on vascular wall function particularly in 
individuals with an increased predisposition for cardiovascular disease (Aragones, 
Ferre et al. 2012). By late pregnancy (mean 35.5 weeks’), obese women had greater 
concentrations of LDL-III (p=0.014) and lower concentrations of the intermediate 
sized LDL-II (p=0.002), equating to 35% displaying a Pattern B profile in contrast to 
14% of overweight and 0% of lean women. With just over a third of obese women 
classified as having Pattern B, the results reaffirm current evidence that only a 
proportion of obese women exceed the normal metabolic capacity of pregnancy 
induced hypertriglyceridaemia, accumulate ectopic fat stores, and thus face an 
increased risk of GDM.   
 
Across the UPBEAT cohort included in this thesis, concentrations of plasma LDL 
increased in a stepwise manner with advancing gestation but to a lesser degree in the 
intervention arm. In a prospective observational study of 299 Brazilian women 
(59.8% lean, 26.2% overweight and 14% [n=32] obese) the rate of change for LDL 
and triglycerides in obese women was significantly lower compared to lean subjects 
such that by the end of pregnancy, concentrations were comparable across all groups 
(Farias, Franco-Sena et al. 2015). Possible explanations for this and similar findings 
published recently (Meyer, Stewart et al. 2013, Scifres, Catov et al. 2014) may lie in 
altered gene expression in the adipose tissue of obese women. Using quantitative 
reverse transcription PCR (qRT-PCR), Lappas et al. demonstrated reduced 
expression of genes involved in multiple pathways of lipid metabolism including 
fatty acid and intracellular transport, lipolysis, and triglyceride synthesis in both 
subcutaneous and omental fat of obese women at term (Lappas 2014). By examining 
matched controls with normal glucose tolerance and GDM, they were able to extend 
on their previous work to confirm that insulin resistance in pregnancy is 
characterised by impaired cellular uptake, synthesis and breakdown of lipid 
components in the adipose tissue of women with pre-existing obesity and GDM 




As the normal physiology of visfatin continues to be mapped out, its possible 
pathogenic role is less clear (Arner 2006). Greater concentrations of visfatin have 
been reported in states of insulin resistance (IR) including T2DM and obesity 
(Fukuhara, Matsuda et al. 2005, Chen, Chung et al. 2006). For GDM, data has been 
conflicting with both higher (Ferreira, Rezende et al. 2011) and lower concentrations 
(Haider, Handisurya et al. 2007, Park, Kim et al. 2013) observed when compared to 
women with normal glucose tolerance (NGT). Almost all published data for GDM 
has included samples obtained at 24 weeks’ onwards, but a significant increase in 
visfatin, prior to the diagnosis of GDM at 11-13 weeks’, was found by Nicolaides et 
al. (Ferreira, Rezende et al. 2011) In contrast to adiponectin, visfatin concentrations 
in this study were not significantly affected by maternal age, BMI, smoking status, 
parity or ethnicity, a finding confirmed more recently by Park et al.(Park, Kim et al. 
2013). The relationship of adiponectin with these clinical variables is discussed in 
detail in 8.2 Prediction of GDM in UPBEAT pilot, page 165. 
Visfatin is expressed and secreted predominately by visceral adipose tissue with 
evidence of a placental origin during pregnancy (Ma, Cheng et al. 2010). The 
contribution of placental visfatin to systemic maternal concentrations is unclear since 
increased expression of visfatin has been noted in omental fat of pregnant women 
compared to non-pregnant controls with little difference in circulating 
concentrations, suggesting an auto or paracrine function (Briana and Malamitsi-
Puchner 2009).  It has been described in the literature as an “insulin-mimetic” with 
“anti-diabetogenic” properties. A series of review articles confirm that visfatin 
stimulates adipose and muscle uptake of glucose, inhibits hepatic gluconeogenesis, 
increases phosphorylation of proteins involved in post-receptor insulin signalling and 
binds to the insulin receptor although most likely to a different location than insulin 
itself (Fukuhara, Matsuda et al. 2005, Arner 2006, Kim da, Kang et al. 2014). 
Considering these roles, it has been postulated that high concentrations of visfatin, 
observed in selected GDM studies, is a consequence of hyperglycaemia and impaired 
adipokine action, similar to mechanisms of hyperinsulinaemia seen in IR in response 
to insufficient or impaired insulin secretion.  
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At present it is unclear whether a reduction in visfatin, achieved following a lifestyle 
intervention as found in this thesis, has beneficial implications for health. Outwith of 
pregnancy, current evidence would indicate favourable associations of reduced 
visfatin concentrations with T2DM risk although the direction and mechanisms 
involved in this relationship are not fully understood.  
Analysis of the UPBEAT study (n=1555) will provide important information as to 
whether modification of biomarkers associated with metabolic dysfunction and 
cardiovascular morbidity is achievable during the window of opportunity that 
pregnancy presents. Women with previous GDM have a 7-fold increased risk of 
developing T2DM (Bellamy, Casas et al. 2009) therefore any intervention that may 
interrupt the cycle perpetuated by obesity to reduce or delay the onset of T2DM 
beyond pregnancy would be important. 
8.2 Prediction of GDM in UPBEAT pilot 
The second study in this thesis addressed the potential for the use of a combination 
of biomarkers and clinical factors in the prediction of gestational diabetes in the 
UPBEAT pilot cohort. 
Research into the prediction of adverse outcomes in other pregnancy related 
conditions such as pre-eclampsia has shown that a combination of clinical history 
and early pregnancy clinical measures, together with addition of biomarkers 
measured in biological samples may provide an effective strategy in early pregnancy 
risk assessment (Akolekar, Syngelaki et al. 2013). Several studies have adopted this 
approach in prediction of GDM (Ferreira, Rezende et al. 2011, Lacroix, Battista et al. 
2013), but to our knowledge, not previously in a population of obese women. 
This study highlights novel biochemical and clinical factors for the prediction of 
GDM in obese pregnant women and suggests that an algorithm based on simple 
clinical variables plus adiponectin may provide a clinically useful method for 
prediction of GDM in this population.  
Four previous studies have identified a number of patient characteristics and 
biomarkers associated with the prediction of GDM in cohorts of mixed BMI 
(Savvidou, Nelson et al. 2010, Ferreira, Rezende et al. 2011, Nanda, Savvidou et al. 
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2011, Gobl, Bozkurt et al. 2012). These have been undertaken in populations of 
mixed risk, including non-Caucasian ethnicity (Ferreira, Rezende et al. 2011, Nanda, 
Savvidou et al. 2011, Gobl, Bozkurt et al. 2012), a family history of diabetes 
(Savvidou, Nelson et al. 2010, Ferreira, Rezende et al. 2011, Nanda, Savvidou et al. 
2011, Gobl, Bozkurt et al. 2012), previous history of GDM (Ferreira, Rezende et al. 
2011, Nanda, Savvidou et al. 2011, Gobl, Bozkurt et al. 2012), increased pre-
pregnancy BMI (Savvidou, Nelson et al. 2010, Ferreira, Rezende et al. 2011, Nanda, 
Savvidou et al. 2011), increased maternal age (Ferreira, Rezende et al. 2011, Nanda, 
Savvidou et al. 2011, Gobl, Bozkurt et al. 2012) and of differing parity (Savvidou, 
Nelson et al. 2010).  
Savvidou et al. measured nine biomarkers in the first trimester and found that high 
tPA and low HDL increased the AUC-ROC from 0.824 with clinical risk factors 
alone to 0.861 in a group of all comers regardless of baseline BMI (Savvidou, 
Nelson et al. 2010). The addition of adiponectin to prediction models for GDM has 
consistently increased the AUC-ROC to values above those achieved with clinical 
measures alone. Further inclusion of adipokines and biomarkers has frequently 
demonstrated a modest, non-significant increase in the AUC-ROC. For example, in a 
case controlled study of 400 women, those with GDM were reported to have 
increased maternal serum visfatin and decreased serum adiponectin concentrations at 
11-13 weeks. The addition of adiponectin to the prediction model using clinical 
measures alone resulted in a significant change in the AUC-ROC whereas there was 
a non-significant increase with addition of visfatin (AUC-ROC 0.828 [maternal 
characteristics alone], 0.854 [adiponectin] and 0.855 [adiponectin and visfatin]) 
(Ferreira, Rezende et al. 2011). Nanda et al. measured three biomarkers and found 
that in the GDM group, compared to controls, adiponectin and sex hormone-binding 
globulin (SHBG) were lower. When screening for GDM by maternal characteristics 
alone, the detection rate was 61.6% (false-positive rate of 20%) increasing to 74.1% 
with the addition of adiponectin and SHBG (Nanda, Savvidou et al. 2011).  
Alternative approaches to GDM risk assessment have included measurement of 
biomarkers in the preconception period, a recent report finding that maternal 
characteristics, fasting plasma glucose, glycosuria and preconception dyslipidaemia 
yielded an AUC-ROC of 0.90 for the prediction of GDM (Gobl, Bozkurt et al. 
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2012).  However, the various diagnostic criteria for GDM used in previous studies 
have limited comparisons between previous attempts to predict GDM. Importantly, 
none has specifically addressed risk assessment in obese pregnant women, which has 
important implications for clinical practice given the recognition of obesity as the 
major risk factor for GDM, and the likelihood that the biomarker profile in women 
with a high BMI may be dissimilar from other risk groups.  
Our results suggest that clinically useful prediction of GDM in obese pregnant 
women may be achievable using a combination of clinical characteristics (older age, 
increased blood pressure [SBP and DBP], parity ≥2 and black ethnicity) combined 
with the plasma concentration of adiponectin but more data is required from larger 
adequately powered studies prior to recommended use in clinical practice; this will 
be expanded in 8.2.1 Limitations, page 170. To reflect current clinical practice, 
routine clinical measurements recorded at antenatal visits were included. The 
inclusion of detailed maternal anthropometry (including skin-fold thicknesses), 
which is undertaken in all women participating in the UPBEAT trial, suggested a 
limited potential role for taking such measurements routinely as an aid to GDM 
prediction. Positive linear associations between upper arm skinfold thickness and 
maternal glucose concentration at 24-28 weeks’ have been reported by Tomedi et al. 
in a sub-sample of 214 women participating in the Study of Nutrition and Pregnancy 
Trial (mean BMI 28kg/m2) (Tomedi, Simhan et al. 2014). For every standard 
deviation increase in arm skinfold thickness (8.8mm biceps and 11.7mm triceps), a 
4.3mg/dL increase in maternal glucose (0.2mmol/l) was observed. Importantly, 
results were adjusted for established clinical confounders (pre-pregnancy BMI 
ethnicity, age, parity, education level and family history of diabetes) and 
measurements recorded at one time period only <13 weeks’ gestation when fat 
accretion is minimal and hence most likely to reflect true pre-pregnancy 
anthropometry. Practical barriers to greater uptake in clinical medicine include the 
additional time required for triplicate measures and the requirement of adequate 
training for staff.  
Adiponectin, an adipocyte derived adipokine, is now recognised as being strongly 
associated with improved glucose metabolism although the causality of this 
relationship remains debated. Irrespective of causal direction, adiponectin appears to 
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provide a good ‘read-out’ of whole body insulin sensitivity. In a recent meta-analysis 
of non-pregnant individuals adiponectin was shown to be strongly predictive of type 
2 diabetes, and inversely related to measures of insulin resistance and BMI. In this 
study, we have shown similar values for adiponectin at 28weeks’ gestation 
(5.39µg/ml [2.08]) to a previous report for a small cohort of obese women studied in 
Glasgow, which showed lower values than lean controls and a strong association 
between adiponectin and BMI (p=0.002) (Meyer, Stewart et al. 2013). 
The role of adiponectin in obese pregnant women may extend beyond usefulness as a 
biomarker. In the Hyperglycemia and Adverse Pregnancy Outcome (HAPO), serum 
concentrations of adiponectin declined as glucose and maternal BMI increased and 
adiponectin was inversely associated with birth weight, neonatal skin fold thickness 
and total body fat (estimated using anthropometry), giving rise to the hypothesis that 
this cytokine may play a role in fetal growth regulation by modulation of placental 
nutrient transport in addition to maternal glucose homeostasis (Lowe, Metzger et al. 
2010). Data in support of a placental origin of adiponectin remains equivocal, with 
evidence favouring maternal origin of adiponectin measured in the blood of pregnant 
women (Aye, Powell et al. 2013). Maternal adiponectin has, therefore, the potential 
to be a ‘functional’ target for interventions in obese pregnant women whereby 
achievement of increased plasma concentrations could parallel a reduced risk of 
macrosomia, although in the UPBEAT pilot study we found no significant increase 
in the intervention arm. However, adiponectin has been shown to be modifiable by 
dietary intervention in non-pregnant populations (Esposito, Pontillo et al. 2003). 
Lifestyle interventions in pregnant women of differing pre-pregnancy BMI 
categories have been equivocal in regard to effects on glucose metabolism and 
insulin resistance although none has previously measured adiponectin (Barakat, 
Cordero et al. 2012, Oostdam, van Poppel et al. 2012). On completion of UPBEAT 
(n=1555), the influence of the intervention on plasma adiponectin concentration in 
the whole cohort will therefore be explored.  
To the best of our knowledge there is only one other recently published study of 
adiponectin and GDM in an exclusively obese population (Ramirez, Miller et al. 
2014). Comparisons of findings with those in this thesis are limited due to numerous 
differences in protocol design despite similar outcomes for adiponectin. Ramirez et 
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al. recruited almost exclusively Hispanic women (92%) women at 24-28 weeks’ 
gestation, with maternal blood sampled at one time point only.  Within 2 weeks of 
enrolment, 30 cases of GDM were confirmed using the 2-step approach of 50gram 
glucose challenge followed by 100gram OGTT instead of the IADPSG 
recommendations. Although the total sample was smaller than the UPBEAT pilot, 
the incidence of GDM was higher (44.4% v 27.4%) as potentially anticipated in this 
ethnic group. In contrast, generation of the UPBEAT prediction model, incorporated 
adiponectin values predating the diagnosis of GDM at 15+0-17+6 weeks’ which is 
likely to carry greater relevance when translated into routine clinical care.  
The UPBEAT pilot findings, regarding adiponectin, are consistent with other reports 
in women of all BMI categories prior to the development of GDM or with 
established disease (Retnakaran, Hanley et al. 2004, Nanda, Savvidou et al. 2011). A 
Brazilian case controlled study, confirmed significantly lower concentrations of 
serum adiponectin in women with GDM, independent of BMI, in the third trimester 
(28-36 weeks’) (p=0.0015). Entry to the study was unrestricted by pre-pregnancy 
BMI however in keeping with published data, women with GDM were older with 
greater pre-pregnancy BMI (28.9 v 23.2kg/m2, p<0.001) (Gueuvoghlanian-Silva, 
Torloni et al. 2012). In contrast, although adiponectin was significantly lower in 
women who developed GDM in a previous study in women of mixed risk, it did not 
contribute to the final model which combined two factors (HDL-c and t-PA antigen), 
both recognised to be related to adiponectin via linked hepatic/circulating 
triglyceride-mediated pathways (Sattar, Wannamethee et al. 2008).  
Low serum adiponectin concentrations appear to be associated with ethnic groups 
known to have a higher risk of developing incident T2DM later in life (Lindsay, 
Funahashi et al. 2002). In the present study, women of black ethnic origin had 
significantly lower plasma levels of adiponectin than non-black women, in keeping 
with findings from previous work examining pregnant women of South Asian origin 
(Retnakaran, Hanley et al. 2004). Whilst we acknowledge our diverse ethnic 
population is not representative of the UK, having a large proportion of women of 
black ethnic origin (>80%) has yielded further insights into the relationship between 
adiponectin and ethnicity.   
 170 
We also observed a strong association between concentration of adiponectin and 
smoking status with a 50% reduction observed in smokers (p<0.001). Similar 
findings have previously been reported in a non-pregnant population in which the 
plasma adiponectin concentration increased in a stepwise fashion with “never, past 
and current smokers” (Miyazaki, Shimada et al. 2003).  
To date, current studies of dietary/ physical (Han, Middleton et al. 2012, Poston, Bell 
et al. 2015) and pharmacological (Chiswick, Reynolds et al. 2015) interventions have 
failed to demonstrate prevention of GDM in overweight or obese women. 
Nonetheless early prediction of GDM in this high-risk group has potential clinical 
implications. Positive maternal outcomes in terms of limited GWG reduction, 
increased physical activity and dietary modifications have been reported (Dodd, 
Cramp et al. 2014, Poston, Bell et al. 2015), with such findings forming part of an 
important overarching public health strategy. Whilst obstetric and neonatal outcomes 
are unchanged including the incidence of LGA, the LIMIT study reported a 
significant relative risk reduction of 18% in infant birth weight >4kg (Dodd 2014). 
Until improvements to defined clinical outcomes are demonstrated, the provision of 
lifestyle intervention programmes to all overweight and obese women is financially 
restricted. However since obese women remain at risk of adverse obstetric and long-
term metabolic sequelae, identifying those at greatest risk within this population 
would seem a reasonable approach.  
8.2.1 Limitations 
Fasting blood samples were not obtained at randomisation (15+0-17+6 weeks’), 
precluding the measurement of the fasting glucose or insulin concentration and thus 
assessment of HOMA-IR. However, as fasting is not mandatory for antenatal clinic 
visits, this study was designed pragmatically, to be relevant to current clinical 
practice in obese women.  
The most notable limitation of the prediction model was the sample size for the 
number of predictors considered (GDM n=28 and non-GDM n=77).  Extended 
reading in this field has raised multiple important principles detailed in the 
Transparent reporting of a multivariate prediction model for Individual Prognosis or 
Diagnosis (TRIPOD) statement (Collins, Reitsma et al. 2015). For logistic regression 
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analysis as used in prediction models or risk scores, statistical guidance recommends 
a minimum of 10 cases per independent variable (Hosmer, Lemeshow et al. 2013), a 
figure extended up to 30 by  Steyerberg et al. (Steyerberg, Vickers et al. 2010). More 
than ten clinical variables were included in preliminary univariate analysis, 7 of 
which were found to be significant (age parity ≥2, black ethnicity, SBP, DBP, triceps 
skinfold and sum of skinfolds). A total of 18 biomarkers were included in the 
analysis and following adjustment for the main clinical predictors (with the 
exception of anthropometry) only adiponectin was predictive of GDM.  
Applying these key principles, for the clinical predictors alone (n>10), 100 cases of 
GDM are required in contrast to the 28 cases in this study. Inclusion of all clinical 
and biochemical variables (n>30) would require 300 cases of GDM and a population 
sample size of over 900 subjects. This was an exploratory project using data from the 
UPBEAT pilot study with an inappropriately small sample size therefore the results 
are to interpreted with caution. Replication of this prediction model or development 
of a new one on the now complete UPBEAT cohort (n=1555, GDM cases=172) 
would need to take the recently published guidance into consideration.  
Internal validation of the model using discrimination with ROC curve analysis was 
performed. Other methods of internal validation including calibration were not used 
and external validation was outwith the scope this thesis. The initial aims was to 
utilise the completed UPBEAT cohort for the purpose of external validation but 
following review of the TRIPOD statement, revaluation together with redevelopment 
of this prediction model is advisable (Collins, Reitsma et al. 2015).  
The sample size calculation was for outcomes defined for the UPBEAT study and 
not specifically for those measured in this thesis. Data on similar studies in obese 
pregnant women was unavailable for power calculations in the preliminary stages of 
the protocol development for UPBEAT. The pilot study was powered for a change in 
dietary and PA behaviours at 28 weeks’ when the OGTT was performed. Phase 2 of 
UPBEAT, known as the “exploratory stage” was set within predefined time limits 
and the pilot size of 183 subjects was derived from this. This was an adequate 
number to allow for power calculations for the primary endpoints of GDM and LGA 
in the main RCT with an estimated variance of the true value of 7%. 
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In this high risk group, it is possible that some women with GDM may have had 
undiagnosed T2DM since initial screening with FBG or HbA1c was not undertaken, 
as IADPSG recommendations for universal testing for overt diabetes at the first 
antenatal visit have not been implemented. Thus, it is possible that low early 
pregnancy adiponectin concentrations may have been influenced by T2DM in a 
small minority of women.  However others have shown that low adiponectin 
concentrations are strongly predictive of GDM in women in whom T2DM was 
excluded antenatally (Hedderson, Darbinian et al. 2013).   
The algorithm developed in this study was based on the diagnosis of GDM by 
IADSPG criteria; it follows that it is potentially valid only for this method of 
diagnosis. Whilst IADPSG is increasingly being adopted, e.g. by the WHO, it would 
be appropriate to evaluate the predictive potential of the model in larger studies 
adopting other commonly used criteria.   
8.3 Summary 
In summary, we have made the novel observation that the risk of developing GDM 
in obese pregnant women may be predicted in the early second trimester of 
pregnancy by using an algorithm which incorporates routine clinical variables as 
well as the biochemical marker adiponectin. Our findings therefore extend prior 
studies and collectively suggest that by additionally measuring adiponectin in high-
risk women before routine clinical diagnosis of GDM, a potential therapeutic 
window for intervention could be created. Since GDM is associated with increased 
risk of incident type 2 diabetes and 10 year cardiovascular risk in mothers (Fraser, 
Nelson et al. 2012), as well as maternal and neonatal pregnancy complications, 
successful intervention has the potential to improve both short and long term 
outcomes. We conclude that further large scale studies of GDM prediction in obese 
pregnant women are warranted. This study highlights novel biochemical and clinical 
factors for the prediction of GDM in obese pregnant women and suggests that an 
algorithm based on simple clinical variables plus adiponectin may provide a 
clinically useful method for prediction of GDM in this population, and thereby 
identification of those women who might benefit most from an intervention. Whilst 
more accurate risk assessment may be costly, the recent demonstration of cost 
effectiveness using the IADPSG criteria for GDM diagnosis, suggests that initial 
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added costs may be offset by later gain. Earlier studies adopted the 1990 WHO 
criteria for GDM and until now, prospective evaluation of the IADPSG guidelines on 
pregnancy outcomes with cost effectiveness analysis has been unknown. In the first 
large study of its kind, the St. Carlos Gestational Diabetes Study reported significant 
reductions in multiple adverse clinical outcomes, coupled with estimated financial 
savings of €14, 000 per 100 women evaluated despite the increase in GDM rate (35.5 
v 10.6%) when comparing 2 cohorts of women diagnosed by IADPSG and the 2-step 
100 gram OGTT, currently recommended by the American College of Obstetricians 
and Gynaecologists (Duran, Saenz et al. 2014).    
 
The next step: offspring outcomes  
Offspring of obese women and those with GDM face an increased lifetime risk of 
abnormal metabolic outcomes associated with morbidity, inferring a role of 
intrauterine hyperglycaemia or early life exposures on the developing infant 
(Clausen, Mathiesen et al. 2008). Animal models have demonstrated multiple 
sequelae of maternal hyperglycaemia including impaired insulin signalling and 
pancreatic β-cell function, abnormal hypothalamic development associated with 
energy dysregulation and altered fat distribution in pups (Poston 2010). It is 
hypothesised that modification of the intrauterine environment to reduce fetal 
exposure to hyperglycaemia may influence maternal programming however the long 
term effects have not been addressed in large prospective RCTs other than a recent 
follow up study from the LiP cohort discussed in 1.5, page 58. Body composition 
measured by DEXA, anthropometry and surrogate markers of metabolic function 
(insulin, lipids, glucose and blood pressure) were recorded in 157 children up the age 
of 2.8 years in The Lifestyle in Pregnancy and Offspring (LiPO) follow-on study. No 
detectable effect of the intervention was found between the two arms of children 
participating either in the main trial or between the reference group of 97 children 
born to women of normal BMI (Tanvig, Vinter et al. 2014, Tanvig, Vinter et al. 
2014). Retention of participants for longitudinal data is notoriously difficult and at 
present the LiPO is the largest published cohort from an exclusively obese sample. 
Whether positive findings of such interventions translate into clinically meaningful 
offspring effects, remains unanswered but collaborative working from the LIMIT 
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(Dodd, Turnbull et al. 2014), ROLO (Walsh, Mahony et al. 2014) and UPBEAT 
(Briley, Barr et al. 2014) groups will generate important answers.   
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9 DISCUSSION: IGPOP, A PILOT STUDY OF AN 
LGI DIETARY INTERVENTION 
The third study in this thesis (IGPOP) carried out necessary preliminary 
investigations to inform a clinical trial of an LGI slow digesting carbohydrate 
supplement in obese pregnant women. 
Evidence to support LGI diets in pregnancy has not been consistent or reproducible 
but has yielded important information regarding safety.  It should be noted however, 
with exception of the LIMIT study (inclusion BMI≥25kg2), that none of the trials 
thus far have been designed specifically for obese pregnant (OP) women (Louie, 
Markovic et al. 2011, Marathe, Rayner et al. 2013, Moses, Casey et al. 2014, Walsh, 
Mahony et al. 2014).  
In the main, pregnancy outcomes in LGI dietary RCTs are unchanged but a review 
of the data does suggest several benefits with regards to reduction in GWG (Rhodes, 
Pawlak et al. 2010, Walsh, McGowan et al. 2012), positive associations with 
maternal HbA1c and plasma glucose concentrations (Scholl, Chen et al. 2004, 
Walsh, McGowan et al. 2012) and a reduction in progression to insulin therapy in 
GDM, coupled with reduced healthcare costs (Moses, Barker et al. 2009). 
Additionally, for women with GDM, diets with high glycaemic load (GL) are 
associated with an overall reduction in quality reflected by lower intakes of 
monounsaturated and polyunsaturated fats together with vitamin E and potassium 
(p<0.001) (Louie, Markovic et al. 2013).    
The most recent systematic review and meta-analysis of dietary interventions in 
GDM identified 9 eligible RCTs (n=884), categorised by intervention type as 
follows: LGI (n=4), low CHO (n=2), total caloric restriction (n=2) and others (n=1) 
based on ethnic variations of diet (Viana, Gross et al. 2014). With a reduction in 
mean birth weight and treatment with insulin the authors recommended LGI diets as 
the optimal dietary approach. 
As rates of maternal obesity, IGT, and GDM rise at an alarming rate, the need to 
identify the most effective low-cost intervention cannot be underestimated.  
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We tested two nutritional drink supplements of identical macronutrient composition 
in obese pregnant women (BMI 37kg/m2) without GDM, as part of a calorie 
controlled diet (CHO 60.7%, fat 20.8% and protein 18.5%). The supplements 
differed only by nature of CHO, generating a low GI value of 27 for the intervention.  
In contrast to the control, composed of 100% rapidly digesting CHO, the 
intervention supplement contained slow digesting CHO (68%), resistant starch 
(15.5%) and fibre (3.5g). As a consequence, the %E from fat did not increase.  
Using CGMS, we demonstrated that consumption of a slow digesting low glycaemic 
index (SD-LGI) nutritional supplement, specifically developed for use in pregnancy, 
significantly reduced glucose concentrations over a 24 hour period in addition to day 
and night periods when examined separately, compared to habitual living (p<0.001 
for all).  
Women were not required to record meal times on the CGMS system during the 
habitual phase of the study (Saturday and Sunday) therefore comparisons of post 
prandial glucose concentration (PPG) were only available for controlled study days 
between the intervention and control.  PPG was significantly lower following the 
intervention for breakfast only (p=0.03, 0.34 and 0.71 for breakfast, lunch and 
dinner). In clinical practice, this is often the most challenging time to maintain BG 
levels within accepted ranges for women with diabetes in pregnancy due to the 
normal physiological secretion of insulin counter-regulatory hormones together with 
high concentrations of processed CHO contained in breakfast foods (Porcellati, 
Lucidi et al. 2013). This often results in larger doses of insulin being used, associated 
with a greater risk of hypoglycaemia or alternatively removing CHO altogether, a 
difficult option for many women.  Therapeutic options using resistant or LGI CHO 
to reduce morning postprandial hyperglycaemia may have the potential for important 
clinical translation and wide usage not only in GDM but all types of diabetes in 
pregnancy, owing to the limitations of current agents (Porcellati, Lucidi et al. 2013).  
Numerous factors including meal composition, pre-meal glucose concentration, 
activity levels, insulin secretion, gastric emptying and hepatic glucose metabolism 
determine post prandial glucose. Hence, the reduction in post prandial glucose 
observed following traditional CHO restriction, can be explained only in part by the 
lower total CHO load. Since the rate of gastric emptying is delayed by fat, the 
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observed increase in %E from fat to approximately 45% following traditional dietary 
strategies recommended by the American College of Obstetricians and 
Gynaecologists (2013), will undoubtedly influence PPG, although the relative 
contribution of these two factors remains unquantified (Marathe, Rayner et al. 2013). 
In this thesis, improvements in post prandial glucose concentrations were observed 
without a reduction in CHO load or increase in %E from fat, excluding this 
mechanism as a confounder and thus supporting the role of CHO modification.   
In this study we were able to demonstrate improvements in post prandial glucose, 
without the adverse consequences of greater dietary fat, by using complex CHO. 
Importantly in this obese population, the addition of the nutritional supplement to the 
controlled diet did not exceed recommended daily energy requirements for the 
gestational age, (24hr total calorie content 2014kcal with 303kcal contribution from 
the supplement) (Rasmussen and Yaktine 2009).  
Obese women remain at greatest risk of lipotoxicity and its metabolic sequelae. This 
occurs as a consequence of increased hydrolysis of maternal triglycerides (TGs) 
from dietary sources and expanded adipose depots generating FFAs, which 
contribute to IR, cross the placenta and enter fetal adipocytes (Jarvie, Hauguel-de-
Mouzon et al. 2010, Catalano and Hauguel-De Mouzon 2011). Maternal 
concentrations of FFAs and TGs correlate positively with cord blood measures 
indicating an altered intrauterine environment, shown to be strongly predictive of 
accelerated fetal growth (Schaefer-Graf, Graf et al. 2008).  
It is possible that LGI diets are more effective in obese compared to lean women, 
where the degree of insulin resistance and beta cell dysfunction/depletion is 
exaggerated, in terms of improved pregnancy outcomes and overall glycaemia, 
(Langer, Yogev et al. 2005, Catalano 2007). The majority of adequately powered 
studies comparing LGI diets in women with GDM (Louie, Markovic et al. 2011, 
Louie, Markovic et al. 2013, Moreno-Castilla, Hernandez et al. 2013, Moses, Casey 
et al. 2014) and without GDM, (Walsh, McGowan et al. 2012, Moses, Casey et al. 
2014) have reported mean BMIs of 24-27kg/m2. In the heterogeneous LIMIT 
population (n=2212), 42% of women were classified as overweight and 58% obese 
(Dodd, Turnbull et al. 2014).  Unlike LIMIT where controls received no dietary 
advice, most RCTs including those outwith of GDM, have included standard healthy 
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eating dietary advice for all participants, thereby reducing the effect of any 
intervention.  An early study by Moses et al., reported improved obstetric outcomes 
(birth weight, ponderal index and incidence of LGA) comparing LGI to a “high-fibre 
moderate-to-high GI (HGI)” diet (n=62, mean BMI 25.5kg/m2, mean GI 51 v 58 for 
LGI and HGI respectively) however this result was not replicated in the larger RCT 
(mean BMI 24.5kg/m2) from the same group where the control group received 
healthy eating advice (Moses, Luebcke et al. 2006, Moses, Casey et al. 2014). In 
both studies the intervention arm achieved a significantly lower GI than the control 
but in the former, associated with improved clinical outcomes, a greater point 
difference in GI was found (7 versus 3) (Moses, Luebcke et al. 2006).  
These factors may in part explain the lack of consistent positive findings for studies 
of LGI diets in pregnancy. Additional confounders include different methods of 
diagnosing GDM, the optimal target glucose range before introduction of 
pharmacotherapy and the ethnicity of subjects which would influence not only 
genetic susceptibility to GDM but dietary habits also.   
Considering the potential therapeutic benefits of LGI diets in pregnancy, improving 
glycaemic control using this approach in high-risk obese women to limit progression 
to GDM is an area that warrants further exploration. As obese women do not 
routinely receive dietary advice in pregnancy, future research should include 
comparison of LGI diets against habitual intake and activity. Participation in any 
such study would inevitably introduce a degree of bias with control subjects more 
likely to improve their eating behaviours but as found in this small pilot study, the 
greatest reductions in glucose concentration were observed between the intervention 
and habitual diets at all time periods; 24 hour, day-time, night-time and FBG 
(p>0.001 for all). In contrast, smaller yet significant reductions in glucose 
concentrations were recorded between the intervention and control at 2 time periods; 
24 hour and day-time (p<0.001 for both).     
Glucose concentrations were generally lower on the 1st of each 2 day test period for 
the intervention and control.  Visits on these days were conducted in the clinical 
research facility (CRF), a highly controlled environment, with limited ability to 
exercise.  This could indicate issues with non-adherence to the prescribed diet on 
“home” days or more likely reflect a chance finding. Several methods were used to 
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improve compliance in the IGPOP study. Women were requested to return all empty 
food packets and drink cartons and complete a food and exercise diary. This was 
reviewed together with the dietician at each CRF visit. Open contact with the study 
team via a dedicated mobile telephone number was also available for additional 
support.  
Hernandez et al. conducted a study similar to IGPOP, evaluating the effect of a 
complex CHO-lower fat (HCC-LF) diet without nutritional supplements in 
overweight and obese pregnant women (mean BMI 34kg/m2), using CGMS in 
controlled and free living environments (Hernandez, Van Pelt et al. 2014). In this 
small, randomised cross-over study (n=16), subjects had GDM diagnosed by 
Carpenter and Coustan criteria (FBG 5.3mmol/l, 1 hour 10.0mmol/l, 2 hour 
8.6mmol/l or 3 hour 7.8mmol/l following 100 gram OGTT) therefore the comparator 
diet followed current practice of CHO restriction (CHO 40%, fat 45% and protein 
15%). No data for habitual diet was given. Using mean glucose concentrations at 
various time points, no difference between diets was found but glucose AUC was 
significantly greater for day and 24 hour periods (p=0.03 and 0.02 respectively) and 
post prandial glucose at 1 and 2 hours (p≤0.01 and 0.001) following the intervention 
HCC-LF diet. Nonetheless glucose values did not exceed current international 
treatment targets for GDM (1 hour <7.8mmol/l and 2 hour <6.7mmol/l) (Metzger, 
Buchanan et al. 2007) and the clinical relevance of this modest increase in glucose 
exposure on pregnancy outcomes requires further assessment.  
In the same study, the AUC for plasma insulin and C-peptide was greater (p≤0.001) 
and unchanged for TGs following the HCC-LF intervention diet (Hernandez, Van 
Pelt et al. 2014). For FFAs, a significant 19% reduction was observed. In 
comparison, we found no difference in plasma concentrations of insulin, C-peptide 
and TGs following the SD-LGI intervention supplement but a small increase in 
NEFA (p=0.049) following linear regression analysis. This may reflect differences 
between maternal obesity in the context of normal glucose tolerance and GDM. The 
trend in NEFA/FFAs was similar across both studies reaching a nadir at 120minutes. 
Comparisons of biochemistry data from the 2 studies is summarised below (Figure 
51).   
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Figure 51 Comparison of biochemistry data for NEFA and triglycerides from the IGPOP study 
following consumption of a SD-LGI supplement drink in obese pregnant women and following a 
high-complex CHO low fat diet in women with GDM participating in a study by Hernandez et al. 
(Hernandez, Van Pelt et al. 2014). Data presented as mean±SEM. 
Both populations were obese and ethnically diverse but it should be noted that 
women in the Hernandez study had GDM and were of greater gestational age (29-32 
versus 24-28 weeks’). By definition, when considering these two factors together, 
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women in their study were more likely to have a greater degree of IR.  Results 
differed by study day in IGPOP despite equivalent controlled conditions for both 
visits to the CRF.  This is likely to be a chance finding as the 2 day washout period 
was deemed adequate when compared to similar projects and preparation was the 
same for each visit (Hernandez, Van Pelt et al. 2014).  In both studies sample size 
was small (n=16) and IGPOP was powered only for change in glucose 
concentrations and not maternal biochemistry.  Following review of the available 
data, with particular reference to the reduction in NEFA achieved in the Hernandez 
study and similar trends in the IGPOP study, validation of these findings in a larger 
population may yield important results as to how an obesogenic environment could 
be modified.  
 
9.1 Limitations 
9.1.1 Study design 
Randomisation  
The simple randomisation software incorporated in the database design did not take 
into account the order of the drink consumed; sequence 1=intervention/control and 
sequence 2=control/intervention.  Subsequently, the allocation sequence for the 
initial 22 women was unbalanced with 13 randomised to sequence 1 and 9 to 
sequence 2. In primary analysis, this was shown to have introduced substantial bias 
in the CGMS data (Schulz and Grimes 2002).  
From a statistical perspective, simple randomisation is not adequate for this type of 
crossover study design and is more appropriate for sample sizes >200 subjects, since 
it carries a greater probability of group imbalance, as observed with IGPOP (Lachin, 
Matts et al. 1988, Schulz and Grimes 2002). In this situation, results can be affected 
by participant characteristics amongst other factors. Therefore in order to correct for 
this and minimise bias, a stratified random subsample of 8 patients by sequence, 
equally weighted by ethnicity was selected.  
Additionally, inherent limitations of the FreeStyle® Navigator system, with regards 
to sensor stability and accuracy, are likely to have influenced preliminary analysis of 
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the full unbalanced cohort. The first generation Navigator required an initial period 
of 10 hours before glucose values were reported due to post-insertion variability of 
sensor function (3-10 hours) caused by local skin trauma and healing (Weinstein, 
Schwartz et al. 2007). At this time, sensor signal was noted to be reduced leading to 
inaccuracies. To correct for this, 2nd generation software incorporated an algorithm 
named TRUstart™, requiring 5 SMBG calibrations to minimise the probability of 
unstable signal (Geoffrey, Brazg et al. 2011). This 2nd generation system was used in 
the IGPOP study with CGMS data obtained only after a successful 1hour calibration, 
following manufacturer’s recommendations. Despite this corrective software 
however, issues of sensor instability are considered to be negligible only after 24 
hours. To discard the 1st day of CGMS data in this small proof of concept study 
would have resulted in 50% data loss. The addition of an extra day prior to each 
crossover phase, to generate 24 hours of CGMS data and in turn minimize sensor 
instability, would have impacted recruitment particularly for women in employment 
or with young children.  
Since completion of this study, the next generation Navigator II with improved 
accuracy has been licensed for clinical use (https://abbottdiabetescare.co.uk/our-
products/other-meters/freestyle-navigator-2) and alternative methods of measuring 
ISF glucose have been launched. The Abbott FreeStyle® Libre uses latest 
technology to record glucose concentrations in a non-continuous manner using 
similar enzymatic subcutaneous sensor technology with readings generated only 
when the user swipes a reader across the sensor (http://www.freestylelibre.co.uk/).  
To obviate such issues in a larger RCT, an appropriate randomisation process would 
be adopted and most up-to-date sensors used. 
Due to study design, only CGMS data from the 1st night could be included for each 2 
day test period (Thursday–Friday and Monday-Tuesday) since the prescribed diet 
technically ended on midnight of the 2nd day, leaving the remainder of the night 
uncontrolled for. Nocturnal results are therefore underpowered but remain promising 
for a treatment effect of the SD-LGI supplement with lower glucose estimates for the 
intervention compared to the control and habitual diets (p=0.09 and p<0.001 
respectively). Clear instructions to avoid any oral intake overnight would have 
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allowed for inclusion of the 2nd night but from review of the data it was clear that 
individual subjects had eaten from midnight onwards.  
Women with confirmed GDM were ineligible for the study. Screening for GDM 
with a 75 gram OGTT, which would have excluded undiagnosed GDM or T2DM 
was not performed prior to entry. For one participant, a diagnosis of T2DM was 
highly likely and she was referred for appropriate medical follow up.   
In keeping with the local demography of Guys and St Thomas’ NHS Foundation 
Trust, we had a high number of women from Black ethnic minorities (15/22 and 
12/16) who have a significantly greater risk of GDM and T2DM compared to White 
European women of equivalent BMI (Ferrara 2007). The large reductions in glucose 
concentrations observed on the intervention diet compared to habitual living may not 
therefore be as pronounced in a Caucasian population, due to cultural differences in 
diet. Conversely the results indicate that those at greatest risk of GDM may stand to 
gain the greatest benefit from such dietary interventions in pregnancy as suggested 
by Louie et al. (Louie, Markovic et al. 2011).  
Habitual data was only collected at the weekend when eating and activity behaviours 
often differ from during the week when lifestyle is more regulated. This is an 
important point to consider when drawing conclusions from the data and in the 
design of future studies. 
9.1.2 CGMS technology 
A summary of other relevant limitations limited not only to the FreeStyle® 
Navigator but all commercially available systems is given below: 
1. Sensor drop out with loss of data occurs at extremes of temperature, when 
connection is lost with the receiver unit and in situations such a sleeping 
when additional external pressures are applied involuntarily. Although there 
is no clinical restriction to wearing the sensor on the abdomen in pregnancy, 
all women elected to use the upper arm thereby increasing the amount of 
nocturnal drop out whilst sleeping in a lateral position.  
2.  Some women experienced local skin irritation and problems with the sensor 
falling out particularly in the summer heat when the adhesive did not perform 
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optimally. In this instance, alternative adhesives were tried and the sensor 
relocated. 
3. The FreeStyle® Navigator only permits the mandatory calibrations when 
BG>3.3mmol/l. In this non-diabetic population, many subjects experienced 
BG<3.3mmol/l resulting in a “failed calibration” with interruption to glucose 
recordings until BG reached the desired range when a calibration was 
permitted.  
9.2 Summary 
Using CGMS, we demonstrated that consumption of a slow digesting low glycaemic 
index (SD-LGI) nutritional supplement, specifically developed for use in pregnancy, 
significantly reduced the plasma glucose concentration over a 24 hour period in 
addition to day and night periods when examined separately, compared to habitual 
living (p<0.001 for all) in obese women with no history of GDM in the index 
pregnancy. Postprandial glucose was lower if the test supplement was given with 
breakfast, but no different if given with other meals (p=0.03, 0.34 and 0.71 for 
breakfast, lunch and dinner).  
This approach to dietary management of hyperglycaemia in pregnancy may be 
specifically pertinent for obese women to reduce the increased energy contribution 
from greater fat consumption typically observed with current practice to restrict 
CHO.  
9.3 Future research following on from IGPOP 
IGPOP was a proof of concept study to investigate the effects of the SD-LGI 
supplement and inform the design of the large RCT “NIGO Health- Nutritional 
Intervention During Gestation and Offspring Health” which has now commenced 
(ISRCTN: NCT02285764). NIGO Health is part of EarlyNutrition, a research 
project funded by the European Union, to investigate the effect of early nutrition and 
lifestyle on metabolic programming (www.project- earlynutrition.eu).  
The research programme is centered on 5 scientific themes, designed to explore 
mechanisms of early nutrition programming, long-term outcomes of early 
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programming from infancy to adulthood and potential dietary interventions in 
pregnancy. 
In keeping with EarlyNutrition’s ethos of international collaboration, the NIGO 
Health protocol, funded in part by Abbott Nutrition (Spain and USA), has 
incorporated results from IGPOP and has been developed in unison with colleagues 
from IGPOP, together with principle investigators from the two recruitment sites 
(Granada, Spain and Munich, Germany).  
NIGO Health is a prospective RCT specifically for obese pregnant women (target 
n=324) comparing SD-LGI nutritional supplementation plus regular dietary support 
against routine clinical care (habitual diet). The intervention group will receive 
dietary recommendations for pregnancy based on recognised national standards and 
instructions on how to incorporate the study beverage into these recommendations 
without causing an extra calorie burden.  
Primary outcome is maternal blood glucose AUC at 28 weeks’ following a 75gram 
OGTT and secondary outcomes include neonatal body composition within 72 hours 
of birth and maternal FBG at 36 weeks’ gestation. Maternal blood will be collected 
at intervals in addition to cord blood, for the purposes of mechanistic and epigenetic 
studies.    
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10 CLINICAL RELEVANCE AND RESEARCH 
ARISING FROM THIS THESIS 
With 17-40% of pregnancies considered unplanned (Wellings, Jones et al. 2013) and 
poor compliance with existing preconception services (Glinianaia, Tennant et al. 
2014), focussing on early pregnancy in our contemporary obese antenatal population 
is equally important as directing resources on the preconception period only.  
10.1 UPBEAT Biomarkers and Prediction of GDM 
Understanding the role of adipose tissue in IR and identifying specific adipokines 
remains central to on-going research. Fetal over growth is only explained in part by 
the Pedersen hypothesis. The pro-inflammatory cascade, mediated by macrophage 
secretion of adipocytokines and insulin mediated lipolysis are perhaps more relevant 
in an obese population. The range examined in this thesis is comprehensive in 
comparison to similar studies and results are consistent with data supporting the role 
of adiponectin but thus far studies remain underpowered. The same biochemical 
analysis will be repeated on the full UPBEAT cohort (n=1555, GDM n=172 standard 
care group and n=160 intervention group, p=0.68) with further collaborations 
planned with the similar populations in the LIMIT and ROLO trials to generate 
meta-analyses (Walsh, McGowan et al. 2012, Dodd 2014).  
We did not demonstrate a difference in the concentration of free fatty acids between 
women with and without GDM nor any clear influence of the intervention but since 
FFAs are directly influenced by diet, larger studies are required to further the results 
of the small pilot studies in obese pregnant women previously discussed (Harmon, 
Gerard et al. 2011, Hernandez, Van Pelt et al. 2014).  
Evidence to suggest that adiponectin may be a modifiable target following a lifestyle 
intervention in various obese non-pregnant groups ranging from those with 
significant CV risk (Navaneethan, Fealy et al. 2015) to adolescents are emerging 
(Rambhojan, Bouaziz-Amar et al. 2015). Increased concentrations of adiponectin 
associated with reductions in measures of IR and CV risk have typically been in the 
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context of weight reduction therefore studies in pregnancy with progressive weight 
gain are still needed.     
Lifestyle and dietary interventions may not have significantly reduced GDM 
incidence or adverse obstetric outcomes in obese women thus far but multiple 
positive maternal outcomes have been reported.  
Universal GDM screening for all obese women recommend by NICE, in 
combination with new OGTT diagnostic glucose thresholds (NICE 2015) are not 
currently adopted by all UK obstetric centres due to pressures on clinical service and 
cost implications particularly in urban areas with high obesity rates. A robust GDM 
prediction model would therefore serve to better identify those women requiring an 
OGTT. At present a range of screening strategies are used for example across King’s 
Health Partners where a 2-step approach measuring a random venous glucose 
concentration prior to OGTT is followed. Conversely the ability to predict those 
women with a low probability of developing GDM would reduce the burden of 
additional OGTTs performed and help to streamline the diagnostic pathway. 
Utilising prediction models, in a similar to those routinely used in cardiovascular 
medicine would facilitate delivery of interventions to those who would benefit most 
and if delivered in groups, minimise the impact on current clinical services.  
Motivation to improve lifestyle factors during pregnancy is invariably high. As such, 
more accurate prediction of health risks in and beyond pregnancy would enable 
women to make informed decisions for their future health. It is not known whether 
maternal benefits of these relatively short duration interventions (GWG reduction, 
increased physical activity and dietary modifications) (Dodd, Cramp et al. 2014, 
Poston, Bell et al. 2015) extend beyond pregnancy or influence later health and 
further longitudinal assessment of these study cohorts would be useful. This would 
add to current knowledge that intensive exercise and metformin reduce progression 
to T2DM in women with previous GDM by up to 40% (Aroda, Christophi et al. 
2015).  
Incorporating recommendations of the TRIPOD statement, the GDM prediction 
model will be redeveloped and repeated on the now complete UPBEAT study of 
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1555 women. External validation will then need to be performed to ensure 
reproducibility of the model before widespread clinical usefulness can be evaluated.   
10.2 Improving Glycaemic Profiles in Obese Pregnant Women 
Medical nutrition therapy centred on global CHO reduction to limit postprandial 
glycaemia (PPG) and attenuate the effects of glucose-mediated pregnancy 
complications has been the initial approach to GDM management for over 20 years 
(Metzger 1991). At present, wide variations in dietary advice exist without 
international consensus. Nonetheless conventional practice to restrict CHO 
composition to 30-40%, from an average of 50-60%, is considered optimal for 
controlling glycaemia and limiting excessive weight gain although this has typically 
resulted in greater fat consumption e.g. CHO 40%, fat 45%, protein 15% (2013). 
This approach has remained relatively unchallenged but as evidence gathers in 
favour of modifying CHO composition/quality as opposed to quantity, to limit 
potential adverse effects of increased maternal fat intake, the focus is beginning to 
shift (Porcellati, Lucidi et al. 2013).  
More recently, outwith of pregnancy, the American Heart Association (AHA) and 
American College of Cardiology (ACC) have published a joint statement 
recommending a diet of similar macronutrient composition to that followed in the 
IGPOP study (CHO 60.7% and fat 20.8%) for reducing cardiovascular risk (CHO 
55-59% and fat 26-27%) (Eckel, Jakicic et al. 2014).  
Traditional approaches of in managing hyperglycaemia pregnancy with CHO 
reduction typically result in greater total fat consumption. With significant and 
increasing numbers of obese pregnant women this approach may warrant review to 
examine CHO composition rather than total composition to avoid any additional 
caloric burden to this high-risk group.  Further evaluation of the nutritional 
supplement in an adequately powered RCT has been established.  
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UPBEAT trial consortium                                                                                                                               
The 8th International Diabetes in Pregnancy Symposium, Berlin, April 2015 (poster) 
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S, Fernández LG, Rueda R, Poston L                                                                                          
The Power of Programming, Munich, March 2014 (oral) 
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R Maitland, N Patel, S Barr, C Sherry, B Marriage, JM López-Pedrosa, H Murphy, R 
Rueda,  L Poston                                                                                                                                          
Diabetes Pregnancy  Study Group (DPSG) annual meeting, Malta, October 2013 
(oral poster)   
Prediction of gestational diabetes (GDM) in obese pregnant women (UPBEAT 
Study)   
RA Maitland, N Sattar, P Seed, A Briley, S Thomas, D Pasupathy, L Poston                                  
Diabetes UK Annual Professional Conference, March 2013 (oral) 
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International Association of Diabetes and Pregnancy Study Groups (IADPSG) 
criteria in the UK Pregnancies Better Eating and Activity Trial (UPBEAT) pilot 
study                                 
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12 APPENDIX 1: IGPOP SUPPLEMENTARY 
DOCUMENTS 
Supporting documents granted ethical approval for use in the IGPOP study, are 
included in this chapter for review. A hard copy of the stage 2 participants handbook 
is also provided with the thesis.  
The following documents are summarised below:  
1. IGPOP Stage 1 and 2 participants’ preparation sheet 
2. IGPOP Stage 1 participants’ information sheet 
3. IGPOP Stage 1B participants’ information sheet  
4. IGPOP Stage 2 participants’ information sheet 
5. IGPOP Stage 2 meal choices with detailed dietary macronutrient composition  
 
12.1 IGPOP Study Preparation Sheet 
Instructions for the night before the study visit (for all four visits):  
• Do not eat or drink anything after 10pm the night before the study visit (water is 
allowed at anytime including the morning of the study visit). 
• Prior to fasting have a standard meal containing between 30-50 grams of 
carbohydrate 
o Please see the instructions and examples provided overleaf. 
• Avoid heavy intensity physical activity/ exercise the evening before the visit. 
• Avoid alcohol and caffeine the evening before the visit. 
 
Please remember to bring the following with you to the research facility: 
• Taxi receipts if applicable (however the majority of taxi journeys will be arranged 
through an Addison Lee account). 
• Maternity notes (if applicable) – please bring these to every visit.  
• You may wish to bring a few layers of clothing as the air conditioning in the 
research facility can be quite cold.   
• There will be a waiting period between blood samples; therefore you may wish to 
bring some reading material with you. There is also wifi if you wish to bring a 




Directions to the research centre: 
 
 
Instructions for the evening meal: In order to provide an accurate assessment of your 
glucose (blood sugar) levels on the study day, it is important to standardise the previous 
evening meal to include between 30-50 grams of carbohydrate. Meal suggestions are 
provided in table 1, however you can substitute for others as listed in table 2, provided the 
total does not exceed 50g carbohydrate. The most accurate way to know how much 
carbohydrate you are eating is by weighing the food.   
 
A few points to consider:  
• If you are planning on eating pre-packaged food, use the ‘nutritional information’ 
table on the back which will tell you the carbohydrate content, look for the ‘total 
carbohydrate’ rather than the ’of which sugars’. Remember to look at the ‘per 
pack/ per portion’ carbohydrate values as these will also be listed as per 100g.  
• If you leave any food or share any pre-packed food, please factor this in to your 
estimation of carbohydrate intake.  
• Starchy and sweet foods are the main source of carbohydrates, however fruits, 
vegetables, fruit juices and milk also containing carbohydrates as well as sauces 
such as gravy, ketchup and pickles in smaller amounts.  
• Meats, fish and fats such as butter and oils do not contain carbohydrates, therefore 
can be eaten freely.  
 
Clinical Research Facility, 4th floor, North Wing, St Thomas’ hospital 
Westminster Bridge Road, London, SE1 7EH 




Table 1. Example meals: 
Meal Carbohydrate content  
Homemade meal examples:   
Chicken and curry sauce (150g) with small average portion 
rice (100g – approximately 3 tablespoons) 
4grams  
Roast beef / chicken + 3 small roast potatoes , 2 tablespoons 
peas + gravy 
40grams  
2 tablespoons cous cous + meat /fish + salad + 1 yoghurt 
(200g) 
45grams 
Medium jacket potato with cheese or tuna and side salad. 50grams 
Ready meals examples:   
Sainsbury's Fish Pie, Be Good To Yourself 450g 41grams per pack 
Sainsbury's Chilli Con Carne, Be Good To Yourself 400g 50grams per pack 
ASDA Good For You Chicken Tikka Masala & Pilau Rice 49grams per pack 
ASDA Good For You Tomato, Chicken & Basil Pasta (350g) 46grams per pack 
TESCO Light choices chicken and vegetable pasta 400g 50grams per pack 
TESCO Light choices white fish &steamed potates 400grams 
(plus x1 200g yogurt) 
30grams per pack+15grams 
for yogurt=45 grams 
 
 
Table 2. Carbohydrate contents of common foods 
Food Portion size Carbohydrate content 
(grams) 
White or Wholemeal bread 1 thick slice (large loaf – 45g) 
1 medium slice (large loaf – 35g) 




Granary Bread  1 medium slice (35g)  25  
Pitta Bread  1 standard (75g)  45  
Burger Roll  1 (50g)  25  
All Rice – white, brown, 
basmati  
   
Small portion (100g)  
Medium portion (180g)  




White & Wholemeal 
Spaghetti  
Pasta (any shape)  
Small portion (150g)  
Medium portion (230g)  




Macaroni Cheese  Average portion (220g)  30  
Couscous  1 tablespoon (33g)  15 
Tinned Spaghetti  Small tin (215g)  25  
Baked/ kidney/ butter beans 3 tablespoons (120g)  20  
New potatoes, boiled  1 average (40g)  5  
Chips  Per 5 chips (50g)  10  
Roast Potato  1 small (50g)  10  
Mashed Potatoes  1 Scoop (60g)  




   
2 tablespoons (60g)  
Canned, 2 tablespoons (60g)  
5  
10  
Sweetcorn canned  2 tablespoons 15  
Yorkshire Pudding  1 average (80g)  20 
Contact details:  Dr Rahat Maitland, Diabetes Research Doctor Tel: 07974940221 
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Pizza (cheese & tomato) - 12"  1/2 thin crust (150g)  50 
Thick Sausages/Fish fingers  2 (40-50g)  10 
Breaded fish  1 fillet (150g)  20 
Breaded chicken  1 individual (170g)  15 
Stuffing 1 tbsp (30g)  5 
Fishcake 1 (50g)  20 
Sugar or Glucose  2 level teaspoons (8g)  8  
Honey, Jam or Syrup  2 level teaspoons(8g)  8  
Fizzy Drinks (Not Diet) e.g. 
Coca Cola  
100mls/4floz  5  
Orange Juice  100mls/4floz  10  
Fresh milk: Skimmed & Full 
Cream, Semi-skimmed  
200mls (1/3 pint)  10  
Natural Yoghurt  Small Carton (125g)  10  
Low fat Yoghurt  Small Carton (125g)  20  
Diet Yoghurt e.g. Shape, 
Muller Light  
Small Carton (125g)  




12.2 IGPOP Stage 1A Patient Information Sheet  
 
Participant Information Sheet 
You are being invited to take part in a research study. Before you decide to take part, it is 
important for you to understand why the research is being done and what it will involve. 
Please take time to read the following information carefully and do not hesitate to ask us if 
there is anything that is not clear or if you would like more information. Feel free to talk to 
others about the study and take time to decide whether or not you wish to take part. This 
research contributes towards a medical doctoral (MD) educational qualification.  
PART 1 
Title of project: Blood sugar profiles following consumption of low glycaemic index 
nutritional products.  
1. What is the purpose of the study? 
This study will test the blood sugar response to drinks with a different glycaemic index 
values. The glycaemic index of a food is the response of blood sugar to that particular food 
or drink, compared with an equivalent amount of a standard food (glucose). Foods or drinks 
with a high glycaemic index affect blood sugar levels quickly and foods or drinks with a low 
glycaemic index affect blood sugar levels slowly. We plan to test the glycaemic index of 
three different drinks when compared to a drink with the same amount of carbohydrate (a 
control drink). Once the blood glucose response to these drinks has been determined they 
will be used in a second study, which you are not required to take part in. This research is 
sponsored by a commercial organisation and will be carried out in a research healthcare 
setting by healthcare professionals.  
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2. Why have I been chosen? 
You have been selected because you are a female aged 18-40 years and fit into one of the 
groups of women below based on weight and pregnancy status.  
We will be testing the nutritional supplement in 4 different groups of women; pregnant and 
non pregnant and lean and obese (as defined by your weight for height) to see if this makes a 
difference to how the supplements affect blood sugar levels. 
5. Lean non-pregnant (BMI 18.5-25kg/m2) 
6. Obese non-pregnant (BMI ≥30kg/m2) 
7. Lean pregnant (BMI 18.5-25kg/m2) 
8. Obese pregnant* (BMI ≥30kg/m2) 
 The pregnant women will be between 24-28 weeks gestation and have single pregnancies 
only. You would not be able to take part if you have diabetes that was diagnosed either 
before or during your pregnancy. The study would require four morning visits to the hospital 
and each time you would need to come fasted.   
3. What is being tested?  
We will be testing three different drinks which vary in their glycaemic index, plus a control 
drink (4 in total). These drinks contain only nutrients which are part of our normal diets 
(fats, sugars, starches, protein and vitamins and minerals), and the three drinks will vary in 
the proportion of these nutrients. The drinks do not contain anything that is not considered 
food.  
4. What will happen to me if I take part? 
It is up to you to decide of you want to take part. The data and samples collected for the 
study are not part of any routine care you may be receiving. If you do decide to take part you 
will be given this information sheet to keep and will be asked to sign a consent form. You 
are still free to withdraw at any time and without giving a reason. A decision to withdraw at 
any time, or a decision not to take part, will not affect the standard of any health care you 
receive. If you withdraw from the study, we will use any data collected up to the point of 
your withdrawal. 
If you decide to take part you will be asked to attend the research centre on four separate 
occasions over a period of seven or eight days at two day intervals (e.g. every other day),  
Once we have received your signed consent form we will send you a pre-appointment study 
pack prior to your first appointment at the study centre. This contains a medical screening 
questionnaire to confirm your eligibility to take part and detailed instructions on what to do 
the night before the study.  Complete the medical screening questionnaire and return to the 
research team in the prepaid envelope as soon as possible.  A member of the research team 
will contact you on receipt of your form to confirm that you are eligible to be included in the 
study and to arrange a date for you to start the study. 
You will need to provide written consent to participate and to complete a medical screening 
questionnaire. You need to be able to visit the research centre in the morning fasted on four 
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occasions for approximately 4.5 hours (days 1, 3, 5, 7 and 8). A number of measurements 
will be taken including blood samples as detailed in the box above. We appreciate how busy 
you are and are grateful for the time given to come to the hospital. As you will need to come 
to the hospital fasted on every occasion we will arrange complementary taxi transport. 
Compensation will be provided for the inconvenience of taking part in the form of £150 
worth of shopping vouchers. 
1. What are the possible disadvantages and risks of taking part? 
The drawing of blood may include some discomfort when the needle enters the finger. If any 
of your blood sugar measurements are outside of the normal range your GP will be informed 
in writing to enable these to be retested and managed as appropriate. 
2. What are the possible benefits of taking part? 
This study is unlikely to have any personal benefit to you. As a result of participating in the 
study you can receive a summary of your body measurements (weight, body mass index, 
blood pressure and blood sugar level).    
Both principle investigators are registered health professionals and therefore have the 














3. What do I have to do? 
You will need to provide written consent to participate and to complete a medical screening 
questionnaire. You need to be able to visit the research centre in the morning fasted on four 
At the research centre the following procedure will be followed:  
Evening before the appointment: 
Consume a standard evening meal (as described by the research team) and then, after 8 
pm, do not eat or drink anything other than water.   
Appointment day:  
  Do not eat or drink anything other than water until after your visit to the study centre. 
Attend an early morning appointment at the study centre, (St Thomas Hospital, 
London). You will be required to be at the study centre for approximately 4.5 hours. 
• A trained person will take small finger-prick blood samples from your finger at 
nine timepoints within the 4.5 hours.  
• On three occasions you will be asked to consume a drink containing different 
proportions of nutrients which are part of our normal diets (fats, sugars, starches, 
protein and vitamins and minerals) so that your body’s blood sugar response to 
these can be assessed. 
• On one further occasion you will be asked to consume a control drink containing 
the same amount of carbohydrate so that your body’s response to this can be 
assessed. 
• A trained person will take measurements of your blood pressure, weight and 
height.  
You will then be offered a meal and be free to leave the study centre.  
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occasions for approximately 4.5 hours (days 1, 3, 5, 7 and 8). A number of measurements 
will be taken including blood samples as detailed in the box above. We appreciate how busy 
you are and are grateful for the time given to come to the hospital. As you will need to come 
to the hospital fasted on every occasion we will arrange complementary taxi transport. 
Compensation will be provided for the inconvenience of taking part in the form of £150 
worth of shopping vouchers. 
4. What are the possible disadvantages and risks of taking part? 
The drawing of blood may include some discomfort when the needle enters the finger. If any 
of your blood sugar measurements are outside of the normal range your GP will be informed 
in writing to enable these to be retested and managed as appropriate. 
5. What are the possible benefits of taking part? 
This study is unlikely to have any personal benefit to you. As a result of participating in the 
study you can receive a summary of your body measurements (weight, body mass index, 
blood pressure and blood sugar level).    
Both principle investigators are registered health professionals and therefore have the 
necessary expertise to undertake the research project described.  
If you are interested and are considering taking part, please continue to read the 
additional information in Part 2 before you make a decision. 
PART 2 
6. What if there is a problem? 
Any complaint about the way you have been dealt with during the study or any possible 
harm you might suffer will be addressed. If you have a concern about any aspect of your 
participation, please raise this with Dr Rahat Maitland (Rahat Maitland, Research Diabetes 
Doctor) Tel: 07974940221 or 020 7188 7804 or Dr Suzanne Barr (0207 848 3360) who will 
do their best to answer your questions. If you remain unhappy and wish to complain 
formally, you can do so by contacting the normal NHS complaints mechanism. 
7. Will my taking part in the study be kept confidential? 
Yes. All the information about your participation in this study will be kept confidential. A 
code number will be used to identify any information provided from questionnaires and 
samples. This information will be stored securely and only accessed by the named 
investigators. No names will be used in any reports or publications related to this work.  
8. What will happen to any samples I give? 
No samples are being stored, as the glucose the glucose meter will give levels from the 
finger prick test instantly. 
9. What will happen to the results of the research? 
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The results will be published in a scientific journal. The results will also inform a second 
larger study which plans to use the drinks tested. Participants will not be identified in any 
reports or publications arising from the study. 
Your glucose results may be used in future studies with academic and commercial partners 
looking at other pregnancy related problems. All such projects will have been granted ethical 
approval. 
10. Who is organising and funding the research? 
Abbott Nutrition, a commercial company, has funded this study. The midwife and research 
nurses working on this study have their salaries paid by this organisation. The hospital, 
doctors and dietitian do not receive any payment if you help with this research.  
11. Who has reviewed the research? 
The Riverside research ethics committee has reviewed this study. 
If you agree to take part in the study you will keep a copy of this information sheet and a 
signed consent form. 
12. What do I do if I have further questions or want to take part? 
For further information please contact: 
Suzanne Barr, Research Dietician 
Tel: 020 7848 3360 
Rahat Maitland, Diabetes Research Doctor 
Tel: 07974940221 or 020 7188 7804  
 
Members of the Research Team:  
Dr Rahat Maitland  and Dr Suzanne Barr 
Collaborating investigators:  
Professor Lucilla Poston 
Dr Ricardo Rueda 
Dr Barbara Marriage 
Dr Helen Murphy 
Dr Jose M Lopez 
Dr Stephen Thomas 
Dr Christina Sherry 
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12.3 IGPOP Stage 1B Patient Information Sheet  
 
 
Participant Information Sheet 
You are being invited to take part in a research study. Before you decide to take part, it is 
important for you to understand why the research is being done and what it will involve. 
Please take time to read the following information carefully and do not hesitate to ask us if 
there is anything that is not clear or if you would like more information. Feel free to talk to 
others about the study and take time to decide whether or not you wish to take part. This 
research contributes towards a medical doctoral (MD) educational qualification.  
PART 1 
Title of project: Blood sugar profiles following consumption of a low glycaemic index 
nutritional product.  
1. What is the purpose of the study? 
This study will test the blood sugar response to a drink with a low glycaemic index value. 
The glycaemic index of a food is the response of blood sugar to that particular food or drink, 
compared with an equivalent amount of a standard food (glucose). Foods or drinks with a 
high glycaemic index affect blood sugar levels quickly and foods or drinks with a low 
glycaemic index affect blood sugar levels slowly. We plan to test the glycaemic index of a 
drink when compared to a glucose (sugar) drink. Once the glycaemic index value of this 
drink has been determined it will be used in a second study, which you are not required to 
take part in. This research is sponsored by a commercial organisation and will be carried out 
in a research healthcare setting by healthcare professionals. 
2. Why have I been chosen? 
 
You have been selected because you are a female aged 18-40 years, have a normal body 
mass index (normal weight for height [BMI 18.5-25kg/m2]), are not pregnant and have no 
known diabetes. The study will require two morning visits to the hospital and each time you 
would need to come fasted.   
3. What is being tested?  
We will be testing a drink which is thought to have a low glycaemic index plus the standard 
glucose drink. The drink contains only nutrients which are part of our normal diets (fats, 
sugars, starches, protein and vitamins and minerals). The drinks do not contain anything that 
is not considered food.  
4. What will happen to me if I take part? 
It is up to you to decide of you want to take part. The data and samples collected for the 
study are not part of any routine medical care you may be receiving. If you do decide to take 
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part you will be given this information sheet to keep and will be asked to sign a consent 
form. You are still free to withdraw at any time and without giving a reason. A decision to 
withdraw at any time, or a decision not to take part, will not affect the standard of any health 
care you receive. If you withdraw from the study, we will use any data collected up to the 
point of your withdrawal. 
If you decide to take part you will be asked to attend the research centre on two separate 
occasions over a period of three days with a rest day in between (e.g. every other day),  
Once we have received your signed consent form we will send you a pre-appointment study 
pack prior to your first appointment at the study centre. This contains a medical screening 
questionnaire to confirm your eligibility to take part and detailed instructions on what to do 
the night before the study.  Complete the medical screening questionnaire and return to the 
research team in the prepaid envelope as soon as possible.  A member of the research team 
will contact you on receipt of your form to confirm that you are eligible to be included in the 















5. What do I have to do? 
You will need to provide written consent to participate and to complete a medical screening 
questionnaire. You need to be able to visit the research centre in the morning fasted on two 
occasions for approximately 2.5 hours (days 1 and 3). A number of measurements will be 
taken including blood samples as detailed in the box above. We appreciate how busy you are 
At the research centre the following procedure will be followed:  
Evening before the appointment: 
Consume a standard evening meal (as described by the research team) and then, after 8 
pm, do not eat or drink anything other than water.   
Appointment day:  
  Do not eat or drink anything other than water until after your visit to the study centre. 
Attend an early morning appointment at the study centre, (St Thomas Hospital, 
London). You will be required to be at the study centre for approximately 2.5 hours. 
• A trained person will take small finger-prick blood samples from your finger at 
seven time points within the 2.5 hours.  
• At one appointment you will be asked to consume a drink containing 50g glucose 
(sugar) so that your body’s response to this can be assessed. 
• On the other occasion you will be asked to consume a drink containing different 
proportions of nutrients which are part of our normal diets (fats, sugars, starches, 
protein and vitamins and minerals) so that your body’s blood sugar response to this 
can be assessed. 
• A trained person will take measurements of your blood pressure, weight and 
height.  
You will then be offered a meal and be free to leave the study centre.  
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and are grateful for the time given to come to the hospital. As you will need to come to the 
hospital fasted on every occasion we will arrange complementary taxi transport. 
Compensation will be provided for the inconvenience of taking part in the form of £75 worth 
of shopping vouchers. 
6. What are the possible disadvantages and risks of taking part? 
The drawing of blood may include some discomfort when the needle enters the finger. If any 
of your blood sugar measurements are outside of the normal range your GP will be informed 
in writing to enable these to be retested and managed as appropriate. 
7. What are the possible benefits of taking part? 
This study is unlikely to have any personal benefit to you. As a result of participating in the 
study you can receive a summary of your body measurements (weight, body mass index, 
blood pressure and blood sugar level).    
Both principle investigators are registered health professionals and therefore have the 
necessary expertise to undertake the research project described.  
If you are interested and are considering taking part, please continue to read the 
additional information in Part 2 before you make a decision. 
 
PART 2 
8. What if there is a problem? 
Any complaint about the way you have been dealt with during the study or any possible 
harm you might suffer will be addressed. If you have a concern about any aspect of your 
participation, please raise this with Dr Rahat Maitland (Rahat Maitland, Research Diabetes 
Doctor) Tel: 07974940221 or 020 7188 7804 or Dr Suzanne Barr (0207 848 3360) who will 
do their best to answer your questions. If you remain unhappy and wish to complain 
formally, you can do so by contacting the normal NHS complaints mechanism. 
9. Will my taking part in the study be kept confidential? 
Yes. All the information about your participation in this study will be kept confidential. A 
code number will be used to identify any information provided from questionnaires and 
samples. This information will be stored securely and only accessed by the named 
investigators. No names will be used in any reports or publications related to this work.  
10. What will happen to any samples I give? 
No samples are being stored as the glucose levels from the finger prick test will be given 
instantly by the glucose meter. 
11. What will happen to the results of the research? 
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The results will be published in a scientific journal. The results will also inform a second 
larger study which plans to use the drinks tested. Participants will not be identified in any 
reports or publications arising from the study. 
Your glucose results may be used in future studies with academic and commercial partners 
looking at other pregnancy related problems. All such projects will have been granted ethical 
approval.  
12. Who is organising and funding the research? 
Abbott Nutrition, a commercial company has funded this study. The midwife and research 
nurses working on this study have their salaries paid by this organisation. The hospital, 
doctors and dietitian do not receive any payment if you help with this research.  
13. Who has reviewed the research? 
The Riverside research ethics committee has reviewed this study. 
If you agree to take part in the study you will keep a copy of this information sheet and a 
signed consent form. 
14. What do I do if I have further questions or want to take part? 
For further information please contact: 
Suzanne Barr, Research Dietician 
Tel: 020 7848 3360 
Rahat Maitland, Diabetes Research Doctor 
Tel: 07974940221 or 020 7188 7804  
Member of the research team:  
Dr Rahat Maitland  and Dr Suzanne Barr 
Collaborating investigators:  
Professor Lucilla Poston 
Dr Ricardo Rueda 
Dr Barbara Marriage 
Dr Helen Murphy 
Dr Jose M Lopez 
Dr Stephen Thomas 
Dr Christina Sherry 
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IG-POP (Improving glycaemic profiles in obese pregnancies) Stage 2 
 Background 
We all know that people are getting heavier and this can lead to many different types of 
health issues. Many women who are obese when they are pregnant have no problems and 
deliver a healthy baby. However we do know that obese women are more at risk of 
pregnancy related complications than women who are lean. These complications include 
miscarriage, high blood pressure and gestational diabetes (GDM). GDM can cause the baby 
to grow excessively and be larger than expected which can cause problems at delivery. We 
also know that pregnant women with GDM have a higher risk of developing diabetes later in 
life after their baby is born.  
In gestational diabetes blood glucose levels (sugar) are higher than normal for pregnancy. 
We know that women who are heavier have higher glucose (sugar) levels than lean women, 
which may not be high enough to have actual gestational diabetes. Changing the diet is one 
of the best ways to help keep the blood sugar levels down and prevent gestational diabetes. 
We want to see if a nutritional supplement made especially for obese pregnant women can 
help to lower glucose levels and reduce the chances of getting gestational diabetes. The 
nutritional supplement is already sold overseas for people who are overweight and are keen 
to try and lower their blood glucose level almost like spreads, which you see advertised on 
the TV to help people lower their cholesterol levels. This supplement has been changed 
slightly to provide a range of pregnancy specific vitamins and minerals.  
It would be very useful to see how long this new nutritional supplement works for and how 
long it can help lower your blood glucose levels. To do this we can use the most up to date 
technology. A tiny sensor is used and the tip (less than half a cm) is put in just under the 
skin. This measures the glucose levels every minute without having to do lots of blood tests. 
We know that it is safe to use in pregnancy and it can be worn for up to 5 days and give us 
lots of helpful information. Once it has been put in, you can’t feel it. 
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We are also interested in whether the emotional and physical changes that occur during 
pregnancy are affected by a woman’s weight when she becomes pregnant. For example, 
research has suggested that a large proportion of pregnant women experience periods of 
anxiety, low mood and binge eating during pregnancy but little is known about how these 
are related to women’s weight.  This part of the study called “Investigating Attitudes to 
Eating in Pregnancy” will explore mental health and eating patterns in pregnancy.  
Why have I been chosen?  
You have been asked to take part because you are pregnant and had a body mass index 
(BMI) of 30 or more when you first saw your midwife or doctor.  
What do I have to do if I take part? 
You will be seen by a member of the research team who could be a midwife or doctor who 
will answer any questions you may have. You will be asked a few questions about you 
medical and obstetric history to make sure you can take part in the study and some questions 
about your current eating habits. At this time we will also show you the small glucose sensor 
so you can have a look to see how it works and also have a trial of wearing it. Once you 
have agreed to take part you will be asked to sign a consent form and be given a copy of this 
to keep.   
The whole study lasts 7 days but you will only need to come to the hospital on 2 visits to 
take part. Before the actual study starts we will send you a food diary to fill in with help on 
how to do this which will be reviewed by a dietician. The visits will be in the morning and 
you will need to come to hospital fasted. You will then have your breakfast in the hospital 
and a mid-morning snack also. During this time blood samples will be taken at regular times 
but this will be through a cannula (like those used for drips) to avoid you having lots of 
blood tests. The glucose sensor will be fitted and we will make sure you know how to 
manage it. After this has been done you go can go home and we will make sure you have a 
contact number if you have any problems. After the weekend you will come back to the 
hospital fasted again. You will have your breakfast and mid-morning snack with us and we 
will take some blood samples again. After this you can go home. We will contact you 2 days 
later to arrange either removing and picking up the glucose sensor at your home or arranging 
a time for you to come back to the hospital to have it removed. 
All blood samples will be processed and frozen. These will be barcoded and stored so no one 
will know the sample is yours for up to 6 years. Further studies investigating other 
pregnancy related problems may be carried out in the future using these samples with 
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academic and commercial partners but all such projects will have been granted ethical 
approval.  
If you agree to take part in the main study we would also like to ask you take part in the 
separate study called “Investigating Attitudes to Eating in Pregnancy.” You don’t have to 
take part in this unless you want to.  
We would like to hear about your experiences during pregnancy in a one-to-one interview. 
This interview will not have set questions; the interviewer will introduce some topics but 
then you can be in control of the discussion. These topics will be related to pregnancy, 
weight, eating and mood. We really want to hear your perspective. The interview will be 
carried out by the PhD student working on this project 
We would also like to do two questionnaires with you; one includes questions about mental 
health and the other is about binge eating experiences. 
This would happen during one of your main study appointments. The questionnaires and 
interview should take around 1 hour in total, and should be able to fit into breaks in the main 
study appointment. If you find that you have a lot to say during the interview, the session 
may take a little longer, but this is completely up to you and your travel expenses to get 
home will still be covered.  
Do I have to take part?  
Whether you decide to take part or not is entirely up to you. Your decision will not affect the 
care you receive in any way. If you agree to take part, you are free to withdraw at a later 
stage, without giving a reason. You can also decide whether or not you would also like to 
take part in the “Investigating Attitudes to Eating in Pregnancy” part of the study. If you do 
choose withdraw at anytime we will ask if you mind us using the results we have collected 
so far from you for analysis.  
Will my taking part be kept confidential? 
All information will be kept strictly confidential. Any information stored about you will 
have your name, address and other identifying details removed. All computers used will be 
password protected. Only people directly involved in the study will have access to the 
information. A letter explaining that you have taken part in this study will be inserted into 
your antenatal handheld notes that you keep. If any unexpected or abnormal findings are 
discovered as a result of the study we will refer you to the correct doctor for further follow 
up and let your GP know. 
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If you participate in the “Investigating Attitudes to Eating in Pregnancy” interview, we will 
ask your permission to audiotape the session. The audiotapes will be stored in a locked 
secure place at all times and will be destroyed at the end of the study.  
If your responses during the questionnaires or interview suggest that you are suffering from 
an eating disorder or mental health problem, the interviewer will discuss with this you and 
will contact her research supervisor (a psychiatrist specialising in mental health around 
pregnancy). She may refer you to your GP, but only if you agree to this. The only exception 
to confidentiality will be if you disclose information which suggests a risk of serious harm to 
any person (including yourself). In this case, your GP and other clinical staff involved in 
your care will be informed. This would be discussed with you during your appointment.  
What are the benefits of taking part? 
You are unlikely to benefit personally from taking part in either study. 
You may help design a nutritional supplement that would help obese women keep their 
blood glucose levels low and reduce their chances of getting gestational diabetes. This may 
help many pregnant women in the future and if we can reduce gestational diabetes this 
would also influence the health of their children possibly for the whole of their lives. You 
will receive a detailed dietary review from a research dietician who will give you some 
constructive feedback.  
If you take part in the “Investigating Attitudes to Eating in Pregnancy” study you may help 
to increase healthcare professionals’ understanding of what pregnant women feel about a 
range of topics related to weight, mental health and eating patterns.  
What are the side effects of taking part? 
There are no real side effects known as the nutritional supplement is already widely used in 
the USA and it will be changed slightly to make it more specific to the nutritional needs of 
pregnancy.  
There are no side effects from using the small glucose sensors. Some women may find the 
dressing that covers the skin mildly irritating but no serious reactions have been reported.  
If you take part in the “Investigating Attitudes to Eating in Pregnancy” study some of the 
subjects that will be discussed during the interview and parts of the questionnaires may be of 
a sensitive nature. However, you do not have to discuss anything which makes you feel 
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uncomfortable and can take a break, move on from that part of the discussion or end the 
interview at any time if you want to.   
What happens if anything goes wrong? 
In the unlikely event that you are harmed by taking part in this study no special insurance 
applies. However if you are harmed due to negligence normal NHS indemnity may apply but 
you have to pay for this action. You will be given contact details for the research team if you 
have any problems at any time during the study. 
Regardless of whether anything goes wrong, if you wish to complain about any aspect of the 
way of the way you have been approached or treated during the course of the study the 
normal NHS complaints mechanism is available to you. 
What will happen to the results of the study? 
The results will be published in medical journals. Feedback on the overall findings will be 
available to participants following data analysis and we will also give you feedback on your 
food diaries by post or email one the study is finished.  
Who is paying for this research? 
Abbott Nutrition, a commercial company have funded this study. The midwife and research 
nurses working on this study have their salaries paid by this organisation. The hospital, 
doctors and dietician do not receive any payment if you help with this research.  
This “Investigating Attitudes to Eating in Pregnancy” study is being carried out as part of a 
PhD Studentship funded by the Medical Research Council.  
What about travel and other costs? 
We appreciate how busy pregnant women are and are grateful for the time given to come to 
the hospital. As you will need to come fasted on every occasion to the hospital we will 
arrange complementary taxi transport. We are also aware that you may require some time off 
work and have some problems with childcare on the days you need to come to hospital. We 
will therefore reimburse you up to the value of £200 for any inconvenience incurred.   
To show our appreciation we will invite all women and their new babies for a lunch so you 
can meet other women in the group, share your experiences and talk to the research team 
again. We would like to take a professional photograph of you and you baby at this time and 
will give you a copy to keep as a memento. You will also receive a new nappy bag. 
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We will give you a £20 shopping voucher to reimburse your time if you also take part in the 
“Investigating Attitudes to Eating in Pregnancy” study. 
Who has reviewed this study? The Riverside research ethics committee has reviewed and 
approved this study. 
What do I do if I have further questions or want to take part? 
For further information please contact: 
Rahat Maitland, Diabetes Research Doctor or Suzanne Barr, Research Dietician Tel:020 
7188 7804  
 
12.5 Meal Choices For IGPOP Stage 2 
In the pre-study visit, food preferences were documented, including allergies and 
religious requests.  In such circumstances, slight deviation from the set menus was 
made following review by the research dietician to ensure any changes complied 
with the controlled diet. Participants were offered a choice of Menu A or B for each 
of the study days held at the CRF.  
Table 37 Alternative Meal Choices (Menu B) for CRF study days 1 and 5 (Thursday and Monday) 











fibre (g) GI  
09.30 BREAKFAST               
Rice krispies (20g variety pack)  73 17 2 2 0 0 93 
Intervention or control 
supplement  152 23 17 7 4 2 27 
Meal total 224 40 19 9 4 2 
 13.00 LUNCH              
Sainsbury’s tomato and 
mozzarella pot (300g) 381 55 10 15 11 5 35 
Cheddar cheese (60g) 219 0 0 14 18 0 34 
Nature's Finest Tropical Fruit 
Salad pot (in juice) 113g 67 14 13 3 0 1 50 
Meal total 667 69 23 32 29 5 
 15.00 AFTERNOON              
Intervention or control 
supplement  152 23 17 7 4 2 27 
18.30 DINNER                
Sainsbury’s British Classic 
Shepherd's pie (450g) 461 48 2 23 19 6 35 
Ambrosia Chocolate custard 
(150g) 171 28 22 5 4 1 38 
Meal total 632 76 24 27 23 6 
 20.30 SUPPER & MISC              
Philadelphia tub (35g) snack 55 1 1 3 4 0 34 
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Philadelphia tub (35g) snack 55 1 1 3 4 0 34 
Poppy & sesame thin crackers x 4 80 10 0 2 4 1 65 
Sainsbury’s grape pack (80g) 53 12 12 0 0 1 46 
Meal total 243 25 16 8 12 2 
 
        Meal total excluding 
supplements 1766 209 81 76 67 15 
 Total  1918 232 97 83 71 17   
Dietary data were generated using the WISP dietary data software  
*Estimation of GI. For intervention supplement, GI given is calculated from Stage 1b IGPOP.   
Table 38 Alternative Meal Choices (Menu A) for CRF study days 2 and 6 (Friday and Tuesday) 











fibre (g) GI  
08.00 BREAKFAST               
Rice krispies (20g) pack)  73 17 2 2 0 0 81 
Intervention or control supplement  152 23 17 7 4 2 27 
Meal total 224 40 19 9 4 2 
 11.00 SNACK              
Muller Amore Spanish Orange 
Yogurt (150g) 218 26 24 4 11 0 38 
13.00 LUNCH               
John west snack pot Mediterranean 
style tuna salad 211 22 10 19 4 5 45 
Poppy & sesame thin crackers x 4 80 10 0 2 4 1 65 
Sainsbury’s olive spread (15g) 80 0 0 0 9 0 0 
Meal total  371 32 10 20 17 6 
 15.00 AFTERNOON              
Intervention or control supplement  152 23 17 7 4 2 27 
18.30 DINNER                
Sainsbury’s mushroom risotto 
(400g) 502 65 4 9 22 2 69 
Yeo Valley Organic Natural Yogurt 
(150g) 124 10 10 7 6 0 38 
Nature's Finest Tropical Fruit Salad 
pot (in juice) (113g) 67 14 13 3 0 1 50 
Meal total  693 89 27 19 28 3 
 20.30 SUPPER & MISC              
Philadelphia tub (35g) snack 55 1 1 3 4 0 34 
Philadelphia tub (35g) snack 55 1 1 3 4 0 34 
Poppy & sesame thin crackers x 4 80 10 0 2 4 1 65 
Meal total  190 12 3 7 12 1 133 
        Meal total excluding supplements 1478 173 59 55 61 12 
 Total  1848 222 99 66 75 13   
 
Dietary data were generated using the WISP dietary data software  
*Estimation of GI. For intervention supplement, GI given is calculated from Stage 1b IGPOP.   
 
Table 39 Alternative Meal Choices (Menu B) for CRF study days 2 and 6 (Friday and Tuesday) 













08.00 BREAKFAST               
 210 
Cornflakes (17g from variety pack)  61 14 1 2 0 1 81 
Intervention or control supplement  152 23 17 7 4 2 27 
Meal total  212 37 18 9 4 2 108 
11.00 SNACK               
Muller Amore Spanish Orange 
Yogurt (150g) 218 26 24 4 11 0 38 
13.00 LUNCH               
Quorn lasagne (250g) 249 33 4 12 7 5 35 
Poppy & sesame thin crackers x 4 80 10 0 2 4 1 65 
Sainsbury’s olive spread (15g) 80 0 0 0 9 0 0 
Meal total  409 42 4 14 19 6 
 15.00 AFTERNOON              
Intervention or control supplement  152 23 17 7 4 2 27 
18.30 DINNER                
Sainsbury’s chicken, bacon & 
mushroom pasta bake (400g) 505 56 5 26 19 5 69 
Yeo Valley Organic Natural 
Yogurt (150g) 124 10 10 7 6 0 38 
Nature's Finest Tropical Fruit Salad 
pot (in juice) (113g) 67 14 13 3 0 1 50 
Meal total  696 80 28 36 25 6 
 20.30 SUPPER & MISC              
Philadelphia tub (35g) snack 55 1 1 3 4 0 34 
Philadelphia tub (35g) snack 55 1 1 3 4 0 34 
Poppy & sesame thin crackers x 4 80 10 0 2 4 1 65 
Meal total  190 12 2 8 12 1 
 
        Meal total excluding supplements 1507 172 52 66 60 14 
 Total 1877 221 94 77 75 16  
Dietary data were generated using the WISP dietary data software  
*Estimation of GI. For intervention supplement, GI given is calculated from Stage 1b IGPOP.   
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13 APPENDIX 2: UPBEAT PILOT RESULTS  
Table 40 Description of subjects at baseline (15+0-17+6 weeks’ gestation) by randomised treatment. 
Characteristic Control (n=58)    Intervention (n=59) 
    
All (n=117) 
Age (years)  
 
18-25      
26-30  
31-40  
35 plus      
                               
30.8 (4.9) 
 
11 (19.0%)   
12 (20.7%)      
23 (39.7%)  
12 (20.7%)                                      
30.7 (5.8) 
 
13 (22.0%)  
16 (27.1%)  
14 (23.7%) 







Height (m)  
Weight (kg) 
BMI (kg/m2) 
    
1.64 (0.07) 
96.86 (16.82) 
35.86 (4.75)                 
1.65 (0.07)       
98.38 (12.72)  




SBP (mmHg)  
DBP (mmHg) 
   
115.7 (7.7)  
71.1 (6.9)           
119.4 (9.4)  











32.4 (9.0)  
25.9 (8.5)  
33.3 (9.9)   
31.7 (8.7)   
 
90.6 (18.7)                        
 
33.9 (8.4)     
26. 0 (8.7)  
34.8 (9.1)  
29.4 (9.3)    
 
















 0/58 (0%)  
2/58 (3.4%)                  
 
34/59 (57.6%) 
22/59 (37.3%)  
1/59 (1.7%)   









2 or more          
 
23 (39.7%)   
28 (48.3%)  
7 (12.1%)                                   
 
27 (45.8%) 
18 (30.5%)  





Previous GDM history 
No 
Not applicable (para 0) 
Unknown 
Yes 



















































 Results are given as n (%) or mean (SD) 









Treatment effect: Difference 
















0.4 (-0.3 to 11) 



















-1.2 (-3.1 to 0.8) 





Mid arm  
Baseline 
Post-intervention 











0.0 (-0.9 to 0.9) 



















0.6 (-4.0 to 5.2) 



















-1.6 (-4.2 to 0.9) 



















0.8 (-1.3 to 2.9) 





Data are presented as n=arithmetic mean (SD) 
Baseline (15+0-17+6), Post-intervention (27+0-28+6), late gestation (34+0-35+6) 
1n=59, 2n=53, 3n=46, 4n=58, 5n=54, 6n=44 
* Effect of randomised treatment estimated by random effects Generalised Least Squares (GLS) 
regression clustering by patient with robust standard errors and adjustment for visit and GDM status 
 
Table 42 Summaries of circumference measurements (cm) by GDM status 
 GDM (n=29) 
 






















Average of all 
visits* 














All visits* 112.7 (110.2 to 115.2) 112.6 (110.5 to 114.8) 0.06 (-3.2 to 3.3)  1.0 


















All visits* 37.5 (36.3 to 38.7) 37.3 (36.5 to 38.1) 0.2 (-1.3 to 1.7) 0.8 
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 GDM (n=29) 
 


























































All visits* 68.2 (65.4 to 71.1) 70.2 (68.7 to 71.7) -2.0 (-5.3 to 1.2) 0.21 
Data are presented as n=mean (SD) 
Baseline (16+0-18+6) weeks’, Post-intervention (27+0-28+6 weeks’), Late gestation (34+0-35+6 weeks’) 
1n=29, 2n=26, 3n=78, 4n=64, 5n=77 
*Comparison between GDM & non-GDM women by random effects Generalised Least Squares 
(GLS) regression clustering by patient with robust standard errors and adjustment for visit and 
randomised intervention (Arellano 1987). 
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14 APPENDIX 3: IGPOP BIOCHEMISTRY 
RESULTS 
Table 43 Plasma insulin concentrations presented by visit number to the CRF measured up to 210 
minutes following consumption of intervention (B) and control (D) in 16 obese pregnant women  
Time 
(minutes) 
Insulin visit 1 (mU/l)* Insulin visit 2 (mU/l)* 
 Intervention (B) Control (D) Intervention (B) Control (D) 
0 5.9 (3.7-9.2) 5.9 (4.8-7.3) 6.0 (4.4-8.0) 5.9 (3.2-10.7) 
15 13.4 (5.7-31.3) 13.2 (5.4-32.7) 14.3 (7.1-28.8) 17.0 (11.2-25.8) 
30 50.8 (33.7-88.6) 34.2 (9.6-121.2) 73.8 (42.8-127.2) 55.8 (31.2-99.9) 
45 54.6 (33.7-88.6) 70.9 (39.8-126.4) 74.7 (53.2-104.9) 64.4 (36.9-112.6) 
60 43.2 (22.1-84.1) 55.1 (31.2-97.1) 62.4 (45.2-86.1) 42.2 (23.0-77.5) 
75 16.7 (6.5-43.0) 39.4 (23.5-66.1) 39.3 (21.4-72.1) 15.4 (6.6-35.6) 
90 17.8 (7.8-40.5) 32.7 (20.1-53.2) 27.6 (13.9-55.0) 21.8 (10.7-44.2) 
105 12.8 (6.9 23.8) 23.8 (10.6-53.7) 30.4 (20.3-45.6) 10.8 (4.8-24.5) 
120 11.7 (7.2 19.1) 18.5 (11.6-29.4) 25.6 (13.5-48.6) 10.8 (5.6-21.0) 
135 6.5 (3.7-11.4) 13.3 (8.6-20.6) 16.7 (4.3-64.7) 8.9 (5.6-14.0) 
150 5.8 (2.9-11.4) 11.2 (6.7-18.6) 8.4 (1.6-44.9) 8.3 (5.1-13.5) 
165 5.2 (2.6-10.4) 10.7 (5.8-19.8) 9.3 (3.6-24.2) 7.6 (4.4-13.1) 
180 4.3 (2.1-8.8) 6.2 (4.4-8.6) 7.3 (2.5-21.2) 5.2 (2.9-9.2) 
195 3.1 (1.8-5.4) 4.9 (3.7-6.5) 6.1 (1.3-28.3) 4.9 (2.7-9.0) 
210 4.0 (1.9-8.4) 3.7 (2.8-5.0) 5.2 (1.2-22.4) 4.9 (3.3-7.2) 
*Data presented as geometric mean (95% CI) 
Table 44 Plasma C-peptide concentrations presented by visit number to the CRF measured up to 210 
minutes following consumption of intervention (B) and control (D) in 16 obese pregnant women  
Time 
(min) 
C-peptide visit 1 (pmol/l)* C-peptide visit 2 (pmol/l)* 
 Intervention (B) Control (D) Intervention (B) Control (D) 
0 372. 8 (261.0-532.5) 361.3 (248.7-524.8) 360.6 (248.2-523.7) 452.1 (341.1-599.2) 
15 573.4 (366.9-896.2) 511.5  (283.7-922.4) 493.1 (273.7-888.3) 618.6 (439.7-870.3) 
30 1250.9 (895.0-1748.3) 1115.2  (575.9-2159.5) 1462.8 (950.8-2250.5) 1397.6 (957.6-2039.8) 
45 1605.5 (1196.9-2153.5) 1744.0 (1063.9-2858.7) 1698.4 (1231.9-2341.4) 1764.1 (1296.4-2400.4) 
60 1555.5 (1107.5-2184.8) 1678.6 (1176.1-2395.8) 1813.7 (1248.7-2634.4) 1596.8 (1161.0-2196.2)  
75 1308.9 (870.2-1969.0) 1515.4 (1158.0-1983.2) 1476.7 (950.7-2293.8) 1331.1 (977.7-1812.3) 
90 1112.7 (725.1-1707.5) 1383.3 (991.5-1930.1) 1259.4 (747.2-2122.8) 1268.0 (916.5-1754.1) 
105 1021.5 (600.9-1736.4) 1231.1 (729.9 2076.3) 1250.6 (759.6-2058.8) 1080.9 (754.6-1548.3) 
120 908.6 (574.4-1437.2) 998.1 (631.5-1577.3) 1184.6 (746.6-1879.7) 900.1 (612.0-1323.7) 
135 694.9 (440.7-1095.8) 876.3 (594.0-1292.9) 1083.3 (602.2-1948.9) 788.8 (523.4-1188.7) 
150 613.3 (400.1-940.1) 789.8 (552.0-1130.2) 848.9 (474.9-1517.3) 709.1 (486.1-1034.4) 
165  517.4 (321.4-832.8) 730.7 (458.3-1164.9) 699.1 (338.1-1445.7) 639.6 (430.7-949.7) 
180 429.4 (252.1-731.4) 532.2 (334.7-846.3) 613.3 (297.1-1265.6) 534.7 (369.7-773.3) 
195 322.3 (139.7-743.6) 449.3 (299.3-674.6) 550.9 (192.1-1579.7) 501.4 (360.4-697.5) 
210 366.5 (218.1-615.8) 380.0 (264.7-545.7) 475.0 (161.8-1394.2) 447.0 (324.5-615.8) 
*Data presented as geometric mean (95% CI) 
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Table 45 Plasma NEFA concentrations presented by visit number to the CRF measured up to 210 
minutes following consumption of intervention (B) and control (D) in 16 obese pregnant women 
Time 
(min) 
NEFA visit 1 (pmol/l)* NEFA visit 2 (pmol/l)* 
 Intervention (B) Control (D) Intervention (B) Control (D) 
0 0.62 (0.45-0.80) 0.47 (0.35-0.59) 0.56 (0.39-0.72) 0.67 (0.55-0.79) 
60 0.27 (0.15-0.38) 0.29 (0.15-0.43) 0.34 (0.15-0.53) 0.26 (0.16-0.35) 
120 0.29 (0.19-0.39) 0.14 (0.08-0.21) 0.19 (0.01-0.37) 0.17 (0.10-0.25) 
180 0.63 (0.40-0.85) 0.25 (0.13-0.38) 0.23 (0.13-0.33) 0.42 (0.25-0.59) 
210 0.76  (0.56-0.95) 0.39 (0.27-0.51) 0.41 (0.15-0.67) 0.65 (0.42-0.87) 
*Data presented as arithmetic mean (95% CI) 
Table 46 Plasma triglyceride concentrations presented by visit number to the CRF measured up 210 
minutes following consumption of intervention (B) and control (D) in 16 obese pregnant women 
Time 
(min) 
Triglyceride visit 1 (mmol/l)* Triglyceride visit 2 (mmol/l)* 
 Intervention (B) Control (D) Intervention (B) Control (D) 
0 1.40 (1.06-1.74) 1.25 (0.92-1.59) 1.26 (0.94-1.59) 1.39  (1.11-1.67) 
60 1.47 (1.16-1.78) 1.41 (1.04-1.77) 1.44 (0.96-1.93) 1.47 (1.19-1.75) 
120 1.54 (1.15-1.93) 1.29 (0.98-1.60) 1.30 (0.83-1.78) 1.40 (1.10-1.71) 
180 1.54 (1.11-1.96) 1.32 (0.95-1.70) 1.21 (0.86-1.56) 1.34 (1.04-1.64) 
210 1.52 (1.14-1.91) 1.33 (0.94-1.73) 1.29 (0.81-1.77) 1.46  (1.17-1.76) 
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